{
  "responseHeader":{
    "status":0,
    "QTime":5,
    "params":{
      "q":"(Background: adenoid cystic carcinoma OR adenocyst OR malignant cylindroma OR adenocystic OR adenoidcystic OR ACC OR ADCC OR Doc_title: adenoid cystic carcinoma OR adenocyst OR malignant cylindroma OR adenocystic OR adenoidcystic OR ACC OR ADCC) AND (Background: KIT OR \"PBT\" OR \"SCFR\" OR \"C-Kit\" OR \"CD117\" OR \"MASTC\" OR Doc_title: KIT OR \"PBT\" OR \"SCFR\" OR \"C-Kit\" OR \"CD117\" OR \"MASTC\")"}},
  "response":{"numFound":391,"start":0,"docs":[
      {
        "Meeting_name":" C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression",
        "Background":"['Epithelial-mesenchymal transition (EMT) is associated with salivary adenoid cystic cancer (ACC) progression and metastasis. Here, we report that ectopic overexpression of c-kit in ACC cell lines is sufficient for acquisition of mesenchymal traits, enhanced cell invasion, along with stem cell properties defined by the presence of a CD133+/CD44+ cell subpopulation. c-kit positively regulated expression of known EMT inducers, also activating TGF-to contribute to EMT. c-kit itself was induced by TGF-in ACC cell lines and required for TGF--induced EMT. Xenograft experiments showed that c-kit cooperated with oncogenic Ras to promote tumorigenesis in vivo. Finally, in human specimens of ACC, we found that c-kit was abnormally overexpressed and correlated with the prognosis of ACC. Our findings define an important function for c-kit in ACC progression by orchestrating EMT, and they implicate this gene product as a marker of poor prognosis in this disease.']",
        "Doc_id":"AACR_2014-131",
        "Doc_title":" C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression",
        "_version_":1606189005654720512},
      {
        "Meeting_name":" miR-221 ans miR-222 expression in salivary gland tumors",
        "Background":"['Background', ' MicroRNAs (miRNAs) are a class of short noncoding RNAs, that regulate the gene expression by binding to the 3 - untranslated region of target mRNAS and by blocking the translation or degradation of the mRNAs that mediate various pathophysiological process including the pathogenesis of diverse human cancers and important cellular functions such as proliferation, apoptosis, differentiation, and cell signaling. Salivary gland tumors are complex, due to their broad histological spectrum resulting from multiple tumor cell differentiation. We previously detected that the protein c-kit is involved in the process of salivary gland morphogenesis and tumorigenesis; other recent studies reported alterations in KIT gene in adenoid cystic carcinoma. The aim of the present study is to determine the expression of microRNAs targeting KIT in pleomorphic adenoma (PA) and adenoid cystic carcinoma (ACC), the most common benign and malignant salivary gland neoplasms, respectively, and that originate from the intercalated duct region. Material and Methods', ' Twenty-five pleomorphic adenoma, 14 adenoid cystic carcinoma and 10 non-neoplastic salivary gland samples were used and miRNA expression was evaluated by Real Time RT-PCR using TaqMan miRNA Assays (miR- 221 and 222). Results', ' Expression of miR-221 was detected in 13 CAC samples and 19 PA samples. In CAC, expression of miR-221 was downregulated in 4 out of 13 (30,77%) samples, upregulated in 4 out of 13 (30,77%) samples, and normal in 5 out of 13 (38,46%) samples. In PA, miR-221 expression was downregulated in 7 out of 19 (36,84%) samples, upregulated in 2 out of 19 (10,53%) samples, and normal in 10 out of 19 (52,63%) samples. Expression of miR-222 was detected in 14 CAC samples and 22 PA samples. In the majority of CAC samples, the expression of miR-222 was similar to that observed in non-neoplastic samples. In PA samples, expression of miR-222 was downregulated in 7 out of 22 (31,8%) samples, upregulated in 8 out of 22 (36,4%) samples, and normal in 7 out of 22 (31,8%) samples. Conclusion', ' The expression of miRNAs 221 and 222 do not present a definite pattern to discriminate PA from ACC. This might be due to different mechanisms involved in their tumor biology or due to their common site of origin (the intercalated duct) which could add some similar biological features to both neoplasms.']",
        "Doc_id":"AACR_2015-4015",
        "Doc_title":" miR-221 ans miR-222 expression in salivary gland tumors",
        "_version_":1606189036216516608},
      {
        "Meeting_name":" Histone demethylase NDY1/KDM2B as a driver of survival and proliferation of normal and neoplastic mast cells",
        "Background":"['Proliferative disorders of mast cells exhibit a range of clinical behavior from benign cutaneous forms to aggressive systemic mastocytosis and mast cell leukemia. While these disorders are rare in people, they are among the most common malignancies in the dog, a circumstance that provides a useful model for an orphan disease. Growth of both normal and neoplastic mast cells is driven by c-kit (CD117), a tyrosine kinase receptor for stem cell factor. Ligand-independent, constitutive activation of c-kit via mutation is a common feature of mastocytic neoplasia. Therefore, tyrosine kinase inhibitors (TKIs) that target c-kit have activity in aggressive mastocytosis in people and in dogs. However, resistance to c-kit targeted TKIs is common in both species, highlighting a need for other therapeutic targets.Our data indicates that chromatin modification may be important in mast cell biology. Specifically, we have shown that the JmjC domain lysine 36 specific histone H3 demethylase, NDY1/KDM2B, supports the proliferation and immortalization of bone-marrow derived mast cells. It is well known that NDY1/KDM2B is a driver of hematopoietic transformation and is associated with malignant progression in certain solid tumors (breast, pancreatic and urothelial carcinoma). Therefore, we investigated the effects of knockdown of NDY1/KDM2B in neoplastic human and canine mast cells in vitro and in xenografts. Our data demonstrate that this knockdown inhibits proliferation and induces apoptosis in vitro and inhibits tumor growth in vivo. Therefore, targeting therapy of NDY1/KDM2B or downstream effectors in mast cell tumors could be a beneficial addition to the existing therapeutic modalities.Supported by grants from the Morris Animal Foundation (D14CA) and NIH (R01CA109747).']",
        "Doc_id":"AACR_2015-3635",
        "Doc_title":" Histone demethylase NDY1/KDM2B as a driver of survival and proliferation of normal and neoplastic mast cells",
        "_version_":1606189003469488128},
      {
        "Meeting_name":" Predictive factors of c-kit-positive cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in distant metastasis formation in non-small cell lung cancer",
        "Background":"['Cancer stem cells (CSC) are a rare subpopulation of undifferentiated cells that are responsible for tumor initiation and tumor regeneration after chemotherapy. Although a universal marker for CSCs has not been identified, previous studies showed that c-kit (CD117) functioned as a stem cell factor (SCF) receptor, and SCF-ckit signaling axis was essential for self-renewal and proliferation of lung CSCs. During tumorigenesis, subsets of tumor cells disseminate from primary tumors by undergoing phenotypic changes that allow the cells to penetrate blood vessels. These changes are accompanied by a process described as epithelial-mesenchymal transition (EMT). EMT endows epithelial cells with enhanced invasive potential by the loss of their epithelial characteristics and the acquisition of a mesenchymal phenotype. The aim of this study is to correlate c-kit-positive CSCs and EMT-positive, subpopulations of circulating tumor cells (CTCs) with clinicopathological parameters to verify whether these biomarkers contribute to cancer distant metastasis in non-small cell lung cancer (NSCLC). A total of 31 patients with NSCLC were enrolled into this study and evaluated for CTC levels at baseline. Peripheral blood samples (5 ml, anticoagulated with EDTA) were collected, transferred to the CanPatrol CTC tube, and then processed within 8 hours. The CanPatrol CTC enrichment technique was used to isolate and characterize CTCs. The first step of this technique was to isolate CTCs via a filter-based method; then, an quantifiable, quadruple-colorimetric RNA in situ hybridization (ISH) method was used to examine CTCs for expression of four epithelial (E) biomarkers (cytokeratins (CKs)8,18 and 19; and epithelial cell adhesion molecule (EpCAM)), two mesenchymal (M) biomarkers (vimentin and twist), c-kit and CD45. Using this technique, CTCs were detected in 25(80.6%) of 31 blood samples, and five categories of CTCs were defined using EMT biomarkers ranging from exclusively epithelial (E) to intermediate (E > M, E = M, M > E) and exclusively mesenchymal (M). Of the CTC-positive samples, 13(52%) samples contained c-kit-positive CTCs, and the percentage of cells with c-kit expression was 27.8%, with 2.1%, 4.6%, 2.1%, 18.3% and 0.8% in exclusively E, E > M, E = M, M > E and exclusively M CTCs, respectively. The expression of c-kit showed a high statistically significant correlation with distant metastasis (P = 0.0001). Compared with the non metastatic or regional metastatic carcinoma, mesenchymal CTCs (including M > E and exclusively M) were predominant in patients with distant metastatic carcinoma (P = 0.033). However, the sample size of this study was small, further validation needed to be done with a larger sample size. In summary, mesenchymal CTCs or/and c-kit may be potential predictive factors for invasion and metastatic spread of NSCLC.']",
        "Doc_id":"AACR_2015-385",
        "Doc_title":" Predictive factors of c-kit-positive cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in distant metastasis formation in non-small cell lung cancer",
        "_version_":1606189024818495489},
      {
        "Meeting_name":" A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin)",
        "Background":"['Background', ' Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) frequently stains strongly for c-KIT (CD-117) expression. We therefore evaluated imatinib mesylate as a treatment for MCC. Methods', ' Eligibility included patients with measurable metastatic or unresectable MCC with CD117 expression by immunostaining. A Zubrod performance status of 0-2, adequate hematologic, renal, and hepatic function was also required. Imatinib 400 mg daily was administered orally in 28-day cycles. Results', ' A total of 25 patients were accrued to this trial from 13 institutions, with 6 accrued through Intergroup participation by the Eastern Cooperative Oncology Group. Two patients were ineligible (one was found not to express CD117 on central pathology review, and one lacked measurable disease). These 23 patients were included in the analysis. Imatinib was well tolerated with Grade 1 or 2 nausea, diarrhea, and hematologic toxicity as the most frequent side effects. There were no complete responses (0%) and 1 confirmed partial response (4%) in the 23 evaluable patients (4% objective response rate, CI 0 -22%). In addition, stable disease was observed in 3 patients (9, 4 and 3 months). Median progression-free survival was 1 month (95% CI', ' 1-2 months). Estimated 6 month PFS was 4%. Median overall survival was 5 months (95% CI 2-8 months). The estimated one-year overall survival was 17% (95% CI', ' 0% - 33%). There were three on-study deaths. All were attributed to tumor progression. One patient achieved a partial response and another had prolonged disease stabilization while receiving treatment. DNA sequencing of c-KIT was performed on tumor tissue from on a non- responding patient and the one patient with long-term stable disease (9 months). Neither demonstrated an activating mutation in c-KIT. Unfortunately, the patient with partial response withdrew consent for the study and DNA sequencing could not be performed. Conclusions', ' The majority of patients progressed rapidly within 1-2 cycles of treatment. The observed progression-free survival and overall survival were not adequate to conclude that this agent was active in advanced MCC. The planned second stage of patient accrual was not opened.']",
        "Doc_id":"ASCO_33146-65",
        "Doc_title":" A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin)",
        "_version_":1606189026608414721},
      {
        "Meeting_name":" Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses.",
        "Background":"['Background', ' The curative rate of radiotherapy for unresectable malignancies of the nasal cavity and paranasal sinuses was only 10-15%. Proton beams are characterized by their rapid fall-off at the distal end of the Bragg peak and sharp lateral penumbra, depending on energy, depth, and delivery. These physical characteristics give proton beam therapy (PBT) better dose distribution than X-ray irradiation. Therefore PBT may improve treatment outcome of diseases which are located in proximity to risk organs. We retrospectively analyzed the clinical profile of PBT for unresectable malignancies of the nasal cavity and paranasal sinuses. Methods', ' We reviewed 40 patients in our database fulfilling the following criteria', ' unresectable malignant tumors of the nasal cavity, paranasal sinuses and/or the skull base; and recieved definitive PBT (>60GyE) from January 1999 to December 2006. Acute and late toxicities were graded according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE ver. 3.0). Results', ' Patient characteristics were as follows', ' median age; 57 years (range, 22 to 84), male/female; 22/18, tumor type SCC/ACC/Olfactory neuroblastoma/ melanoma/others; 11/6/9/6/8, Induction chemotherapy yes/no; 10/30, PBT alone/PBT with concurrent CDDP; 39/1. With a median active follow- up of 45.6 months, 3-year progression-free and overall survival was 50.5% and 60.4%, respectively. The most common acute toxicities were mild dermatitis (grade 2', ' 32.5%), but no severe toxicity was observed (grade 3', ' 0%). Five patients (10%) experienced grade 3-4 late toxicities, namely cerebrospinal fluid (CSF) leakage, cataract, decreased visual acuity, central nerve-VI disorder, and bone necrosis in one patient each. One treatment-related death was reported, caused by CSF leakage grade 4 (2.5%). Conclusions', ' The clinical profile of PBT for unresectable malignancies of the nasal/paranasal sinuses is much better than those of radiotherapy in previous reports and seems to be sufficient to establish it as a promising treatment option for these patients.']",
        "Doc_id":"ASCO_43122-74",
        "Doc_title":" Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses.",
        "_version_":1606189032713224192},
      {
        "Meeting_name":" PACSA",
        "Background":"['Background', ' SGC of head and neck (SGCHN) are rare tumors including adenoid cystic carcinoma (ACC) and non-ACC, with no standard systemic treatment for R/M patients (pts). Pazopanib (Pb) is an oral small molecule inhibitor of VEGFR, PDGFR and KIT. We conducted a multicenter single arm phase II study to assess the antitumor activity of Pb in ACC and non-ACC SGCHN. Methods', ' Pts with confirmed progressive R/M SGCHN received Pb 800 mg daily until progression (PD). Response was assessed every 12 weeks (RECIST). Primary endpoint was the 6-mo PFS rate. Secondary endpoints included response rate (CR/PR), overall survival, toxicity. For ACC pts, the trial was designed with inacceptable and promising 6-mo PFS rates of 20% and 40%, requiring 43 evaluable pts (alpha error = 0.07, power = 0.93). For non-ACC pts, trial was exploratory on 20 pts. A study of tumor growth rates is ongoing. Results', ' From 2013 to 2015, 72 pts were enrolled', ' 49 ACC and 20 non-ACC (3 ineligible excluded) including 11 adenocarcinoma (ADK), M', 'F = 32', '37, median age 59 yrs (range 27-84), PS 0-1 = 42', '27, prior radiation', ' 64 (93%), prior systemic therapy', ' 40 (58%). The most frequent adverse events (AE) (% of pts) were fatigue (81%), nausea (59%), diarrhea (54%), high blood pressure (BP) (43%), and anorexia (33%). 31/69 pts experienced grade 3 AE, primarily fatigue and high BP. Two grade 4 AE (cerebrovascular stroke, hepatitis) and 1 death (infection) were possibly related to treatment. Median FU was 13 mo. Among 46 ACC pts evaluable for efficacy (3 non progressive excluded), best response was 1 (2%) PR, 35 (76%) SD, 10 (22%) PD. 4 pts withdrew, 7 discontinued therapy due to AE. 6-mo PFS rate was 43% (95%CI = 29;57) with 20 pts without PD at 6 mo, median PFS was 5.9 mo. Median OS was 16.6 mo with 1 year OS = 64.8%. For 18 non-ACC pts evaluable for efficacy (2 non progressive excluded), best response was 1 PR (6%), 13 SD (72%), 4 PD (22%). 4 pts discontinued therapy due to AE. 6-mo PFS rate was 50% (95%CI = 29;71), median PFS was 6.7 mo (8 mo for ADK), median OS was not reached with 1 year OS = 75%. Conclusions', ' There were no new safety signals, tolerance was as expected. PACSA is positive with a 6-mo PFS rate > 40% observed in ACC and non-ACC pts. Pb is promising and deserves further studies. Clinical trial information', ' NCT02393820']",
        "Doc_id":"ASCO_163251-176",
        "Doc_title":" PACSA",
        "_version_":1606189015390748672},
      {
        "Meeting_name":" C-kit expression promotes prostate cancer cell migration and invasion through Brca2 downregulation",
        "Background":"['In many human cancers, expression or activity of the receptor tyrosine kinase (RTK) c-kit is often associated with increased malignancy. In prostate cancer (PCa), we reported an association between expression of c-kit and clinical progression, with the highest expression seen in castrate-resistant metastatic bone specimens. We also found de novo c-kit expression in experimental intraosseous tumors formed by otherwise c-kit negative PCa cells. However, the biological consequences of c-kit expression and activation in PCa cells remain unknown. Here, we show that c-kit overexpression in PC3 and C4-2B PCa cells significantly enhances their migratory and invasive ability in vitro. Consistent with this result, we found that expression and activation of c-kit in PCa cells decreased the expression of E-cadherin and increased the expression of vimentin, suggesting an epithelial mesenchymal transition-like phenomenon. Furthermore, activation by c-kit ligand in PC3 and C4-2B cells transfected with c-kit lead to phosphorylation of Akt. This contributes to the enhanced invasiveness of c-kit-expressing PCa cells, as demonstrated by an inhibitory effect by PI3K/Akt inhibitors LY294002 and Wortmannin. In an attempt to identify genes differentially expressed in c-kit-expressing and -non-expressing PCa cells, we used a microarray containing 84 genes, representing growth factor receptors, transcription factors, cell cycle, and DNA repair genes. The analysis of the array demonstrated a consistent down-regulation of Brca2 in both c-kit-expressing PC3 and C4-2B cells, further validated by qRT-PCR and immunoblotting. Re-introduction of Brca2 into c-kit-expressing PCa cells suppressed c-kit-enhanced invasiveness to levels similar to those shown by c-kit-non-expressing cells, and led to reduced phosphorylation of Akt. Our results provide evidence that c-kit expression in PCa cells, an event which is induced upon interaction with the bone microenvironment, promotes tumor migration and invasion through an Akt-dependent mechanism regulated by Brca2 down-regulation. The identification of this novel signaling axis and its importance in PCa migration and invasion reveal potential therapeutic targets for regulating the expansion of PCa metastatic lesions in bone.']",
        "Doc_id":"AACR_2012-4273",
        "Doc_title":" C-kit expression promotes prostate cancer cell migration and invasion through Brca2 downregulation",
        "_version_":1606188994570223616},
      {
        "Meeting_name":" Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML",
        "Background":"['c-Kit is an attractive target for the treatment of a variety of solid tumors [gastrointestinal tumors (GIST), small cell lung cancer (SCLC), melanoma] and acute myelogenous leukemia (AML) due to its role as an oncogenic driver and high level of expression. Several targeted therapies, such as imatinib, sunitinib and regorafenib, bind to c-Kit and are approved for clinical use. However, due to their insufficient activity on cancers expressing wildtype c-Kit or insensitive forms of mutant c-Kit, the clinical response has been quite varied. Moreover, despite initial anti-cancer benefits in c-Kit mutant settings (such as in GIST), resistance to c-Kit inhibitor therapies emerges due primarily to the development of additional mutations in c-Kit.In an attempt to broaden the treatment of patients whose cancers express c-Kit (wildtype and mutant) and to enhance potency with comparable or better tolerability than the current therapeutics, we developed a c-Kit-targeting antibody-drug conjugate (ADC) that disrupts tumor growth through anti-mitotic activity. Hybridomas from mice immunized with the c-Kit extracellular domain (ECD) were screened for selective c-Kit binding and degradation. A humanized lead antibody (Ab) was identified, which rapidly internalized upon binding cell-surface c-Kit, but did not block binding to the c-Kit ligand (SCF). The Ab exhibited minimal-to-no cytotoxicity against c-Kit+ cell lines in vitro. To generate cytotoxic activity and to potentially overcome resistance to current c-Kit-targeting therapies, the Ab was conjugated to the maytansinoid DM1, a powerful anti-tubulin agent, via a non-cleavable linker, SMCC (technology licensed from ImmunoGen, Inc.). The ADC demonstrated robust anti-proliferative activity against cell lines expressing mutant c-Kit (GIST) and wildtype c-Kit (SCLC, AML) in vitro. The ADC also demonstrated potent anti-cancer activity in GIST and SCLC tumor xenograft models in vivo.In summary, the anti-c-Kit ADC is highly selective and active against cancers with elevated c-Kit expression regardless of their mutational status, thus representing a promising novel therapeutic approach for the treatment of c-Kit+ solid tumors, such as GIST and SCLC, as well as hematological malignancies such as AML and aggressive systemic mastocytosis (ASM).']",
        "Doc_id":"AACR_2015-1695",
        "Doc_title":" Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML",
        "_version_":1606188970868211712},
      {
        "Meeting_name":" Elucidation of c-KIT- dependent signaling to MITF",
        "Background":"['MITF, the master regulator of melanocytes, is a basic basic- helix- loop-helix- leucine zipper transcription factor that is essential for the development of melanocytes. MITF is also a lineage- survival oncogene in melanoma and recently, it has been shown that germline mutations in MITF predispose to this malignant disease. In melanoma, MITF has been proposed to act as a rheostat where high levels of MITF contribute to a proliferative phenotype whereas low levels result in a more invasive phenotype. The biological output generated by high or low levels of MITF is well characterized. However, how the activity of MITF is regulated to mediate these effects is less well known. It has been proposed that MITF is phosphorylated upon ligand induced activation of the receptor tyrosine kinase c- KIT. C-KIT engages the MAP kinase signaling cascade where ERK2 directly phosphorylates Ser73 of MITF and P90RSK phosphorylates the Ser409 residue of MITF. As a consequence, MITF activity increases and the protein is subjected to ubiquitin dependent degradation.Here, we show for the first time that c-KIT induces phosphorylation of MITF through the survival PI3 kinase- AKT pathway, the P38 stress pathway as well as the well-known MAP kinase-ERK signaling pathway. In addition, we show that the SRC kinase upstream of ERK is essential for c-KIT induced MITF activation. Moreover, we used several c-KIT phosphorylation site mutants to map the specific sites that are involved in the mediating transcription activation potential of MITF. These mutants also show less effects on MITF-mediated proliferation.We have generated phosphorylation specific antibodies against Ser73 and Ser409 of MITF and characterized the phosphorylation pattern of MITF using these reagents. Our results suggest that there is a particular relationship between Ser73 and Ser409 with subsequent effects on function. Based on our findings, we propose that phosphorylation of MITF might act as negative feedback mechanism that keeps MITF activity in check. Our model challenges the current knowledge of MITF modulation and provides insights that may have a profound impact on our understanding of the role of MITF in melanocyte and melanoma biology.']",
        "Doc_id":"AACR_2012-3093",
        "Doc_title":" Elucidation of c-KIT- dependent signaling to MITF",
        "_version_":1606189000479997952},
      {
        "Meeting_name":" Systems biology identification of processes/pathways facilitating the development of high-grade serous ovarian cancer",
        "Background":"['Previously, based on well-known stem cell phenotypes (sphere formation, potent tumorigenicity, embryonic gene expression, and chemoresistance), we used patient tumors to isolate high-grade serous (HGS) ovarian cancer-initiating cells (OCICs) that express the cell surface markers CD44 (a hyaluronate receptor) and CD117 (c-kit) (Zhang et al., 2008, Cancer Res 68', '4311). Here, to identify biological pathways that underlie HGS ovarian tumorigenesis, including the specific role of OCICs in that process, we performed integrated analyses of global gene expression, DNA copy number, and DNA methylation patterns. To that end, OCICs and bulk (i.e., disaggregated but unsorted) tumor cells were compared to primary human normal ovarian surface epithelial (nOSE) cells that, along with fallopian tube epithelial (FTE) cells, represent hypothesized cells-of-origin for HGS pelvic cancers. Principle components analysis and unsupervised hierarchical clustering revealed distinct DNA methylation and gene expression profiles for replicate (n=3) samples of each cell type (i.e., OCIC, bulk tumor, and nOSE). Gene ontology and additional unsupervised analyses of gene expression signatures corresponding to the epithelial-to-mesenchymal transition (82 of 159 signature genes), TGF-beta (47 of 86 genes), and Wnt (75 of 151 genes) pathways demonstrated well-defined segregation of the three cell types, with mesenchymal and Wnt signaling hierarchies being nOSE > OCIC > bulk tumor cells. To examine early events in HGS ovarian tumorigenesis, previously published (Tone et al., 2008, Clin Cancer Res 14', '4067) gene expression datasets were employed to show that nOSE, OCIC, and bulk ovarian tumor cell transcriptomes distinctly segregate from normal (FTE) and malignant fallopian epithelial transcriptomes. Interestingly, the largest divergence was between the nOSE and FTE gene expression profiles. Finally, DNA methylation and gene expression patterns were integrated, implicating specific networks/circuits in ovarian carcinogenesis. Taken together, these results support a mesenchymal-to-epithelial transition during ovarian tumorigenesis, reveal legitimate therapeutic targets (at the pathway level), and raise uncertainty that surface epithelial cells of the fallopian tube and ovary are reciprocal cells-of-origin for HGS pelvic carcinomas.']",
        "Doc_id":"AACR_2012-5206",
        "Doc_title":" Systems biology identification of processes/pathways facilitating the development of high-grade serous ovarian cancer",
        "_version_":1606189004247531520},
      {
        "Meeting_name":" Early progenitor cells but not late luminal progenitor cells preserve in invasive breast carcinoma.",
        "Background":"['Background CD133 and CD117 represent markers of human breast tissue differentiation. CD133 is an early progenitor marker while CD117 represents late luminal progenitor marker (Lim, et al, Nature Medicine 2009). Morphologic expression of the two markers has not been well established in paraffin embedded tissue of human breast lesions.Design In this study, we evaluated CD133 and C117 expression in different human breast lesions. Group 1 consisted of 15 benign breast cases (5 reduction mammoplasty cases with no significant pathology and 10 fibroadenoma or fibrocystic changes). Group 2 (malignant group 2) included 13 breast cases with invasive ductal carcinoma (IDC). Group 3 (malignant group 3) was composed of 12 BRCA-mutant breast cases but only six cases had IDC. All sections from paraffin embedded tissue were immunohistochemically stained for CD133 (AC133 clone) and CD117 (monoclonal antibody). Expression of the two markers in normal breast glands adjacent to lesions (normal controls), benign lesions (benign controls) and IDC were evaluated and positive rate was calculated.Results Both CD133 and CD117 were expressed in normal breast glands (normal controls) of all three groups and benign breast lesions (Table 1). However, the expression of CD133 was detected in the majority of IDC lesions as compared to low positive percent of CD117 expression in both groups 2 and 3 (Table 1). Recombined tumor cases, based on the molecular luminal status, also showed 56 - 70% CD133 positivity but 0 - 20% CD117 positivity in IDC cells.']",
        "Doc_id":"AACR_2013-5022",
        "Doc_title":" Early progenitor cells but not late luminal progenitor cells preserve in invasive breast carcinoma.",
        "_version_":1606189004973146112},
      {
        "Meeting_name":" PI3 kinase plays important role in c-Kit/V560D mediated oncogenic signaling",
        "Background":"['Oncogenic mutations of c-Kit are often identified in mastocytosis, gastrointestinal stromal tumors (GISTs) and acute myeloid leukemia (AML). The activation mechanism of the most often occurring mutation, D816V in exon 17 of c-Kit, has been well studied while other mutations remain fairly uncharacterized in this respect. In this study, we show that the constitutive activity of the exon 11 mutant V560D is weaker than the D816V mutant except that the phosphorylation of the Src family kinase binding site, Tyr568, is similar in both c-Kit mutants. The ligand for c-Kit, stem cell factor (SCF), induced phosphorylation of downstream signaling proteins, such as Akt and Erk, in c-Kit/V560D expressing cells was stronger than that in c-Kit/D816V expressing cells. Although cells expressing c-Kit/V560D showed increased ligand-independent proliferation and survival compared to wild-type c-Kit expressing cells, these biological effects were less than c-Kit/D816V expressing cells. In contrast to cells expressing wild-type c-Kit, cells expressing c-Kit/V560D are independent of Src family kinases for downstream signaling. However, this independence of Src family kinases is not due to a Src-like kinase activity of the mutant receptor that c-Kit-D816V holds. Blockage of the association of PI3 kinase with c-Kit/V560D by point mutation, but not inhibition of PI3-kinase with pharmacological inhibitors, totally blocked ligand-independent activation of the receptor, suggesting a key role of the non-lipid kinase activity of PI3 kinase in c-Kit/V560D mediated oncogenic signal transduction. Thus, PI3 kinase is an attractive treatment target in c-Kit mutations induced malignancies independent of its lipid kinase activity.']",
        "Doc_id":"AACR_2015-126",
        "Doc_title":" PI3 kinase plays important role in c-Kit/V560D mediated oncogenic signaling",
        "_version_":1606189016224366592},
      {
        "Meeting_name":" Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung",
        "Background":"['Background', 'As the comprehensive genomic analysis of small cell lung cancer (SCLC) progresses, novel treatments for this disease need to be explored. With attention to the direct connection between the receptor tyrosine kinases (RTKs) of tumor cells and the pharmacological effects of specific inhibitors, we systematically assessed the RTK expressions of high-grade neuroendocrine carcinomas of the lung (HGNEC), including SCLC and large cell neuroendocrine carcinoma (LCNEC).Patients and Methods', 'Fifty-one LCNEC and 61 SCLC patients who underwent surgical resection were enrolled in this research. As a control group, 202 patients with adenocarcinomas (ADCs) and 122 patients with squamous cell carcinomas (SQCCs) were also analyzed. Using immunohistochemical staining (IHC), we stained all tumors with antibodies for 10 RTKs; c-Kit, EGFR, IGF1R, KDR, ERBB2, FGFR1, c-Met, ALK, RET and ROS1. We scored the expression of these RTKs for all enrolled tumors, and compared them according to the histological types.Results', 'The LCNEC and SCLC patients exhibited similar clinicopathological characteristics. The IHC scores for each RTK were almost equivalent between the LCNEC and SCLC groups, but they were significantly different from those of the ADC or SQCC groups. Especially, c-Kit was the only RTK that was remarkably expressed in both LCNECs and SCLCs. On the other hand, about 20% of the HGNEC tumors exhibited strongly positive RTK expression, and this rate was similar to those for the ADC and SQCC tumors. Intriguingly, strongly positive RTKs were almost mutually exclusive in individual tumors.Conclusions', 'Compared with ADC or SQCC, LCNEC and SCLC had similar expression profiles for the major RTKs. The exclusive c-Kit positivity observed among HGNECs suggested that c-Kit might be a distinctive RTK in HGNEC. These HGNECs which have strongly positive RTKs could be the targets of personalized therapies.']",
        "Doc_id":"AACR_2015-5004",
        "Doc_title":" Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung",
        "_version_":1606188999424081920},
      {
        "Meeting_name":" Proton beam therapy (PBT) and concurrent chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) for locally advanced non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  PBT with concurrent chemotherapy for the treatment of patients (pts) with locally advanced NSCLC was introduced at our hospital in Dec 2011. We retrospectively evaluated the treatment compliance, toxicity, and efficacy of PBT with concurrent chemotherapy using CDDP plus VNR in pts with locally advanced NSCLC.  Methods', '  The medical records of NSCLC pts who received PBT with concurrent chemotherapy with 80mg/m2 of CDDP (d1) and 20mg/m2 of VNR (d1, 8), q4w, at the National Cancer Center Hospital East between Dec 2011 and Aug 2014 were reviewed.  Results', '  Thirty-three pts received PBT and concurrent chemotherapy with CDDP plus VNR. The patient characteristics were as follows', ' median age 65 years (44-74 years); 23 pts were male; 20 pts had adenocarcinoma, 11 had squamous cell carcinoma, and 2 had NSCLC-NOS; 6 pts had stage II disease, 8 pts had stage IIIA disease, 16 had stage IIIB disease, and 3 developed local recurrence after surgery. The reasons for the selection of PBT included the pts request (n = 21), and lack of suitability of the patient for radical photon radiotherapy due to excessive V20 or dose to the spinal cord (n = 12). The median lung V20 in the PBT was 23% (range', ' 10-32). All pts received the planned PBT dose (60 Gy [n = 16] or 66 Gy [n = 17]). PBT was suspended in 9 pts because of the development of febrile neutropenia (n = 5), esophagitis (n = 3), or fever (n = 1). Three pts (9%) developed grade 3 esophagitis. The grade 2 toxicities included esophagitis (n = 14), dermatitis (n = 10), and pneumonitis (n = 2). There were no cases of grade 3 pneumonitis. The response rate was 58% (95% CI, 39-45). Disease progression was observed in 17 pts. In-field recurrence was observed in 6 pts, distant metastasis was observed in 12 pts, and both types of recurrence were observed in 1 patient. The median progression-free survival was 10.6 months (95% CI, 6.1-15.2). The OS data are immature.  Conclusions', '  PBT and concurrent chemotherapy with CDDP plus VNR are feasible, although the potential complications, such as radiation esophagitis and dermatitis, seem to be rather severe as compared with the severity of these complications encountered during standard chemoradiotherapy using photons.']",
        "Doc_id":"ASCO_147484-156",
        "Doc_title":" Proton beam therapy (PBT) and concurrent chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) for locally advanced non-small cell lung cancer (NSCLC).",
        "_version_":1606189004561055745},
      {
        "Meeting_name":" Proton beam therapy for liver cancer is well tolerated",
        "Background":"['Background', ' The liver is one of the most radiosensitive organs, making radiation therapy (RT) for liver tumors extremely challenging. RT is appropriate only for a minority of liver patients with limited tumor burden; a reduction in the prescribed radiation dose may be needed to lower the probability of radiation-induced liver disease especially in the presence of cirrhosis. Proton beam therapy (PBT) delivers less dose to the liver than photon therapy and is expected to reduce toxicity while also permitting safe dose escalation for some patients with liver tumors. Methods', ' The Proton Collaborative Group REG001-09 trial (NCT01255748) prospectively collects data for PBT patients with a variety of cancer types. To better understand treatment details and outcomes associated with liver PBT, patients enrolled on the PCG registry trial from 5 institutions who received liver PBT for any cancer between 2012 and 2016 were analyzed. Results', ' A total of 43 liver cancer patients were included, most with hepatocellular carcinoma (48.8%) or cholangiocarcinoma (25.6%). The vast majority did not have surgery at any time (86%). Most were treatment naive prior to PBT; 2 previously had RT and 8 had prior chemotherapy (mostly cholangiocarcinoma patients). The median total prescribed PBT dose was 58.05 Gy(RBE) (range 21.7-67.5). The median number of prescribed fractions was 15 (range 12-37). PBT was delivered to only the liver in 90.7% of patients; inclusion of lymph nodes was rare. Uniform scanning was used in 26 (72.1%) and pencil beam scanning in 2 patients (4.7%); the delivery technique used for the remaining patients was unknown (23.2%). With median follow up of 4.4 months (range 1.3-17.9), 3 patients (7%) had an intrahepatic recurrence, 2 patients (4.6%) developed distant metastasis, and 10 patients (23.3%) died. No grade 3 or higher toxicity was reported although 17 patients (39.5%) had grade 2 toxicity predominantly fatigue, anorexia, nausea, or vomiting. Conclusions', ' Although longer follow up is needed to assess late toxicities as well as disease control, early outcomes from the PCG registry trial for liver cancer patients shows that predominantly hypofractionated PBT has a very favorable acute toxicity profile.']",
        "Doc_id":"ASCO_177294-195",
        "Doc_title":" Proton beam therapy for liver cancer is well tolerated",
        "_version_":1606189008285597697},
      {
        "Meeting_name":" Mutational analysis for IDH1 and IDH2 in pediatric leukemia",
        "Background":"['Recently, mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that NADP+dependent isocitrate dehydrogenase (IDH)1/2-mutated AMLs display global DNA hypermethylation and a specific hypermethylation signature, suggesting a shared proleukemogenic effect. To explore the involvements of IDH1/2 in the pathogenesis in pediatric hematological malignancies. We analyzed mutations that involve the activation sites of IDH1/2 using polymerase chain reaction amplification/sequencing in a total of 244 samples of pediatric myeloid malignancies as well as infantile leukemia including 17 AML-derived cell lines, 115 primary cases of AML, 28 primary cases of MDS, 15 primary cases of juvenile myelomonocytic leukaemia (JMML), 6 chronic myeloid leukemia (CML)-derived cell line, 18 primary cases of CML and 45 infantile leukemia(6 AML and 39 acute lymphoblastic leukemia (ALL) patients). Moreover, to assess whetherIDH1/2 mutations overlap with known gene abnormalities, such as FLT3, c-KIT, and NPM1 mutations, mutational analyses of FLT3, c-KIT, and NPM1 were also performed. The common IDH2 R140Q mutation was detected in a single AML case, whereas no IDH1 mutation was detected in samples of myeloid malignancies. Although no IDH2 mutation was detected in infantile leukemias, novel P127S, H133I and I130V of IDH1 mutations were detected in 4 of 45 (8.9%) infantile ALL cases. No IDH1 and IDH2 mutations were detected in the JMML, MDS, or CML samples examined. Six AML samples including one cell line had c-KIT mutations (D816V, N822K, or D419fs), 12 AML cases had FLT3-ITD and 10 infantile leukemia cases had FLT3 mutations (D835E or I836). The NPM1 mutation was detected in 2 of 132 AML samples. The AML case harboring the IDH2 mutation, Case 39 was a 12-year-old boy diagnosed as AML-M2 according to the French-American-British cooperative group classification system having t(8;21)(q22;q22), showed no abnormalities of NPM1, c-KIT, and FLT3. Remarkably, among 4 infantile ALL cases with IDH1 mutations, 3 cases showed mixed lineage leukemia(MLL) rearrangements with t(4;11). The FLT3-D835 mutation was found in 1 of 4 patients with IDH1 mutations. These results suggest that although the involvements of IDH1/2 mutations in the pathogenesis of pediatric myeloid malignancies are extremely rare, closely positioned to near activation site, R132 IDH1, these IDH1 mutations are the candidate second genetic events in a subset of MLL-leukemia.']",
        "Doc_id":"AACR_2012-71",
        "Doc_title":" Mutational analysis for IDH1 and IDH2 in pediatric leukemia",
        "_version_":1606188980913569792},
      {
        "Meeting_name":" Expression and prognostic significance of directed therapy targets and mutational analysis of the EGFR pathway in malignant salivary gland tumors.",
        "Background":"['Background', '  Malignant salivary gland tumors are rare and pleomorphic entities (24 sub types, WHO 2005). Curative treatment relies on surgery sometimes completed by radiotherapy. Management of non-surgical, locally advanced or metastatic tumors is difficult as conventional chemotherapies are ineffective. Directed therapies may provide important benefits for these patients. The aim of this work was to assess the expression and prognostic value of directed therapy targets on salivary gland tumors and search for mutations within the key players of the EGFR pathway.  Methods', '  Immunochemistry on formalin fixed paraffin embedded (FFPE) samples from 124 patients for c-KIT, EGFR, c-ERBB2, MUC1, phospho-mTOR, androgen/estrogens/progesterone receptors and Ki67 was performed and related to progression free interval and survival. DNA was extracted from FFPE samples and conditional for treatment mutations of EGFR/KRAS/BRAF were assessed. An additional high throughput screening for mutations of key oncogenic genes was performed.  Results', '  EGFR was the most expressed marker, found across almost all histotypes. Expression of the other markers was heterogeneous but some potential therapy leads were suggested by high levels of C-ERBB2 and androgen receptors in salivary duct carcinomas or C-KIT over expression in myoepithetial carcinomas. Tumor grade and a high proliferation index (Ki67>20%) were associated with progression free interval and survival. None of the other marker was. No mutation was found in EGFR/KRAS/BRAF. 7% (7/104) of the tumors harbored a mutation at the codon 61 of HRAS. In epithelial and epithelial-myopithlial carcinoma, the mutation rate reached 33%. Mutations of PI3K and p53 were the most frequently found in the broader screen.  Conclusions', '  Several tumor subtypes expressed frequently some targets of directed therapies suggesting potential therapy leads. The EGFR/MAPK pathway seems intact suggesting a low efficacy of small kinase inhibitors such as erlotinib or gefitinib. The mutation of H-RAS, known to be important but not sufficient to trigger urothelial carcinoma, could be a key oncogenic event in tumors with a myoepithelial component.']",
        "Doc_id":"ASCO_95851-114",
        "Doc_title":" Expression and prognostic significance of directed therapy targets and mutational analysis of the EGFR pathway in malignant salivary gland tumors.",
        "_version_":1606188987601387520},
      {
        "Meeting_name":" Antileukemic activity of 2-deoxy-d-glucose in acute myeloid leukemia",
        "Background":"['Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by the clonal expansion and accumulation of immature blasts in the bone marrow. Several receptor tyrosine kinases (RTKs), including internal tandem duplication mutations of the Fms-like tyrosine kinase 3 (FLT3-ITD) or mutations of the Proto-oncogene c-Kit (c-Kit N822K or D816V), are involved in the pathogenesis of AML. Another major point of resistance of leukemic cells to chemotherapy is their inability to activate cell death pathways, because of overexpression of anti-apoptotic proteins (Mcl-1, Bcl-2...). In this study we worked on the antileukemic activity of 2-deoxy-d-glucose (2-DG), a glycolysis and N-linked-glycosylation inhibitor, which have been described in different cancer models to sensitize to chemotherapy.First we evaluated the effects of 2-DG on cell proliferation and apoptosis. We showed that 2-DG inhibited more strongly cell proliferation of MV4-11, MOLM-14, Kasumi-1 and TF1 c-Kit D816V cell lines than U-937. In accordance with this result, 2-DG induced apoptosis in all AML cell lines previously cited excluding U-937. We also used the murine model BaF/3 stably transfected with FLT3-ITD, c-Kit D816V or BCR-ABL, and showed that cells transformed with a membrane tyrosine kinase were more sensitize to 2-DG than cell expressing the cytoplasmic oncogene BCR-ABL. Moreover, 2-DG induced apoptosis in primary FLT3-ITD AML samples (n=9) or c-Kit D816V mutated samples (n=5). At molecular level, 2-DG inhibited N-linked-glycosylation of FLT3-ITD and c-Kit mutants both in cell lines and primary AML samples, leading to a decrease of cell surface expression of these RTKs. We also showed that 2-DG overcomes the resistance to AC-220 in a MOLM-14 ITD/TKD model, by triggering the deglycosylation of the receptor. Furthermore, 2-DG exposure decreased ERK and STAT3/5 signaling but, surprisingly, not the AKT pathway in FLT3-ITD or c-Kit mutated models. Cell exposure to 2-DG and D-mannose, which restores N-linked-glycosylation but not glycolysis, demonstrated that 2-DG induced apoptosis and inhibition of RTKs cell surface expression are independent of the effects of 2-DG on glycolysis.In another part, we have demonstrated that 2-DG was able to decrease protein expression of the anti apoptotic protein mcl-1 in sensitive and resistant cells as well as in primary patient samples. These results correlated with the fact that in some cells, like lymphoma cells, mcl-1 synthesis is glycolysis-dependent. We took advantage of this decrease to associate the 2-DG with cytotoxic agents ABT-737 or cytarabine (Ara-C) and showed that these combinations (Ara-C+2-DG or ABT-737+2-DG) were synergistic.Our study shows that dual targeting of glycolysis and N-linked-glycosylation is an attractive therapeutic strategy in acute myeloid leukemia.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2014-5482",
        "Doc_title":" Antileukemic activity of 2-deoxy-d-glucose in acute myeloid leukemia",
        "_version_":1606188990095949824},
      {
        "Meeting_name":" Molecular profiling of pulmonary pleomorphic carcinoma",
        "Background":"['Background', ' Pulmonary pleomorphic carcinoma (PPC) is rare malignant tumor composed of carcinomatous and sarcomatous cell components which characterized by a more aggressive outcome than other histological subtype of non-small cell lung cancer (NSCLC). Various attempts to establish the clinical features of PPCs have been largely limited by small sample size. Thus, it will be important to further delineate the molecular characteristics of this disease entity to better understand the exact nature of this tumor type. Methods', ' We retrospectively examined the tumor specimen of 61 patients who underwent surgical resection of the lung in Samsung Medical Center from July 1995 to June 2009. Mutational or gene amplification status of epidermal growth factor receptor (EGFR), K-RAS (rat sarcoma virus), c-kit, FGFR (fibroblast growth factor receptor), c-MET (mesenchymal-epithelial trasition factor) was examined with genomic DNA sequencing, real-time PCR and/or fluorescence in situ hybridization(FISH). Overall survival impact was examined. Results', \" Out of 61 patients with pleomorphic carcinoma, it was revealed that 13 (21.3%) patients possessed EGFR tyrosine kinase domain deletion mutations in exon 19, point mutations in exon 20,21, 6 (9.8%) with K-ras point mutations in exon 2 and 3 (4.9%) c-kit point mutations in exon 9. High frequency gene copy number of c-met was found in 11 (18.0%) patients including one amplification by FISH and that of FGFR in 7 (11.5%) patients. A subset of patients demonstrated concurrent existence of multiple mutations, including one with EGFR and K-ras mutation simultaneously. No significant relationships were found between the occurrence and type of mutations and patients' survival or any other clincopathological variables. Conclusions\", ' We describe mutational analysis of a large set of PPC samples. Given the diverse repertoire of mutational profiles observed from PPC samples, clinical trials based on accurate cancer-genotyping should be considered as a legitimate treatment scheme for this rare disease entity in the future.']",
        "Doc_id":"ASCO_52061-74",
        "Doc_title":" Molecular profiling of pulmonary pleomorphic carcinoma",
        "_version_":1606188977224679424},
      {
        "Meeting_name":" Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice.",
        "Background":"['Background', ' Tyrosine kinase is a key enzyme activity utilized in many intracellular messaging pathways. TKIs have proven to be very successful in the treatment of a wide variety of malignant diseases including chronic myeloid leukemia, renal cell carcinoma and gastrointenstinal stromal tumor. Scattered reports have suggested that these agents appear to affect blood glucose levels. Methods', ' We therefore studied the blood glucose (BG) concentrations on clinic blood samples before, during and after TKI therapy retrospectively in both diabetic (19) (all type II diabetes) and non-diabetic (82) patients treated with dasatinib (8), imatinib (39), sorafenib (23) and sunitinib (30) in general clinical practice. Samples were mixed but most were daytime non-fasting. Results', ' All of the agents depressed the BG in a reversible statistically significant fashion. Mean declines were', ' dasatinib - 53 mg/dl (p <.001), imatinib - 9 mg/dl (p = 0.03), sorafenib - 12 mg/dl (p < .001) and sunitinib -14 mg/dl (p < .001). Diabetic patients required some modifications of their medications including cessation of insulin or other hypoglycemic agents. In fact, 8/19 (42%) of the diabetic patients were able to discontinue all hypoglycemic agents including insulin. One diabetic patient developed symptomatic hypoglycemia on sunitinib. Conclusions', ' The mechanism for the hypoglycemic effect of these drugs is unclear, but of the four agents tested, c-kit and PDGFR are common targets for all 4. Clinicians should keep the potential hypoglycemic effects of these agents in mind, particularly in diabetics; modification of hypoglycemic agents may be required. These results also suggest that inhibition of a tyrosine kinase, be it c-kit, PDGFR or some other undefined kinase target, may improve gylcemic control in type II diabetes mellitus and deserves further study as a potential therapeutic option.']",
        "Doc_id":"ASCO_41600-74",
        "Doc_title":" Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice.",
        "_version_":1606189025981366272},
      {
        "Meeting_name":" Improved detection of salivary glands RNA markers in saliva samples.",
        "Background":"['RNA based liquid biopsy in saliva could be part of the diagnostic process and surveillance in patients with Salivary Gland Tumors. There is no established approach for saliva markers in salivary gland tumors. These tumors occur approximately in one out of 100,000 adults per year in the USA. We aim to develop a method to identify RNA shed specifically from the salivary glands.The two most common salivary gland malignancies harbor frequent gene fusions, which may be candidate RNA based markers. In mucoepidermoid carcinoma, the MECT1-MAML2 fusion. In adenoid cystic carcinoma, either a MYB-NFIB or MYBL1-NFIB fusion. We identified collection and processing methods to be tested on healthy individuals saliva samples. We compared three saliva stimulation methods', ' Chewing Gum, Tabasco and Vitamin C powder with unstimulated collected saliva; and also utilized different processing and RNA extraction procedures', ' Trizol based', ' QIAzol method (Qiagen), RNEasy saliva protecting reagent (Qiagen), OrageneRNA (DNA Genotek), and mirVana Kit (ThermoFisher). We evaluated the RNAs quantity and quality with Spectrophotometer and Agilents 2100 Bio analyzer. We identified two salivary gland specifically highly expressed genes (HTN3 and CA6) to be analyzed by quantitative RT-PCR. We have collected and processed 221 samples and analysis is ongoing. Bio analyzer showed that RNA from the unstimulated collected saliva has a higher concentration than stimulated saliva. Unstimulated saliva is expected to contain mucosa cells, bacteria and rests of food, therefore those could also be RNA sources. When salivas RNA is protected by either of the buffers tested, the RIN scores (RNA Integrity Number) obtained by Bio analyzer are higher. Based on our preliminary data, stimulation with either Tabasco, Chewing Gum or Vitamin C followed by RNA stabilization with the OrageneRNA kit and extraction with Trizol resulted in the highest quality and specificity of the RNA for its salivary gland origin. Unstimulated collection followed by the same processing generates a greater RNA yield. This saliva RNA is likely contaminated with RNA form squamous cells, bacteria and food residues, which may decrease the sensitivity of the specific gene expression of HTN3 and CA6. Once established how to best collect and protect saliva for the extraction of nucleic acids originated from the salivary glands, we anticipate accelerating the path to clinically highly demanded kits for the surveillance of salivary gland cancer patients. We plan to prospectively collect samples from Salivary gland tumor patients with the chosen method and evaluate tumor related markers. The detection of tumor markers in bodily fluids will open a new avenue for the diagnosis and the clinical management of patients with this type of tumor. Moreover, our work creates the possibility of a liquid biopsy-based detection of several disease-specific alterations identified in different types of salivary gland tumors.']",
        "Doc_id":"AACR_2017-734",
        "Doc_title":" Improved detection of salivary glands RNA markers in saliva samples.",
        "_version_":1606188985133039616},
      {
        "Meeting_name":" Tandutinib inhibits the PI3 Kinase/Akt/mTOR signaling pathway to inhibit colon cancer growth.",
        "Background":"['Background', ' Despite therapeutic advances, colon cancer remains the second leading cause of death in the United States. The c-Kit receptor can activate distinct signaling pathways including phosphatidylinositol-3- kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR). Aberrant c-Kit activation protects cells from apoptosis and enhances invasion of colon carcinoma cells. Tandutinib is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases including c-Kit and PDGFR. The current study is designed to determine the effect of tandutinib on colon cancer growth and identified a mechanism of action.Method', ' Colon cancer cell lines HCT116, HT-29 and SW480 and normal colon epithelial cells were used in the study. Cell growth was measured by hexoseaminidase and clonogenicity assays. Apoptosis was determined by measuring caspase 3/7 activities. Cell cycle analysis was measured by Flow cytometry. Signaling proteins were quantified by western blot analysis. For in vivo effects, HCT116 xenografts were developed in the flanks of nude mice. Immunohistochemistry was performed for CD31 and Akt/mTOR signaling proteins.Results', ' Tandutinib treatment resulted in a dose and time dependent inhibition of proliferation and colony formation in all three cell lines but did not affect normal colonic epithelial cells. Treatment also induced colon cancer cells to undergo apoptosis and G0/G1 arrest. Apoptosis was further confirmed by increased levels of activated caspase 3 and Bax/Bcl2 ratio, coupled with a reduction in cyclin D1. There was also a downregulation of cyclooxygenase 2 (COX-2), vascular endothelial growth factor (VEGF) and interleukin-8 expression suggesting effects on cancer promoting genes. Moreover, tandutinib inhibited phosphorylation of c-Kit, Akt, mTOR, p70S6 Kinase and 4EBP1. Overexpression of constitutively active Akt1 overcame this inhibitory effect suggesting a critical role for this pathway. To determine the effect of tandutinib on tumor growth in vivo, nude mice harboring HCT116 tumor xenografts in their flanks were administered the compound intraperitoneally every day for 21 days. Tandutinib treatment significantly suppressed tumor xenograft growth, with notably lower tumor volume and weight. Microvessel density, based on CD31 staining was also significantly lower in the tumors following tandutinib treatment when compared to controls suggesting inhibition of angiogenesis. Western blot and immunohistochemistry analyses demonstrated significant inhibition in the expression cancer promoting genes COX-2 and VEGF, and suppressed the activation of Akt/mTOR signaling proteins in the tandutinib-treated xenograft tissues.Conclusion', ' Together, these data suggest that tandutinib is a novel potent therapeutic agent that can target the Akt/mTOR/p70S6K signaling pathway to inhibit tumor growth and angiogenesis.']",
        "Doc_id":"AACR_2013-2584",
        "Doc_title":" Tandutinib inhibits the PI3 Kinase/Akt/mTOR signaling pathway to inhibit colon cancer growth.",
        "_version_":1606189017990168576},
      {
        "Meeting_name":" Imatinib mesylate in thymic epithelial malignancies.",
        "Background":"['Background', '   Study supported by Agenzia Italiana del Farmaco(AIFA code', ' FARM6HJ7CA). Thymic epithelial tumors (TETs) are rare tumors of the mediastinum, with an estimated incidence of about 3 cases per 100,000 inhabitants. Histologic types, defined by the WHO (A, AB, B1, B2, B3 and  Thymic carcinoma-TC), carry a variable prognosis, with TC being associated to the most aggressive clinical behavior. Anthracycline- and platinum-based chemotherapy is active in these tumors, but novel therapeutic options are still needed. Imatinib (Novartis Pharma) is a competitive inhibitor of BCR-ABL, KIT, PDGFRA, and PDGFRB tyrosine kinases. The rationale for its use in TETs lies in the high levels of expression of c-KIT reported in TC and for the reported efficacy of Imatinib in one case of TC (Stroebel, 2004). Methods', '  Phase II trial was initiated to deliver imatinib at 400 mg to a population of patients affected by TETs. Due to the low predicted accrual of patients with TC, patients with all histologic types of TETs were eligible for the trial. Radiographic responses were measured by CT scans performed every 3 months, according to the RECIST criteria. Toxicity was graded according to the CTC of the NCI, version 3.0. 15 patients with advanced TETs (most of them B2 or B3 thymoma, some of them with a squamous component) , who had been pretreated with at least one chemotherapeutic agent, were enrolled at the Department of Molecular and Clinical Oncology and Endocrinology of University Federico II of Naples from March, 2008 to July 2010. Results', '  One third of patients presented with thymic carcinomas. C-Kit was expressed only in some cases of TC, as revealed by immunohistochemistry. No mutations in the C-kit gene (exons 9-11-13 and 17) were found in the TC cases by mutational analysis.  Imatinib was overall well tolerated, with no toxicity-related death. Diarrhea and migraine were the most frequent events, occurring both in 20% of patients, but were manageable and mild. No radiographic responses were recorded. Median progression-free survival was 3 months (range, 2.75-4). Median overall survival was not reached. Conclusions', '  The study was terminated before it reached its target accrual of 42 patients, because of the lack of responses and low accrual rate. Imatinib seems to be not efficacy to treat TET.']",
        "Doc_id":"ASCO_82651-102",
        "Doc_title":" Imatinib mesylate in thymic epithelial malignancies.",
        "_version_":1606189026636726272},
      {
        "Meeting_name":" Differential gene expressions in primary gastric and intestinal gastrointestinal stromal tumors and metastatic liver tumors.",
        "Background":"['Background; Gastrointestinal stromal tumor (GIST) is known to originate from the interstitial cells of Cajal or its precursors with an activating mutation in the c-kit gene. On the other hand, it has been shown that micro GIST with c-kit mutation was commonly found in stomach resected for gastric cancer or in autopsy specimens. It seems that c-kit mutation initiates GIST and other genetic or epigenetic changes occur in the developmental process of GIST. In this study, we compared gene expression profiles among gastric and intestinal GIST as well as their metastatic liver tumors to identify the genes involved in the process of malignant transformation of GIST.Methods; Fresh frozen samples of primary gastric and intestinal GISTs and metastatic liver GISTs were used in the analysis. Total RNA was extracted and gene expression levels were compared by microarray analysis between 3 primary gastric GISTs and 4 metastatic liver GISTs, and among 6 primary gastric GISTs,3 primary intestinal GISTs and 6 metastatic liver GISTs. Protein levels of versican and CD9 were analyzed by immunohistochemistry in 104 primary gastric GISTs and13 metastatic liver GISTs.Results; Expression levels were higher for 165 genes and lower for 146 genes in metastatic liver GIST compared with primary gastric GIST. Among them, we further focused on two genes; versican and CD9, mRNA levels of which were higher and lower, respectively, in the metastatic liver GIST. Immunohistochemical analysis revealed that protein levels of versican and CD9 were higher and lower, respectively, in metastatic liver tumors compared with primary gastricGIST. High expression of versican and loss of CD9 expression correlated with shorter liver metastasis-free survival after gastrectomy. Microarray analysis of primary gastric and intestinal GISTs and metastatic liver GIST classified them into two groups according their gene expressions. One group consisted of primary gastric GIST without postoperative recurrence and the other consisted of clinically malignant GIST, intestinal GIST and metastatic liver GIST. These data suggest that intestinal GIST, regardless of presence of metastasis, shows gene expression profile similar to clinically malignant GIST and further to metastatic tumors and may explain mechanisms by which intestinal GISTs are more likely to show clinically malignant phenotype than gastric GISTs.Conclusions', ' Gene expression profile of primary intestinal GIST was similar to that in metastatic liver GIST but not to that in primary gastric GIST. Versican and CD9 could be potential prognostic markers of gastric GIST with which to predict the risk of postoperative liver metastasis.Citation Format', ' Hirotoshi Kikuchi, Tomohiko Setoguchi, Shinichiro Miyazaki, Ichirota Iino, Yoshihiro Hiramatsu, Kinji Kamiya, Manabu Ohta, Takanori Sakaguchi, Hiroyuki Konno. Differential gene expressions in primary gastric and intestinal gastrointestinal stromal tumors and metastatic liver tumors. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 405. doi', '10.1158/1538-7445.AM2013-405']",
        "Doc_id":"AACR_2013-405",
        "Doc_title":" Differential gene expressions in primary gastric and intestinal gastrointestinal stromal tumors and metastatic liver tumors.",
        "_version_":1606189026047426560},
      {
        "Meeting_name":" Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers",
        "Background":"['Background', '    Modern radiotherapy (RT) techniques such as protons permit delivery of ablative doses of RT to the liver. Prior reports of PBT in hepatocellular carcinoma (HCC) demonstrate local control (LC) rates exceeding 85% but outcomes with high dose RT in pts with ICC remain lacking. We report on clinical outcomes of high dose, HF-PBT in pts with unresectable ICC.  Methods', '    Pts enrolled on an NCI sponsored, multi-institutional, phase II study (NCT00976898). Key eligibility were HCC or ICC, unresectable by multidisciplinary review, Childs A/B, ECOG PS 0-2, no extrahepatic disease, no prior RT. Maximum tumor size was 12 cm if solitary, 10 cm if 2 tumors, and 6 cm if 3. PBT was given in 15 fractions to a maximum total dose of 67.5 GyE. Sample size was calculated to demonstrate > 80% LC at 2 yrs for HCC pts with acceptable precision for estimating outcomes for ICC.  Results', '    From 2009-2014, 93 pts were enrolled, of whom 90 were evaluable. 41 pts had ICC, 2 pts had mixed HCC/ICC, and 47 pts had HCC (reported separately). In this ICC specific-analysis (n = 43), median age was 67 (range 29-87), 16 (37%) were male. 36 (84%) and 5 (12%) pts had Child-Pugh A and B cirrhosis, respectively. 2 (4%) pts had no cirrhosis. 25 (58%) pts had prior systemic therapy. 25 (58%) pts had prior systemic therapy. 39 pts(90.6%)  had 1 tumor, 2 pts (4.7%) had 2 , 2 pts (4.7%) had 3 . Median tumor size was 6.0 cm (range 2.2-10.9). Median RT dose received was 58 GyE (range 15.1-67.5). 6 (14%) pts developed Gr 3 RT-related toxicity, including thrombocytopenia (2), hyperbilirubinemia (2), gastric ulcer (1), pain (1), elevated LFTs (1), and liver failure/ascites (1). With a median follow up of 13 months (range 5d51 mo) among 22 pts still alive, the 2 year LC was 96%. mOS was 21 months (95% CI 13-29) and mPFS was 9 months (95% CI 6-24). When excluding Childs B (N = 38), mOS was 23 months (95% CI 15-49) and mPFS was 10 months (95% CI 5-24); 2 yr OS rate was 48% and 2 yr PFS rate was 38%.  Conclusions', '    High dose PBT for ICC results in high rates of LC and OS. This data forms the basis for the ongoing NRG GI-001 study, a randomized trial of gem/cis +/- hypofractionated RT.  Support', ' NCI # P01CA2123 Clinical trial information', ' NCT00976898']",
        "Doc_id":"ASCO_151769-156",
        "Doc_title":" Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers",
        "_version_":1606188980613677057},
      {
        "Meeting_name":" Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.",
        "Background":"['Background', ' Regorafenib is a novel diphenylurea oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR- , FGFR), and oncogenic kinases (KIT, RET, RAF). In in vivo models, regorafenib has demonstrated a broad spectrum of antitumor activity. Regorafenib administration (21 days (d) on/7 d off dosing) resulted in a 31% partial response (PR) rate in a phase II study in patients (pts) with metastatic renal cell cancer. Methods', ' This phase I dose-escalation study assessed the safety, pharmacokinetics (PK), and efficacy of regorafenib, given orally, once daily in continuous cycles of 21 d, until discontinuation due to toxicity or tumor progression. PK was assessed on d 1 of cycles 1 and 2. Tumor response was evaluated by RECIST. Results', ' Thirty-eight pts with solid tumors and progressive disease were enrolled and treated with doses of 20-140 mg. Frequent tumor types included colorectal (16%), thyroid (13%), adenoid cystic carcinoma (13%), and head and neck cancer (13%). The median treatment duration was 73 d. Drug-related adverse events (all grades, >20% of pts) were rash/desquamation (50%; CTC 3, 3%), hand-foot skin reaction (32%; CTC 3, 11%), fatigue (32%, CTC 1-2 only), extremity pain (29%; CTC 3, 5%), mucositis (24%; CTC 1-2 only), and diarrhea (21%; CTC 3, 3%). DLTs in cycles 1-2 occurred in 2/11 pts at 100 mg (skin toxicity n=1; anemia/thrombocytopenia n=1), 3/6 pts at 120 mg (skin toxicity n=2; thrombocytopenia n=1), and 4/10 pts at 140 mg (skin toxicity n=2; diarrhea n=1; hyperbilirubinemia/AST increase n=1). Steady state exposure of regorafenib increased from 20-140 mg, while exposure of the active metabolites M2 and M5 increased more than dose- proportionally. Two out of 36 evaluable pts achieved a PR (6%; neuroendocrine pancreas carcinoma and squamous-cell carcinoma periorbital) and 22 pts (61%) had stable disease (SD) 6 wk, including one pt with hepatocellular carcinoma and SD of 90 wk. Conclusions', ' Regorafenib was well tolerated and the MTD when administered as once-daily continuous dosing is 100 mg. Clinical activity (PR+SD) was demonstrated in 67% of evaluable pts and an extension cohort at 100 mg is ongoing.']",
        "Doc_id":"ASCO_52786-74",
        "Doc_title":" Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.",
        "_version_":1606189002103193600},
      {
        "Meeting_name":" ALDH1A1 is the best marker by a composite approach for cancer stem cells in ovarian cancer whose integrity is controlled by the hedgehog pathway",
        "Background":"['Cancer Stem Cells (CSCs) express distinct surface markers and have unique functional properties that distinguish them from the rest of the cells in a tumour. There have been variability in the identity of CSC markers in serous adenocarcinoma of the ovary. We have taken a composite approach for evaluating surface markers together with functional assays in primary tumours (n = 20). Expression of CSC markers were evaluated by flow cytometry, immunofluorescence (IF) and immunohistochemistry (IHC) in cell lines (n = 8), primary malignant cells (PMC, n = 20) and normal ovary (n = 2). The ALDEFLUOR assay was used to identify CSCs individually (n = 20) and together with surface markers (n = 6). PMC (n = 5) were grown as spheroids to evaluate expression of markers and ALDEFLUOR assay (n = 3). The role of signaling by Notch, Wnt and Hedgehog pathways were evaluated to ascertain maintenance of CSCs in the spheroid model (n = 3) using specific small molecule inhibitors. PMC (n = 20) were grown in the presence or absence of inhibitors for 2 weeks and CSC markers evaluated to ascertain specificity of effect along with motility assays. We identified 3 novel surface markers in silico (CD9, CD24 and EPHA1) in addition to those previously detected (CD133, CD117, CD44). The surface markers CD117 and CD9 were expressed in ovarian surface epithelium. CD117, CD9 and ALDH1A1 also showed expression in the fallopian tube by IHC. PMC expressed individually CD44 (57.73.2), CD117 (12.56.1), CD133 (09.73.9), CD9 (11.17.2), CD24 (34.64.9), Epha1 (16.43.1) by flow cytometry. Co expression of markers in the same cells (n = 20) were (11.335.32). PMC expressed ALDH1A1 (2.50.2) and a fraction of these cells co-expressed CSC surface markers (2.09  0.08). ALDH1A1 expressing malignant cells (n = 5) were predominantly in G0/G1 phase (67.22.6) of the cell cycle. Spheroids expressed all the above CSC markers by IF. In addition, ALDH1A1 was expressed in spheroids suggesting that these are enriched for CSCs. Spheroid formation in OVCAR3 and UC1101 cells was inhibited completely by the Hedgehog pathway inhibitor (SMO) GDC0449 (3M). Flow cytometry analysis of PMC showed significant reduction in expression of ALDH1A1 (2.50.9), CD44 (18.65.5), CD9 (1.60.8), CD133 (0.50.3), CD117 (18.813.4), CD24 (0.10) after incubation with GDC0449. Similar results were obtained with two other inhibitors, LDE225 (SMO, 2.5nM) and GANT61 (Gli, 5M). Significant reduction in migration of PMC was observed in the scratch assay in the presence of inhibitors. These results demonstrate that ALDH1A1 expression is consistently low in PMC and is the most reliable marker for CSCs. There was wide variability of expression of the surface markers in PMC and none uniquely co-expressed with ALDH1A1. The hedgehog signaling pathway is important in maintaining the integrity of CSCs. Targeting components of this pathway may be an alternate approach for treating ovarian cancer.']",
        "Doc_id":"AACR_2015-1392",
        "Doc_title":" ALDH1A1 is the best marker by a composite approach for cancer stem cells in ovarian cancer whose integrity is controlled by the hedgehog pathway",
        "_version_":1606188990585634816},
      {
        "Meeting_name":" The evolution of diverse cancer stem cells in human liver cancer.",
        "Background":"['Cancer stem cells (CSCs) are considered a pivotal target for the eradication of liver cancer. CSCs have been identified by the use of various stem cell markers; however, it remains unclear how individual CSC markers are expressed in individual tumors. We hypothesized that the distinct marker-positive CSCs show unique features of tumorigenicity/metastasis and chemosensitivity which may reflect the heterogeneous nature of hepatocellular carcinoma (HCC). Gene expression profiling and immunohistochemistry analyses were used to analyze 364 tumor specimens. Fluorescence-activated cell sorting (FACS) was used to isolate marker-positive HCC cells, which were tested for hepatic stem/progenitor cell properties. CSC markers EpCAM and CD90 are independently expressed in primary liver cancer. EpCAM+ cells share features with tumorigenic epithelial stem cells, whereas CD90+ cells share those of metastatic vascular endothelial cells with expression of c-Kit. CD90+ cells facilitate metastasis of EpCAM+ cells through activation of TGF-beta signaling, and this effect is abolished by c-Kit inhibitor imatinib mesylate. These distinct tumorigenic/metastatic CSCs can evolve from marker-negative cells de novo, and their frequencies vary dramatically according to the genomic alterations and genotoxic stress. Our results suggest that liver CSCs are not a single, static entity but rather exist heterogeneously and undergo dynamic changes through genomic alteration and genotoxic stress. The evolution of CSCs explains the enrichment of CSCs in advanced cancer and the limitation of targeting marker-positive CSCs alone for tumor eradication.']",
        "Doc_id":"AACR_2013-262",
        "Doc_title":" The evolution of diverse cancer stem cells in human liver cancer.",
        "_version_":1606189029929254912},
      {
        "Meeting_name":" A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers",
        "Background":"['Background', '  Retrospective reports of PBT in hepatocellular carcinoma (HCC) demonstrate local control (LC) rates exceeding 85%. We prospectively replicate these findings and explore predictors of overall survival (OS) in pts with unresectable HCC receiving high dose, HF-PBT.  Methods', '  Pts were enrolled on an NCI sponsored, multi-institutional, phase II study (NCT00976898). Key eligibility were unresectable HCC; Childs A/B; ECOG PS 0-2; no extrahepatic disease; no prior RT. Maximum tumor size was 12 cm if solitary, 10 cm if 2 tumors, and 6 cm if 3. PBT was given in 15 fractions to a maximum total dose of 67.5 GyE. Sample size was calculated to demonstrate > 80% LC at 2 yrs (LC-2).  Results', '     From 2009-2015, 44 patients were treated. Median age was 70 years (53-89) and 37 (84.1%) were male. 35 (79.5%) pts had Child A or no cirrhosis. 32 (72.7%) pts had 1 tumor, 12 (27.2%) had multiple tumors. Median longest tumor dimension was 5.0 cm (range 1.9-12.0). Median baseline AFP was 18.6 ng/mL (range 1.3-66081) and 29 pts (67.4%) had elevated AFP ( > 7.9 ng/mL). Median RT dose delivered was 58.0 GyE (range 40.5-67.5). 1 pt (2%) had grade 3 RT related toxicity (thrombocytopenia). With a median follow up 21.8 mo among 28 survivors, the LC-2 was 94.8% (95% CI 84.5-99.1%). mOS was 49.9 mo (95% CI 17.8 months- upper limit not reached) and mPFS was 13.9 mo (95% CI 8.4-49.9). OS did not differ by CLIP score, PS, prior treatment, vascular thrombus, baseline AFP, size, or dose. Median AFP change from baseline to 3 mo post treatment was a 32.8% reduction. Median time to AFP nadir in pts with elevated baseline levels was 3.9 mo (0-30.5). % decrease in AFP from baseline to 6 mo post-treatment was significantly associated with lower hazard of death. (HR = 0.993, p = 0.016).  Conclusions', '  High dose hypofractionated proton beam therapy demonstrated a high local control rate for HCC with favorable safety profiles, supporting the ongoing evaluation of radiation in HCC in phase III studies. AFP decrease from baseline to 6 months post-radiation is associated with improved overall survival. Clinical trial information', ' NCT00976898']",
        "Doc_id":"ASCO_159771-173",
        "Doc_title":" A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers",
        "_version_":1606189008534110208},
      {
        "Meeting_name":" Imatinib-induced changes in gene expression and the metastatic potential of human breast carcinoma cells.",
        "Background":"['Background', ' Imatinib mesylate (imatinib) is a potent and selective inhibitor of the tyrosine kinases, Bcr-Abl, c-Kit and platelet-derived growth factor receptors (PDGFRs). Since its advent for the successful treatment of chronic myelogenous leukemia in 2001, the clinical efficacy of imatinib has been investigated in many other human malignancies, including breast cancer. Based on recent reports that chemotherapy selects more invasive and metastasizing cells, we have hypothesized that exposure of breast cancer cells to imatinib could enhance their malignant behavior. Methods', ' MA-11 breast carcinoma cells, originating from bone marrow micrometastases, were exposed to imatinib in vitro for seven days. After four days of recovery in drug-free medium, biological properties and gene expression pattern were compared with those of the parental cell line. In a separate set of experiments, the effects of in vivo administration of imatinib to athymic nude (nu/nu) mice carrying MA-11 tumors were investigated. Results', ' In vitro, imatinib treatment increased the motility and invasiveness of the breast cancer cells, and induced over-expression of drug transporters and of a set of genes associated with aggressive and metastatic behavior (Table). In vivo, nu/nu mice subcutaneously implanted with MA-11 cells and treated with nine daily intraperitoneal doses of 60 mg/Kg imatinib developed with greater frequency distant organ metastases vs. control mice implanted with MA-11 and treated with the vehicle alone. Conclusions', ' Our data caution against the clinical use of imatinib in breast cancer; imatinib-selected breast cancer cells represent an important tool to investigate the pro-metastatic role of differentially expressed genes.Entrez Gene IDEntrez SymbolMicroarray Fold ChangeRT-PCR Fold Change 22943NTS6.910 4804DACT14.05.0 4897FAIM22.510 28513ABCC32.23.3 1000COP12.22.5 558CASP91.92.0 3725PCDHGA115.25.0 4035CACNA1G2.21.7 51339MMP91.61.3']",
        "Doc_id":"ASCO_30318-65",
        "Doc_title":" Imatinib-induced changes in gene expression and the metastatic potential of human breast carcinoma cells.",
        "_version_":1606188984153669632},
      {
        "Meeting_name":" TGF-/SMAD2 signaling drives tumor-progression via c-KIT/STAT3-signaling in advanced HCC",
        "Background":"['Background', ' Current systemic agents for advanced Hepatocellular carcinoma (HCC) achieve minimal survival benefits. Tumor Growth Factor- (TGF-) is a potent tumor suppressor via its SMAD2/3 signaling axis; its inactivation has been implicated in hepatocarcinogenesis. Paradoxically, TGF- serum concentrations are elevated in patients with advanced HCC. The TGF- receptor is currently explored in clinical trials as a therapeutic target. However, the mechanisms mediating the functional switch of the TGF- pathway to an oncogenic role in advanced HCC are unknown.Material and Methods', ' Gene expression profiling of human HCC was performed using the Oncomine database. Immunohistochemical analysis of human HCC samples was performed using Tissue Micro Arrays. Established human HCC cell lines were used for in vitro studies. Gene expression was assessed by qRT-PCR, ELISA and immunoblot analyses. shRNA was used for gene silencing. Cell cycle analysis was performed by FACS. Cell proliferation was assessed by microscopic quantification, MTS- and BrdU-assay. Apoptosis was analyzed by TUNEL assay and DAPI. Migration was evaluated by wound assay, and invasion by Boyden Chamber assay.Results', ' In human HCC, SMAD2 overexpression and decreased expression of the negative TGF-/SMAD regulator SKI was correlated to shortened survival. Intranuclear pSer465/467-SMAD2 was identified in up to 65% of human HCC tumors, and correlated with TNM-stage, survival and pTyr705STAT3. In 50% of human HCC cell lines, the TGF-/SMAD2 axis was functional. Exclusively in HCC cells with intact SMAD-signaling, TGF- induced STAT3 Tyr705-phosporylation and nuclear translocation. We show that TGF-1 transcriptionally regulates expression of the c-KIT ligand Stem Cell Factor (SCF). SCF is overexpressed in advanced HCC tumors, and correlated to pSMAD2, metastases and decreased survival. In human HCC cells, SCF activates STAT3 via auto- and paracrine stimulation of its cognate receptor c-KIT. TGF-1-induced activation of STAT3 is inhibited by SCF-knockdown, inhibition of c-KIT or JAK1. The TGF-1/STAT3 axis neutralizes the cell cycle inhibitory function of TGF- in human HCC cell lines, and instead promotes EMT, tumor cell migration and invasion. Disruption of the TGF-/STAT3 signaling axis inhibits its tumor promoting effects and restores TGF- antiproliferative effects.Conclusion', ' In advanced HCC, TGF-/SMAD2-signaling is constitutively activated and correlated to worse outcomes. The functional switch of TGF- is mediated through aberrant expression of SCF with subsequent stimulation of the c-KIT/STAT3 signaling axis. Disruption of this axis restores TGF- tumor suppressor function. Disruption of the molecular network between TGF-1/SMAD2 and SCF/STAT3 constitutes a novel therapeutic strategy aiming at restoration of a dysregulated tumor suppressor.']",
        "Doc_id":"AACR_2015-1962",
        "Doc_title":" TGF-/SMAD2 signaling drives tumor-progression via c-KIT/STAT3-signaling in advanced HCC",
        "_version_":1606188987837317120},
      {
        "Meeting_name":" Assessing the efficacy of the anti metabolic drug, CPI-613, for targeting of ovarian cancer stem cells",
        "Background":"[\"Cancer stem cells (CSC) are believed to contribute to the recurrent and often platinum resistant ovarian cancer (OvCa). Moreover, it has been suggested that some anticancer treatments result in an increased frequency of CSC relative to non-CSC. More recently, we have determined that the PARP inhibitor olaparib increased the frequency of CD133, CD117 and ALDH positive cells in the established serous OvCa cell lines OVCAR4 and CaOV4 and in primary cell lines derived from serous carcinomas obtained with IRB approval at the time of initial surgery. We also showed that olaparib treatment increased sphere forming capacity, expression of stemness genes and CSC proliferation suggesting that olaparib has the unintended effect of stimulating CSC function. Previous work has shown that the metabolic inhibitor CPI-613 preferentially targets ovarian CSCs due to their altered metabolism. Our objective here was to determine whether CPI-613 could negate the effect of olaparib on CSC function.OVCAR4 and CaOV4 cells were treated with 50 M CPI-613 and the relative frequency of CD133+ and CD177+ cells was assessed at 72 hours post treatment by flow cytometry with cell viability analyzed by MTT. Additionally, the sphere forming capacity of CPI-613 treated cells relative to that of vehicle treated cells was determined in an extreme limiting dilution assay. Finally, the expression of stemness genes in the CPI-613 treated and vehicle treated cells was evaluated by RT-PCR.Treatment of OVCAR4 and CaOV4 cells with CPI-613 decreased the frequency of CD133+ and CD117+ positive cells relative to untreated cells (p <0.001) without affecting cell viability. Additionally, sphere forming capacity was reduced in the CPI-613 treated cells. The decrease in both CD133+ and CD117+ cell frequency and sphere forming capacity suggests that CPI-613 is targeting the CSC population in these cells. Dual treatment with olaparib and CPI-613 blunted the increase in CD133+ and CD117+ cell frequency induced by single agent olaparib. Parallel treatment of CSC-rich spheres resulted in a considerable decrease in cell viability and frequency of CD133+ and CD117+ cellsClinical trials with olaparib in OvCa have resulted in increased progression free survival but no significant difference in overall survival has been observed. This raises the question of whether treatment with olaparib selects for the recurrence of more resistant disease, driven in part by the proliferation of CSCs. Our results suggest that CPI-613-mediated disruption of the mitochondrial respiratory pathway preferentially targets CSC and suppresses olaparib's effects on CSC function. In conclusion, targeting CSCs with non-traditional strategies could augment clinical outcomes and CPI-613 represents a promising candidate for combination with FDA approved olaparib treatment in OvCa.\"]",
        "Doc_id":"AACR_2016-2504",
        "Doc_title":" Assessing the efficacy of the anti metabolic drug, CPI-613, for targeting of ovarian cancer stem cells",
        "_version_":1606189022047109121},
      {
        "Meeting_name":" Stage 1 in vivo evaluation of multi-receptor tyrosine-kinase inhibitor lenvatinib in osteosarcoma patient derived mouse xenograft models.",
        "Background":"['Background', ' Osteosarcoma (OS) is the most common primary bone tumor in children and young adults. Over the past three decades improvement in outcomes for children with OS have remained stagnant. Novel therapies are needed to improve outcomes for these patients. Lenvatinib is an oral small-molecule tyrosine-kinase inhibitor (TKI), targeting multiple receptors including VEGFR1-3, FGFR 1-4, PDGFR, RET, and c-kit. Prior studies have shown that PDGFR-VEGF/VEGFR and FGFR3 are overexpressed in human OS cell lines. Lenvatinib is FDA-approved for the treatment of differentiated thyroid cancer, and, in combination with mTOR inhibitor everolimus, for the treatment of renal cell carcinoma. The current study assessed the in vivo efficacy of lenvatinib in osteosarcoma xenograft models.']",
        "Doc_id":"AACR_2017-697",
        "Doc_title":" Stage 1 in vivo evaluation of multi-receptor tyrosine-kinase inhibitor lenvatinib in osteosarcoma patient derived mouse xenograft models.",
        "_version_":1606189019662647296},
      {
        "Meeting_name":" A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens.",
        "Background":"['Background', '  Famitinib is an oral, small molecular multiple tyrosine-kinase inhibitor (TKI), targeting stem cell growth factor receptor (c-Kit), platelet derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR). So far, few target therapies show acceptable efficiency in advanced recurrent and/or metastatic nasopharyngeal carcinoma (RM-NPC) patients. The primary object of this study is to determine the safety and efficacy of famitinib in patients with RM-NPC. Methods', '  This study recruited histologically diagnosed RM-NPC patients who failed more than two lines of systemic chemotherapy. Other eligible criteria included ECOG PS2, adequate organ function and no prior exposure to other c-Kit, PDGFR or VEGFR TKIs. The patients received famitinib orally at a dose of 25 mg once daily until the disease progression or intolerable toxicity.  Results', '  From May 2011 to Sep 2012, 58 patients (Simons two-stage design, 28+30) were recruited at 8 sites in China. The clinical benefit rate (partial response or stable disease maintained12 weeks, tumor response was evaluated every 4 weeks) is 32.8%, including 5 PR and 16 SD patients. Median PFS was 3.2 months. The most frequently observed hematologic toxicities included thrombocytopenia, leucopenia and neutropenia; non-hematologic AEs were hypertension, proteinuria, and hand-foot syndrome. All adverse events were generally mild-to-moderate (grade 1/2) and manageable with supportive treatment; grade 3/4 incidence was relatively low.  Conclusions', '  This phase II study shows that famitinib demonstrates substantial clinical benefits in patients with advanced RM-NPC and the drug-related adverse reactions were most predictable and tolerable, no special toxicity was reported. Biomarker analysis for responder and non-responder is still ongoing and will be present at the meeting. Clinical trial information', ' NCT01392235.']",
        "Doc_id":"ASCO_116681-132",
        "Doc_title":" A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens.",
        "_version_":1606188974026522624},
      {
        "Meeting_name":" Dual role of mast cells in prostate tumors.",
        "Background":"['Prostatic carcinoma is most often a multifocal disease, with areas of localized, well-differentiated adenocarcinomas coexisting with poorly differentiated lesions within the same tumor. Mast cells (MC), classically known as the primary responders in allergic reactions, have been recently indicate of prognostic value in prostate cancer. We have evidence of a dual role of MC in prostate cancer. Within the same human tumor, MC are specifically enriched and degranulated in areas of adenocarcinoma, whereas few around anaplastic foci. This observation has been confirmed in tumors from TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice, and in two novel tumor cells lines, derived from them, phenocopying well and poorly differentiated adenocarcinoma', ' T1525 and T23, respectively. MC promote the growth of the well-differentiated adenocarcinoma T1525 that does not develop when transplanted into MC-deficient mice, or when MC degranulation is pharmacologically inhibited with sodium cromoglycate. In particular, mast cells are essential for the outgrowth of early-stage tumors due to their matrix metalloproteinase-9 production, become dispensable in advanced-stage, post-epithelial-to-mesenchymal transition, and are protective against neuroendocrine prostate tumor variants. Indeed, pharmacological inhibition or genetic ablation of MC in TRAMP mice results in early development of undifferentiated tumors characterized by marked anaplasia, suggesting that the growth of anaplastic clones may be antagonized by MC.Our data demonstrate that MC can influence the histotype of tumor arising from the prostate and that their targeting may change tumor outcome. As a possible corollary, MC depletion might favor the growth of more undifferentiated and aggressive variants. The common expression of c-Kit by mast cells and neuroendocrine clones suggests a possible competition for the ligand Stem Cell Factor and offers the chance of curing early-stage disease while preventing neuroendocrine tumors using c-Kit-targeted therapy.']",
        "Doc_id":"AACR_2013-2877",
        "Doc_title":" Dual role of mast cells in prostate tumors.",
        "_version_":1606188999135723520},
      {
        "Meeting_name":" The upregulation of cyclooxygenase-2 protein expression by receptor tyrosine kinase inhibitors in bladder cancer in vitro",
        "Background":"['Several types of cancer, including transitional cell carcinoma (TCC) overexpress several receptor tyrosine kinases (RTKs), including the platelet-derived growth factor receptor (PDGFR), c-kit receptor, epidermal growth factor receptor (EGFR), as well as the vascular endothelial growth factor receptor (VEGFR). Receptor tyrosine kinase inhibitors (RTKIs) are used as targeted therapies for patients diagnosed with cancer with high expression of RTKs. Cyclooxygenase-2 (COX-2) is highly expressed in bladder cancer as well other types of cancers and is one of the key proteins during tumorigenesis. In this study, we validated the effects of RTKIs, Masitinib (AB1010) and Axitinib on cell proliferation of human (UMUC-3 and T24) and canine (K9TCC#1Lillie, K9TCC#2Dakota, and K9TCC#5Lilly) bladder TCC cells. Using WB analysis, tested human and canine TCC cells, except T24 cells, expressed PDGFR and c-kit receptors. There was no detectable EGFR and VEGFR expressions in any of tested cells by WB analysis. The K9TCC#1Lillie and K9TCC#5Lilly cells had a high expression of COX-2, however K9TCC#2Dakota and human T24 had moderate expression of COX-2, and no COX-2 expression was detected in UMUC3 cells by WB analysis. Both RTKIs, Masitinib and Axitinib inhibited cell proliferation of the tested human and canine bladder TCC cells in a dose-dependent manner by MTS and apoptosis assays. Interestingly, both tested RTKIs, Masitinib and Axitinib increased COX-2 protein expressions in tested canine TCC cells. Combined treatment of RTKIs with COX-2 inhibitors decreased cell proliferation of tested TCC cells more effectively as either treatments alone. Our results indicate a possible role of COX-2 signaling pathway in developed RTKIs-resistance in bladder cancer cells in vitro. Co-treatment of RTKIs with COX-2 inhibitors might indicate better clinical outcomes in treatments of patients diagnosed with bladder cancer.']",
        "Doc_id":"AACR_2016-4739",
        "Doc_title":" The upregulation of cyclooxygenase-2 protein expression by receptor tyrosine kinase inhibitors in bladder cancer in vitro",
        "_version_":1606189033919086592},
      {
        "Meeting_name":" HSP90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression",
        "Background":"['Background', ' The heat shock protein 90 (HSP90), a molecular chaperone, has provoked great interest as a promising molecular target for cancer treatment, since it is involved in regulating the conformation, stability and functions of key oncogenic proteins. At present, a variety of chemical compounds targeting HSP90 have been developed and have shown convincing anti-neoplastic activity in various preclinical tumor models. Several inhibitors of HSP90 have been reported exhibiting more antitumor efficacy in PTEN-null tumor xenograft. The aim of our study was to evaluate the antitumor effects of a novel HSP90 inhibitor, NVP-AUY922, in human malignant cells, especially in PTEN-null cancer cells. Materials and Methods', ' Human esophageal cancer (TE-1, TE-4, TE-8, TE-10), gastric cancer (NUGC-3, NUGC-3/IL), pancreatic cancer (PANC-1, MIAPACA-2, Bxpc3) and mutant c-kit-driven lymphocytes (Ba/F3-KE11, Ba/F3-K642, Ba/F3-820Mz), mimicking gastrointestinal stromal tumor cells, were examined. WST assay and/or trypan blue exclusion assay were conducted to assess the anti-proliferation effects of NVP-AUY922 in those cells mentioned above. The activity of cell growth-related molecules such as AKT, ERK, and PTEN were investigated by western blot analysis. Genetic modification using siRNA and expression vector were applied for silencing and overexpression of PTEN, respectively, in cancer cells. Results', ' Cell viability assays showed that NVP-AUY922 potently inhibits the proliferation of human cancer cell lines, regardless of 5-FU resistance or c-Kit mutation, by which the sensitivity to imatinib can be affected. PTEN-null TE-4 cells exhibited more sensitivity to NVP-AUY922. Interestingly, The sensitivity to NVP-AUY922 was increased by silencing PTEN expression in intact PTEN-expressing TE-10 cells and decreased by exogenous transduction of PTEN in TE-4 cells. Furthermore, NVP-AUY922 significantly inhibited the activity of AKT and ERK in TE-4 cells, but not in TE-10 cells. Conclusion', ' Inhibition of Hsp90 function by NVP-AUY922 exhibited strong cytotoxicity against most of the cancer cells, including some anticancer drug-resistant cells, revealing its potential for a novel therapeutic alternative to cancer treatment. In addition, this study suggests that the expression status of PTEN determines the sensitivity to HSP90 inhibitor for cancer treatment.']",
        "Doc_id":"AACR_2012-2771",
        "Doc_title":" HSP90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression",
        "_version_":1606189016838832128},
      {
        "Meeting_name":" An underinvestigated toxicity of sunitinib",
        "Background":"['Background', ' Sunitinib, a multitargeted receptor tyrosine kinase inhibitor represents a standard firstline therapy for advanced renal cell carcinoma. Red blood cell (RBC) macrocytosis (with or without anaemia) is a recognized haematological toxicity but its aetiology remains uncertain. Methods', ' The medical records of 73 patients (55 male, 18 female) patients treated with sunitinib between 2007 and 2010 at Poole and Bournemouth NHS Trusts, UK were reviewed. Patient demographics, length of treatment, response, RBC mean cell volume (MCV) indices, and known causes of macrocytosis including B12 and folate deficiency and hypothyroidism were examined. Results', ' Median duration of treatment was 6 months (range 0-30). 38 (51%) have died. 24 (32%) received 2 or less cycles of treatment with the majority stopping due to early progression or death. 30 patients (41%) developed macrocytosis on treatment, but a trend to macrocytosis was identified in most patients positively correlating to time on treatment. 26 (87%) had a macrocytic anaemia. Median time to onset of macrocytosis was 4 months (range 1-11 months). Of the 30 macrocytic patients; 5 were hypothyroid, 7 had untreated borderline hypothyroidism and 13 were euthryoid throughout. Of patients tested to date 1 patient was found to be serum folate deficient at 2.5 ug/L (3-17). Supplementation corrected the macrocytosis. 1 patient was found to be serum B12 deficient; 53 ng/L (180-900) without any obvious comorbid cause. Further retrospective evaluation of other parameters such as red cell folate and reticulocyte count are currently being carried out. Conclusions', ' A significant proportion of patients on sunitinib (41%) develop macrocytosis. On the basis of this case series, the largest to date, underlying causes of macrocytosis (with or without anaemia) appear multifactorial. Biochemical hypothyrodism is common following sunitinib treatment and is likely to represent one of several possible contributing factors. B12 and folate deficiency should not be forgotten as a potentially reversible cause of macrocytosis secondary to sunitinib. C-kit inhibition by sunitinib is a potential mechanism, paralleling the potential C-kit mediated macrocytosis commonly recognised in imatinib therapy.']",
        "Doc_id":"ASCO_72591-104",
        "Doc_title":" An underinvestigated toxicity of sunitinib",
        "_version_":1606188992560103425},
      {
        "Meeting_name":" Genomic medicine using NexGen sequencing to personalized treatment of metastatic adenoid cystic carcinoma (ADCC).",
        "Background":"['Background', 'ADCC is a form of cancer usually originating from saliva gland. The standard treatment is surgical resection followed by adjuvant radiation if indicated. Cases of metastatic disease can behave indolently but ultimately can be fatal and there is no effective therapy. We present the results of NexGen sequencing of a 41yo caucasian female diagnosed with ADCC in 2003 who subsequently developed recurrence in 2005 and pulmonary metastases in 2006. She was treated with multiple agents including radiation. She had further progression with increase dyspnea in 2012. Commercial profiling by Caris Biosciences found expression of VEGFR, PDGFRA and PDGFRB. She was treated with Sorafenib, an oral multikinase inhibitor of the VEGFR, PDGFR, and BRAF without improvement, and she developed further dyspnea requiring oxygen. We performed NexGen sequencing of a biopsied metastatic lesion to identify somatic mutations and to determine if any targeted agent would be of further benefit. Results', ' NextGen sequencing was performed on DNA extracted from formalin-fixed tumor biopsy sample. Blood DNA served as control. Using Illumina TruSeq Exome Enrichment kit, 100 bp paired-end sequencing was performed on the tumor and normal exomes. Resulting sequences were mapped to the Human Reference Genome (hg19) using two bioinformatics workflows', \" CLC Genomics Workbench and BWA/GATK. Single nucleotide variants (SNVs) and small insertions/deletions (INDELs) were separately characterized for normal and tumor exomes. Finally, germline variants (SNVs and INDELs) were subtracted to identify putative somatic mutations in tumor exome. Concensus somatic mutations were obtained from CLC and BWA/GATK workflows. A total of 569 non-synonymous mutations and 35 stopgain mutations were observed in the tumor exome. Mutations in BRCA2, IGF1R, KDR, MTOR, TP63, XPC, RAD17, MLH1, and PTEN were observed in the tumor exome. Mutations in the components of kinase-mediated signaling (IGF1R, KDR, MTOR, PTEN) are potential targets of kinase and mTOR inhibitors whereas mutations in the DNA repair pathways (TP63, XPC, RAD17, MLH1) may be targeted with DNA alkylating agents. The result indicates that patient's tumor harbor several mutations that can be targeted by available cancer drugs. Conclusions\", ' We found several mutated molecular pathways that can be targeted with available agents using exome sequencing. Improvement in outcome could validate the role of exome sequencing in treatment selection of advanced cancers without standard therapy.']",
        "Doc_id":"AACR_2013-2008",
        "Doc_title":" Genomic medicine using NexGen sequencing to personalized treatment of metastatic adenoid cystic carcinoma (ADCC).",
        "_version_":1606189012826980353},
      {
        "Meeting_name":" Vemurafenib-induced RhoB expression leads to melanoma cell resistance.",
        "Background":"['Most of melanoma harbour mutations leading to the constitutive activation of the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) pathway (i.e', ' activating mutations of BRAF, NRAS, c-KIT). Addiction of melanoma to the MAPK pathways led to the development of inhibitors targeting either mutant BRAF, such as Vemurafenib (PLX4032), or MEK. Melanoma treatment recently met a breakthrough with the clinical evaluation of Vemurafenib that demonstrated an unprecedented 80% response rate among patients with BRAF V600E melanomas treated with Vemurafenib, but rapidly limited by drug resistance, which still requires to be elucidated.The MAPK pathway regulates the expression of many genes which can mediate therapeutic response but also resistance, such as RhoGTPases. We analysed the mRNA expression of the RhoGTPases in two BRAF mutated melanoma cell lines, WM266-4 and A375, in response to inhibition of the MAPK pathway by PLX4032. We observed that the mRNA of RhoB was increased by PLX4032 treatment. This result was confirmed in many other BRAF mutated melanoma cell lines by inhibition of the MAPK pathway with BRAF inhibitors (PLX4032 or SB-590885) as well as MEK inhibitors (AZD6244 or AS703026). MEK inhibitors (AZD6244 or AS703026) upregulate RhoB in BRAF wild-type melanoma cells harbouring N-Ras, K-Ras or c-KIT mutation suggesting that inhibiting MAPK pathway is critical for RhoB expression modulation. It is noteworthy that this modulation is cell type dependent, while it was not found in BRAF mutated non-melanoma cells as colon carcinoma cells (Colo205 and RKO).To investigate the role of RhoB induction in cellular responses to BRAF and MEK inhibitors, the RhoB induction was suppressed using RNA interference. The cells treated with siRNA targeting RhoB, WM266-4 and A375 cells, were more sensitive to PLX4032 and AZD6244. Moreover the blockade of RhoB induction led to a significant increase of PLX4032-induced apoptosis as shown by the increase of the subG1 population and PARP cleavage.Our findings show that RhoB upregulation is involved in PLX4032 response and both inhibitions of MAPK pathway and RhoB expression trigger cell death and should prompt a search for agents. Indeed co-targeting MAPK and RhoB pathways, could lead to a synthetic lethality and prevent resistance to either BRAF or MEK inhibitors. Ongoing work focuses on confirming this role in tumour-xenografted mouse models.']",
        "Doc_id":"AACR_2013-3401",
        "Doc_title":" Vemurafenib-induced RhoB expression leads to melanoma cell resistance.",
        "_version_":1606189008087416832},
      {
        "Meeting_name":" Distinct liver cancer stem cells defined by EpCAM and CD90 in human hepatocellular carcinoma",
        "Background":"['Recent evidences suggest that a certain type of hepatocellular carcinoma (HCC) is hierarchically organized by a subset of cells with stem cell features (cancer stem cells', ' CSCs). Although CSCs have been identified using several CSC markers and are now considered a pivotal target for the eradication of HCC, little information is known about the characteristics of marker-positive cells. Here we explored the expression of CSC markers CD90 and EpCAM in primary HCCs and cell lines to investigate the molecular characteristics of each cell type. Gene expression profiling and immunohistochemistry analyses were used to characterize 340 surgically resected HCC tissues and 11 advanced HCC tissues with distant organ metastasis obtained from autopsy. Magnetic-activated cell sorting was used to isolate EpCAM+ or CD90+ cells from surgically resected 12 fresh HCC specimens, which were tested for hepatic stem cell properties including their tumor initiating capacity in NOD/SCID mice. In primary HCC, EpCAM+ and CD90+ cells resided distinctively, and gene expression analysis of sorted cells suggested that EpCAM+ cells had the features of epithelial stem cells whereas CD90+ cells had those of vascular endothelial cells. Clinicopathological analysis indicated that presence of EpCAM+ cells was associated with poorly differentiated morphology and high serum AFP with a tendency of portal vein invasion, while the presence of CD90+ cells was associated with high incidence of distant organ metastasis within two years after surgical resection and advanced TNM stages. Serial xenotransplantation of EpCAM+/CD90+ cells in NOD/SCID mice revealed the rapid growth of EpCAM+ cells in the subcutaneous lesion and highly metastatic capacity of CD90+ cells into the lung. Xenotransplantation experiments of cell lines further demonstrated that EpCAM+ cells had the features of hepatic CSCs with marked tumorigenic capacity whereas CD90+ cells had those of vascular endothelial cells with highly metastatic features. Markedly, CD90+ cells showed the abundant expression of c-Kit and VEGFR1 and chemosensitivity to imatinib methylate (c-Kit inhibitor) and axitinib (VEGFR1/2 inhibitor). Taken together, our data strongly suggest the discrete natures of EpCAM+ and CD90+ cells with specific gene expression patterns and chemosensitivity to the molecularly targeted therapy. The presence of distinct CSCs may determine the clinical outcome of HCC.']",
        "Doc_id":"AACR_2012-5336",
        "Doc_title":" Distinct liver cancer stem cells defined by EpCAM and CD90 in human hepatocellular carcinoma",
        "_version_":1606189031324909568},
      {
        "Meeting_name":" An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging and molecular markers during bevacizumab/irinotecan therapy for recurrent malignant glioma.",
        "Background":"['Background', ' Bevacizumab has been approved by the FDA for treatment of recurrent GBM. Standard MRI using Macdonald criteria is insufficient to adequately predict response to antiangiogenic treatment. The main goal of this study is to prospectively evaluate neuroradiological and nuclear medical imaging markers predictive for response to bevacizumab/irinotecan treatment in malignant glioma patients using advanced MRI and PET techniques. The second goal is to identify biomarkers in glioma tissue and blood relevant to bevacizumab/irinotecan treatment. Methods', ' This is an academic, prospective, single-arm, phase II clinical trial recruiting 35 patients presenting with a first or second tumor recurrence/progression of a histologically confirmed malignant glioma WHO grade III-IV who failed standard therapy. Patients will be treated biweekly with bevacizumab 10 mg/kg and irinotecan 125 or 340 mg/m2. Clinical and biochemical evaluation will be performed every second week, neuroradiologic follow-up every 8 weeks. The primary endpoint of the clinical trial is to determine imaging response criteria during bevacizumab/irinotecan treatment assessed by MRI, using standard MRI T1/T2 sequences, diffusion and perfusion MRI, T1-dynamic and MR-spectroscopy, and PET using 18F-fluoroethyltyrosine (18F-FET) and 18F-fluorothymidine (18F-FLT). The goal of the translational part is to evaluate the predictive and prognostic value of tumor vascularization and the expression of angiogenic pathway molecules (VEGF/VEGFR1-3, PDGF/PDGFR-/, c-KIT, Angiopoietin-1/2, DLL4, Gas6/Axl) in patients with malignant glioma treated with bevacizumab/irinotecan, assessed on glioma tissue using immunohistochemistry and blood by ELISA.']",
        "Doc_id":"ASCO_47299-74",
        "Doc_title":" An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging and molecular markers during bevacizumab/irinotecan therapy for recurrent malignant glioma.",
        "_version_":1606188979447660544},
      {
        "Meeting_name":" Molecular profiling of infiltrating urothelial carcinoma of the bladder.",
        "Background":"['Background', '  Infiltrating urothelial carcinoma (UC) is the most common variant of urinary bladder cancer. The prognosis for muscle infiltrating or metastatic UC of the bladder is poor with no major advances made in the last 20 years. We investigated a large cohort of such patients for specific genetic/biomarker alterations and compared them to other, less common urothelial malignancies.  Methods', '  We reviewed 602 cases; 518 cases (86%) were locally advanced or metastatic UCs of the bladder and the remaining 84 cases (14%) were non-bladder UCs. Multiple methodologies for optimal assessment of biomarker expression (Caris Molecular Intelligence, Caris Life Sciences, Phoenix, AZ) were employed', ' Mutation analysis (Next-generation sequencing, Sanger, pyrosequencing, qPCR, RFLP), in-situ hybridization (fluorescent and chromogenic), immunohistochemistry, and RNA fragment analysis.  Results', '  Bladder UC showed slightly higher rates of HER2/neu gene amplification (12% in bladder vs. 6% non-bladder, p=0.32) and EGFR gene amplification (22% vs. 12%, p=0.25). HER2/neu and EGFR protein expressions were more common in the bladder than in non-bladder sites (10% vs. 1%, p=0.03, and 77% vs. 60%, p=0.5, respectively). Pathogenic mutations in HER2/neu and EGFR were rare. Although c-Kit and c-Met receptor kinases were more frequently overexpressed in bladder than in non-bladder cancers (10% vs. 6% and 25% vs. 8%, respectively), activating mutations were also rare. PIK3CA and/or PTEN mutations were more frequently observed in non-bladder (27%) than in bladder UCs (21%). Non-bladder UC harbored high FGFR3 gene mutation (33%), which was not observed in any of the UC of the bladder (p=0.02). TP53 gene mutations were frequently identified in both bladder and in non-bladder cancers (49% vs. 27%, respectively, p=0.15), while KRAS was frequently mutated in the bladder adenocarcinomas (56%, p<0.001). Other therapeutically targetable biomarkers over-expressed in bladder UC compared to non-bladder UC included androgen receptor (16% vs. 8%, p=0.07) and MGMT (63% vs. 47%).  Conclusions', '  Comprehensive molecular profiling of urothelial carcinoma identifies a number of potentially actionable targets, which can be managed by the novel treatment modalities.']",
        "Doc_id":"ASCO_123838-142",
        "Doc_title":" Molecular profiling of infiltrating urothelial carcinoma of the bladder.",
        "_version_":1606188977438588928},
      {
        "Meeting_name":" Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells.",
        "Background":"['Background', ' Trastuzumab (T) is currently indicated for the treatment of Her-2 positive breast cancers. The NSABP B-31 adjuvant trial suggested a possible clinical benefit for the addition of T to chemotherapy in patients whose tumors were Her-2 negative (low Her-2 expressing, non-amplified by FISH). ADCC mediated by CD56+ natural killer (NK) cells is known to play a role in response to T in Her-2 positive tumors. To investigate the possibility that T may induce ADCC against Her-2 negative tumors, we examined NK cell-mediated ADCC in T-treated, non-amp, low Her-2 expressing BC cell lines. Methods', ' A membrane/cytosol separation kit and immunoblotting were used to assess surface Her-2 levels in the non-amp BC cell lines CAMA-1, T47D, EFM19, MCF-7 and CAL-51. The positive control for Her-2 expression and amplification was HCC1954 and MDA-MB-468 was the negative control. PBMCs were isolated from whole blood of 8 healthy volunteers using a Ficoll-Plaque method. CD56+ NK cells were isolated from the PBMC fraction using magnetic bead based positive selection. Direct NK activity against the K562 cell line and the ability of the NK cells to induce T-related ADCC were measured using flow cytometry. Results', ' Membrane expression of Her-2 was detected in all cell lines examined except the MDA-MB-468 cell line. The direct cytotoxicity of NK cells ranged from 42% to 73% (ratio 10', '1, NK', ' K562). T induced a significant ADCC response in the positive control HCC1954 (p value 0.002) and in each of the five non-amp, low Her-2 expressing cell lines, but not in the negative control MDA-MB-468 (Table). Conclusions', ' These results suggest that Her-2 non-amp BC cells, with low but detectable levels of Her-2 protein, can bind T and initiate ADCC. Future research will include determination of T-induced ADCC response by NK cells from patients with Her-2 non-amp BC. % increase in ADCC in response to 200 nM T (Ratio 1', '1, NK', \" Target cell) HCC1954CAMA-1T47DEFM19MCF-7CAL-51MDA-MB-468 Total Her-2++++++++- % Increase ADCC  std. dev.29  343  1321  325  731  1533  80.6  1 p value*0.0020.0190.0370.0150.0260.0050.627* p value - Student's t test, % ADCC for each cell line  T in triplicate p<0.05 significant.\"]",
        "Doc_id":"ASCO_41330-74",
        "Doc_title":" Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells.",
        "_version_":1606188983749967872},
      {
        "Meeting_name":" Expression of putative cancer stem cell markers in fallopian tube epithelium from women at increased risk of developing high-grade serous ovarian cancer",
        "Background":"['Pre-neoplastic p53 signature containing lesions, termed serous tubal intraepithelial carcinomas (STICs), have been identified in the fimbriae of women predisposed to ovarian cancer and in patients with sporadic high grade serous ovarian cancer (HGSOC). These findings instigated the theory that HGSOC originates from fallopian tube epithelium (FTE) and not from ovarian surface epithelium (OSE), and has now become an accepted paradigm for HGSOC genesis. However, only few studies have investigated the stem cell niche in the human fallopian tube. Instead, most research on ovarian cancer stem cells has focused on cells isolated from primary ovarian tumors or cell lines.In this study we performed immunohistochemistry to explore the presence of putative ovarian cancer stem cells in fallopian tubes from women who had undergone a risk reducing salpingo-oophorectomy (RRSO) due to a germline BRCA1/2 mutation and/or strong family history. Sections of frozen tissue from 14 RRSO patients (10 BRCA1/2 mutation carriers, 4 tested negative for BRCA1/2 mutations) were used in immunohistochemistry for p53 and the proposed cancer stem cell markers ALDH1, CD44, CD117, CD133, LGR5 and SOX2.Presence of a p53 signature (>12 consecutive cell nuclei in normal appearing FTE) was observed in 1 of 10 BRCA1/2 mutation carriers and none of the non-carriers. ALDH1 and CD44 positive staining of varying intensity was found in both FTE cells and stromal cells within the fallopian tube mucosa in all cases. On the other hand, no CD117 positive epithelial cells were observed in any of the samples, though strongly stained CD117+ mast cells were present in all sections. Most FTE cells were weakly positive for CD133 in all sections, while only one case showed positive LGR5 staining of FTE cells. Finally, SOX2 positive FTE cells were found in all samples. In most cases, the fimbriated end of the fallopian tube harbored more SOX2 positive cells than the more proximal end.This is an initial attempt at visualizing proposed ovarian cancer stem cells in the fallopian tubes of women predisposed to developing HGSOC. Further research is needed to validate the significance of these findings, including investigating additional markers, testing different antibodies and performing multiple labeling experiments. Based on the currently prevailing theory that HGSOC originates from STICs in the fimbriated end of the fallopian tube, we find SOX2 to be the most promising candidate for further investigations, since SOX2 was the only marker found to be differentially expressed throughout the fallopian tube. Elucidating the cell of origin and etiology of HGSOC has important implications for early detection and preventive therapeutic approaches.']",
        "Doc_id":"AACR_2016-3348",
        "Doc_title":" Expression of putative cancer stem cell markers in fallopian tube epithelium from women at increased risk of developing high-grade serous ovarian cancer",
        "_version_":1606188980058980352},
      {
        "Meeting_name":" Molecular changes induced by the curcumin biphenyl analogue D6 in melanoma cells",
        "Background":"['Malignant melanoma (MM) is one of the most aggressive cancers that affect humans. It is the most common and fatal skin cancer, with an incidence that is critically increasing in Western populations (15 times in the last 40 years) and for which, in the advanced stages, there is no effective therapy. The search for new compounds able to control it is therefore essential. The hydroxylated biphenyl compound (3E,3E)-4,4-(5,5,6,6-tetramethoxy-[1,1-biphenyl]-3,3-diyl)bis(but-3-en-2-one), namely D6, a structural analogue of curcumin, showed a strong antitumor activity on MM cells both in vitro and in vivo, as we have recently described [1]. The mechanisms of action of this compound are not clear yet, but it inhibits cancer cells growth by inducing apoptosis without affecting normal fibroblasts growth. Firstly we investigated the ability of D6 to enter cells by Liquid Chromatography-Mass Spectrometry (LC-MS) analysis. The LC-MS data showed a quick cellular uptake of D6 with a maximum peak after about 2 hours. To investigate on the effects of D6 treatment on the cell cycle progression in MM cells, we performed flow cytometry analysis, which evidenced a cell cycle arrest in the G2/M phase. Gene expression profiles analysis using Illumina high-density microarrays, was carried out on D6 treated MM cells and normal fibroblasts allowing the identification of 599 transcripts whose expression was modulated by D6 treatment in MM cells but not in normal fibroblast. The analysis of results, performed by Ingenuity Pathway Analysis software, showed the centrality of CDKN1A gene, encoding p21, a major negative cell cycle regulator, which was strongly over expressed, while cyclin B and cdc25 phosphatase, showed both to be down modulated. Other genes which expression interestingly appeared to be decreased by D6 activity were the oncogenes c-kit and PI3K, suggesting a down regulation of both c-kit mediated and PI3K/AKT signal transduction pathways driving to cell proliferation. Modulation of expression of these specific genes has been confirmed at a protein level by western blotting analysis. Moreover our results pointed out an upregulation of several heat shock family genes, which is probably due to a curcumin related anti inflammatory effect of D6. The preliminary results of these analysis show that D6 induces molecular changes in MM cells at both gene expression and protein levels, involving major cell proliferation regulatory pathways. [1] Marina Pisano et al. (2010).Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Molecular Cancer, 9', '137.']",
        "Doc_id":"AACR_2012-3804",
        "Doc_title":" Molecular changes induced by the curcumin biphenyl analogue D6 in melanoma cells",
        "_version_":1606189002354851840},
      {
        "Meeting_name":" Phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (Pts) with metastatic solid tumors.",
        "Background":"['Background', '   PAZ is a tyrosine kinase inhibitor of VEGFR, PDGFR, and C-KIT approved for use in renal cell carcinoma (RCC) and soft tissue sarcoma (STS). ABX is a potent pan-HDAC inhibitor (HDACi). Pre-clinical models suggest that epigenetic modulation with an HDACi potentiates PAZs efficacy and prevents the outgrowth of a resistant phenotype. We therefore designed a Phase I clinical trial combining ABX with PAZ in pts with advanced solid tumors.   Methods', '   The primary objective was to determine the maximal tolerated dose (MTD) of PAZ plus ABX in pts with advanced solid tumor malignancies. Secondary objectives included pharmacokinetics (PK) and efficacy. Altered histone acetylation post treatment denoted HDACi activity and served as pharmacodynamic (PD) markers in peripheral blood mononuclear cells. PAZ was dosed daily and ABX on days 1-5, 8-12, 15-19 of a 28-day cycle, at a starting dose of 400 mg/day and 45 mg/m2 orally twice daily for PAZ and ABX respectively.   Results', '   22 patients with advanced solid tumors were enrolled. There were five dose-limiting toxicities (DLTs) (fatigue', ' N = 2, thrombocytopenia', ' N = 2; grade 2 elevated AST with fever', ' N = 1). The MTD was PAZ 600 mg/day + ABX 30 mg/m2 BID. The most common grade  3 drug regimen-related adverse events observed include thrombocytopenia (12%), fatigue (12%), and diarrhea (8%). 3 of 15 evaluable pts (20%) (including 2 RCC pts) had a confirmed objective partial tumor response, including one pt with prior progression in single agent PAZ. 5 out of 17 evaluable pts (29%) have experienced disease stabilization or better for  6 months. PK and PD analyses are ongoing. An alternate dosing schedule is being explored with ABX administered on D1-4, 8-11,15-18 of a 28-day cycle. The current dose level is 45 mg/m2 BID and PAZ at 600 mg/day with no DLTs observed thus far (N = 2).   Conclusions', '   This is the first trial to explore the combination of ABX with PAZ in RCC and other solid tumor malignancies. The optimal dosing schedule may be ABX taken 4 days/week but requires further investigation. Encouraging preliminary evidence of anti-tumor activity was observed including in a pt with prior disease resistance to PAZ monotherapy. An expansion cohort with 20 pts in RCC and sarcoma is planned. Clinical trial information', ' NCT01543763.']",
        "Doc_id":"ASCO_135105-144",
        "Doc_title":" Phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (Pts) with metastatic solid tumors.",
        "_version_":1606189027516481537},
      {
        "Meeting_name":" Assessment of PITX2, BMP4, FGF4, ERalpha, ERbeta promoter methylation in the circulating tumor cells (CTCs) can predict metastasis and survival in primary invasive duct carcinoma (PIDC) patients",
        "Background":"['Recent studies have focused on hematogenous tumor cell dissemination as predictive factors of breast cancer metastasis and several methods for detecting circulating tumor cells (CTCs) in peripheral blood were described. However, in early-stage breast cancer, molecular characterization of CTCs and their prognostic value is not well established. We previously found a significant correlation between DNA promotor methylation (PM) of PITX2, BMP4, FGF4, ERalpha, ERbeta and breast cancer recurrence and metastasis (unpublished data). Therefore, we sought to compare the frequency of PM of these genes in the CTC and the primary breast tumors (PBT) in relation to recurrence, progression free and overall survival rates (DFS& OS) CTCs were collected from the 10 cm peripheral blood of 80 primary invasive duct carcinoma (PIDC) patients by immunomagnetic beads separation. The number of CTCs was determined by flow cytometry (FCM) and RT-PCR (using CK-19, mammaglobin and CD44) for confirmation and comparison. Patients were first tested for CTC counts immediately before surgery, prior to therapy, at first follow-up (4-6 weeks later) and after 6 months. PM of PITX2, BMP4, FGF4, ERalpha, ERbeta was assessed by methylation specific PCR (MSP) in PBTs and CTCs and correlated with metastasis and survival. The number of CTCs ranged from 0-500/10 ml blood. The concordance between FCM and RT-PCR was 98% (p=0.01). At first assessment, 56 patients have 10 CTCs/10 ml blood and exhibited a significantly shorter progression-free survival (PFS) (12.7 months versus 20.6 months) and overall survival (OS) (28.1 months versus 49.5 months) than women with 10 CTCs was 16.1 months, compared to greater than 36 months in the cohort with <10 CTCs. PM of PITX2, BMP4, FGF4, ERalpha and ERbeta, was reported in 42.90%, 50.00%, 51.20%, 63.10% and 46.40% compared to 63.15%, 73.75%, 62.5%, 81.2% and 78.75% in CTCs. PM of BMP4, and ERbeta was associated with reduced OS and PFS. Conclusions', ' 1) The presence of CTCs in the blood of PIDC patients can impact standard treatment and future research, 2) FCM provides a simple and accurate technique for enumerating CTCs in peripheral blood, 3) the significant increase in PM frequency of all studied genes except FGF4, suggests that aberrant PM may contribute to increased aggression and more liability to metastasis. More studies are still needed to assess the impact of CTCs in PIDC patients and how they might contribute to improving individualized cancer therapies.']",
        "Doc_id":"AACR_2012-2384",
        "Doc_title":" Assessment of PITX2, BMP4, FGF4, ERalpha, ERbeta promoter methylation in the circulating tumor cells (CTCs) can predict metastasis and survival in primary invasive duct carcinoma (PIDC) patients",
        "_version_":1606189038328348672},
      {
        "Meeting_name":" Follicle stimulating hormone (FSH) inhibits apoptosis in ovarian cancer cell through regulating OCT4 stem cell signal pathway.",
        "Background":"['Ovarian cancer is the most lethal malignancy of the female reproductive system with an overall mortality rate of greater than 70%. Our group has demonstrated that Follicle stimulating hormone (FSH) stimulates the proliferation and invasion of ovarian cancer cells, inhibits apoptosis, and facilitates neovascularization by increasing expression of vascular endothelial growth factor (VEGF). OCT4, a stem cell marker, is overexpressed in several types of human cancer and can induce resistance to chemotherapy and inhibition of apoptosis. We have found that FSH stimulates the expression of OCT4 mRNA and protein in a time- and dose-dependent manner. Subcellular analysis by immunofluorescent staining confirmed that FSH stimulation increased OCT4 protein expression in both the cytoplasm and nucleus of ovarian cancer cells. Re-expression of OCT4 in ovarian cancer cells reversed the inhibition of apoptosis induced by FSH, whereas siRNA-mediated knockdown of OCT4 resulted in a significantly rate of apoptosis. Depletion of OCT4 resulted in reduction of p-AKT and survivin, and also blocked FSH-induced upregulation of p-AKT and survivin. Moreover, FSH stimulation induced the expansion of CD44+CD117+ cells with a stem cell-like phenotype. Interestingly, re-expression of OCT4 enhanced the expression of Notch, Sox2, and Nanog, molecules that play critical roles in cancer stem cell proliferation and differentiation. FSH upregulated the expression of Notch, Sox2 and Nanog and these effects were abolished by knocking down OCT4, suggesting that several cancer stem cell pathways are involved in FSH regulation. We have also examined OCT4 expression in surgical specimens of ovarian cancer. Immunohistostaining revealed that OCT4 expression was increased in ovarian carcinoma compared with benign cystadenomas and borderline tumors, and OCT4 expression was significantly correlated with histological grade. Staining for OCT4 was increased in serous cystadenocarcinoma, when compared with clear cell carcinoma. In summary, the OCT4 cancer stem cell signaling pathway may mediate FSH-induced inhibition of apoptosis and could provide a target for treatment of ovarian cancer.']",
        "Doc_id":"AACR_2013-4766",
        "Doc_title":" Follicle stimulating hormone (FSH) inhibits apoptosis in ovarian cancer cell through regulating OCT4 stem cell signal pathway.",
        "_version_":1606189032342028288},
      {
        "Meeting_name":" A phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (pts) with metastatic solid tumors.",
        "Background":"['Background', '  PAZ is a tyrosine kinase inhibitor of VEGFR, PDGFR, and C-KIT approved for use in renal cell carcinoma (RCC) and soft tissue sarcoma (STS). ABX is a potent pan-HDAC inhibitor (HDACi). Pre-clinical models suggest that HDACi-mediated epigenetic modulation of VEGF expression potentiates PAZs efficacy and may reverse therapeutic resistance. We therefore designed a Phase I clinical trial combining ABX with PAZ in pts with advanced solid tumors.  Methods', '  The primary objective was to determine the maximal tolerated dose (MTD) of PAZ plus ABX. Secondary objectives included pharmacokinetics (PK) and efficacy. Altered histone acetylation post treatment denoted HDACi activity and served as a pharmacodynamic (PD) marker in peripheral blood mononuclear cells. PAZ was dosed days 1-28 and ABX days 1-5, 8-12, and 15-19 of 28-day cycle (schedule A) at a starting dose of 400 mg/day and 45 mg/m2orally twice daily respectively. An alternate ABX dosing schedule of days 1-4, 8-11, and 15-18 was also investigated (schedule B).  Results', '  36 patients with advanced solid tumors were enrolled (N = 22 schedule A; N = 14 schedule B). There were six dose-limiting toxicities (DLTs) (5 on schedule A, 1 on schedule B), including fatigue (N = 2), thrombocytopenia (N = 2), and elevated AST/ALT (N = 2). The most common grade  3 related adverse events observed include thrombocytopenia (8%), fatigue (8%), and diarrhea (6%), the majority of which occurred with schedule A. The MTD was PAZ 800 mg/day + ABX 45 mg/m2 BID on schedule B. 5 of 29 evaluable pts (17%) (including 2 RCC pts) experienced a partial tumor response (PR). All 6 pts with prior disease progression on PAZ monotherapy had reduction in tumor burden on study. 12 out of 29 evaluable pts (41%) experienced stable disease or better for  6 months, and two pts with PRs remain on study for > 2 years. PK and PD analyses are ongoing.  Conclusions', '  In the first trial to explore the combination of ABX with PAZ in RCC and other solid tumor malignancies, the combination was well tolerated, particularly with schedule B ABX dosing. Preliminary evidence of anti-tumor activity was observed, notably in pts with progression on prior PAZ monotherapy. The promising efficacy in RCC is being further evaluated. Clinical trial information', ' NCT01543763']",
        "Doc_id":"ASCO_151087-156",
        "Doc_title":" A phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (pts) with metastatic solid tumors.",
        "_version_":1606189018942275584},
      {
        "Meeting_name":" Clinical and molecular profiling of surgically resected small-cell lung cancer",
        "Background":"['Background', '  NCCN and Japanese guidelines suggest surgery for patients with c-stage I small-cell lung cancer (SCLC). However, the clinical impact of surgery with other variables on patients with early-stage SCLC has yet to be determined. Thus clarification of the clinical and molecular profile of SCLC is required. Methods', '  We reviewed the clinical courses of 149 patients with SCLC who had undergone surgery at 16 institutes from January, 2003 through January, 2013. Eighty-nine paraffin-embedded tissue samples were subjected to immunohistochemistry using 8 antibodies, and to next-generation sequencing system (NGS) using MiSeq and TruSight Tumor Panel (Illumina) loading 26 genes (UMIN registration No. 000010116/10117). Results', '  Median relapse-free survival (RFS) and overall survival (OS) were 16.6 (95%CI=7.1-26.2), and 36.7 (17.3-56.2) months, respectively. Multivariate analysis revealed that OS was longer in patients without interstitial pneumonitis (IP) (HR=0.372, 95%CI=0.181-0.767, p=0.007), without history of malignancy (HR=0.446, 0.229-0.868, p=0.017), with preoperative diagnosis (HR=0.401, 0.210-0.767, p=0.006), with c-stage II and under (HR=0.204, 0.065-0.640, p=0.006), and with p-stage IA (HR=0.294, 0.142-0.605, p=0.001). Of the 89 patients whose samples were available, MED12 and TGF-RII were highly expressed in nucleus and cytoplasm, respectively in 92% and 61%. Multivariate analysis demonstrated that high expression of either c-Kit or HER2 in tumors is an independent factor for longer OS (HR=0.396, 95%CI=0.209-0.752, p=0.005). None of the tumors expressed ALK. There was no relationship between the expression of c-Met, EGFR, and VEGFRII and either of RFS or OS. Thirty-five samples were subjected to NGS so far. However, no druggable mutations of BRAF, EGFR, ERBB2, KRAS, KIT, PDGFRA, PIK3CA, FOXL2, GNAQ, GNAS, and FGFR2 were found. Conclusions', '  These results indicate that i) complication of IP and history of malignancy might be major decision factors of surgery, and', ' ii) patients with c-stage II should be considered for surgery in a prospective trial. Immunohistochemistry results assist us in gaining a better understanding of the biology of SCLC.']",
        "Doc_id":"ASCO_125324-144",
        "Doc_title":" Clinical and molecular profiling of surgically resected small-cell lung cancer",
        "_version_":1606189014759505920},
      {
        "Meeting_name":" Development of a spontaneous in vivo cachexia model using the Champions TumorGraft platform",
        "Background":"['Cachexia is present in the majority of patients with advanced cancer progression and is not reversible through nutritional supplementation, leading to loss of skeletal muscle and adipose tissue. There are a lack of quality pre-clinical models for cachexia research. Previously, Champions Oncology reported a mouse cachexia model derived from a primary human renal cell carcinoma tumor implanted in immunocompromised mice. This model, CTG-0804, was developed using the innovative Champions TumorGraft platform, which preserves the biological properties of the original human tumor. The Champions TumorGraft platform demonstrated dramatic weight loss in these mice as the tumor grew. Plasma from these mice also showed elevated levels of human IL-6. We have now further characterized this TumorGraft model by evaluating standard of care (SOC) agents for renal cell carcinoma and anti-IL-6 compounds to determine the mechanism of cachexia. The SOC evaluation revealed that sorafenib, sunitinib, temsirolimus and bevacizumab as single agents provided a survival advantage by inhibiting tumor growth and preventing weight loss in these mice. Blockade of human IL-6 with tocilizumab or ALD518 did not inhibit tumor growth and weight loss still occurred, demonstrating the possibility of other pathways involved in the cachexia mechanism. In addition, the SOC data for sunitinib showed significant tumor growth inhibition, but no regression at the study end point. This correlated with the clinical profile, where sunitinib could not prevent metastasis and the patient eventually progressed. The TumorGraft model was molecularly characterized and mutation analysis revealed a KIT V530I mutation. This mutation has been reported in extra-abdominal aggressive fibromatosis (desmoid tumor) and acute myeloid leukemia patients that have responded to c-kit targeting therapies, such as imatanib and dasatinib. Further characterization of this TumorGraft is ongoing to include additional bioinformatics using gene expression and mutation pathway analyses. In summary, we have continued development of this cachexia model using the Champions TumorGraft platform, along with molecular evaluation, to produce a robust and well-characterized approach for cachexia investigation which can also be applied to other areas of drug development and cancer research.']",
        "Doc_id":"AACR_2014-1217",
        "Doc_title":" Development of a spontaneous in vivo cachexia model using the Champions TumorGraft platform",
        "_version_":1606188992121798656},
      {
        "Meeting_name":" Neurropilin-1 high monocytes play an important role in trastuzumab mediated antibody-dependent cellular cytotoxicity in HER2 positive breast cancer cell lines.",
        "Background":"['PurposeNeuropilin-1 (NRP-1) was initially characterized as a neuronal receptor for specific secreted members of the semaphorin family involved in axon repulsion. However, it was recently reported to play an important role in the immune system. This study aimed to investigate the role of NRP-1 expression on monocytes in trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) targeting the HER2-positive human breast cell line SKBR3.MethodsPeripheral blood mononuclear cells (PBMCs) from healthy volunteers were prepared using Lymphoprep. The cells were stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD14 and allophycocyanin (APC)-conjugated anti-NRP-1 antibodies, and an NRP-1high and NRP-1low monocyte subset was sorted using FACSAria. These cells were used as effector cells in a conventional ADCC assay using SKBR3 as target cells and trastuzumab as an antibody. Target cell cytotoxicity was measured using the LDH cytotoxic test kit. A CD107a degranulation assay was also used to determine the role of NRP-1 expression on monocytes in ADCC. PBMCs were co-cultured with target SKBR3 cells and trastuzumab for 2 h, stained with APC-conjugated anti-NRP-1 and PE-Cy5-conjugated anti-CD107a antibodies, and analyzed by flow cytometry.ResultsThe LDH cytotoxic test revealed significantly higher target cancer cell cytotoxicity in sorted NRP-1 high monocytes (12%) than in NRP-1 low monocytes (4%). Interestingly, microscopic findings showed that most NRP-1 high monocytes covered trastuzumab-treated target cancer cells (showing higher cellular cytotoxicity) while NRP-1 low monocytes did not cover the target cells but changed their morphology from a round to a dendritic shape (showing less cellular cytotoxicity) during ADCC. Moreover, the degranulation assay showed a higher expression of CD107a in NRP-1 high monocytes (17.4%) than in NRP-1 low monocytes (1.16%). Mean fluorescence intensity of CD107a in NRP-1 high and NRP-1 low monocytes was 92.6 and 26.3, respectively.ConclusionsThese data suggest that NRP-1 high monocytes exhibit higher trastuzumab-mediated ADCC than NRP-1 low monocytes in HER2-positive breast cancer cell lines. It may therefore be possible to differentiate HER2-positive breast cancer patients for whom trastuzumab will be less effective by testing for monocyte NRP-1 expression levels.']",
        "Doc_id":"AACR_2013-1536",
        "Doc_title":" Neurropilin-1 high monocytes play an important role in trastuzumab mediated antibody-dependent cellular cytotoxicity in HER2 positive breast cancer cell lines.",
        "_version_":1606189028277747712},
      {
        "Meeting_name":" Defining an elusive multiple myeloma stem cell population in mice",
        "Background":"['Multiple Myeloma (MM) is a debilitating disease of proliferating and malignant plasma cells that is currently incurable. The ability of monoclonal recurrence of disease suggests it might arise from a stem cell-like population capable of self-renewal. The difficulty to isolate the cancer stem-like cell in MM in both mice and men has introduced confusion toward this hypothesis. XBP1s is a key positive regulator for unfolded protein response and a master transcription factor for plasma cell development. It was previously reported that transgenic overexpression of XBP1s in the B cell lineage of mice (XBP1s-Tg), induces a multiple myeloma phenotype resembling human MM. We have now defined a post-germinal center, pre-plasma B cell population that was significantly increased in XBP1s-Tg mice as the hallmarks of MM was demonstrated. This non-memory B cell population resembled a stem/progenitor cell population, with increased expression of aldehyde dehydrogenase (ALDH), Notch1 and c-kit. Importantly, utilizing an in vitro culture for differentiating plasma cells, the increased population began to differentiate into plasma cells, increasing in size and gaining CD138 expression, the hallmark marker for plasma cells. In conclusion, we have defined a transitional pre-plasma cell population that could potentially be a stem/progenitor population of multiple myeloma. These results provide a novel insight into stem cell biology with regard to multiple myeloma and the use of murine models of myeloma to study the disease.']",
        "Doc_id":"AACR_2014-3045",
        "Doc_title":" Defining an elusive multiple myeloma stem cell population in mice",
        "_version_":1606189022013554688},
      {
        "Meeting_name":" CYP3A-inducing antiepileptics decrease sorafenib exposures",
        "Background":"['Background', ' Sorafenib, an oral inhibitor of VEGFR-2, Raf, PDGFR, c-KIT and Flt-3, has established activity against renal cell carcinoma and hepatocellular carcinoma, and has recently demonstrated promising activity for lung and breast cancer. Recently, a variety of protracted dosing schedules of temozolomide have been evaluated as a strategy to further enhance its antitumor activity. We reasoned that sorafenib and protracted, daily temozolomide may provide complementary therapeutic benefit, and therefore performed a phase II trial of this regimen among patients with recurrent glioblastoma. Methods', ' Adult patients with GBM at any recurrence after standard temozolomide chemoradiotherapy received sorafenib administered at 400 mg twice daily and continuous daily temozolomide dosed at 50 mg/m2. Assessments were performed after every other cycle. The primary endpoint was progression-free survival at 6 months (PFS-6) and the secondary end points were radiographic response, overall survival (OS) and safety. Sorafenib pharmacokinetics were assessed on days one and 28 of cycle one. Results', ' Of 32 enrolled patients, twelve (38%) were on CYP3-A inducing antiepileptics (EIAEDs), seventeen (53%) had 2 or more prior progressions, 15 had progressed while receiving 5-day temozolomide, and 12 (38%) had failed either prior bevacizumab or VEGFR inhibitor therapy. The most common grade  3 toxicities were palmer-plantar erythrodysesthesia (19%) and elevated amylase/lipase (13%). Sorafenib pharmacokinetic analyses revealed no differences between patients on day 1 regardless of EIAED status, but significantly lower exposures on day 28 for patients on EIAEDs (p = 0.0431). With a median follow-up of 93 weeks, PFS-6 was 9.4%. Only one patient (3%) achieved a partial response. Conclusions', ' Our study confirms that sorafenib can be safely administered with daily temozolomide, but this regimen has limited antitumor activity among recurrent GBM patients. Coadministration of EIAEDs can lower sorafenib exposures in this population.']",
        "Doc_id":"ASCO_50959-74",
        "Doc_title":" CYP3A-inducing antiepileptics decrease sorafenib exposures",
        "_version_":1606189023864291328},
      {
        "Meeting_name":" Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab",
        "Background":"['Background', ' Pazopanib, a multi-targeted inhibitor of VEGFR, PDGFR, and c-KIT, is an active first-line agent in the treatment of advanced renal cell carcinoma (RCC).  The efficacy of pazopanib in patients (pts) who have progressed on other anti-angiogenesis agents, particularly sunitinib, is unclear. Methods', ' Pts with metastatic clear-cell RCC who had progressed on or were intolerant of first-line single-agent sunitinib or bevacizumab were eligible.  Additional criteria', ' ECOG PS 0 or 1; measurable disease (RECIST); previous nephrectomy unless clinically inappropriate; no active CNS metastases; adequate bone marrow, kidney, liver function; no risk factors for anti-angiogenesis agents; informed consent.  All pts received pazopanib 800mg PO daily. Response was assessed every 8 weeks until progression. Results', ' 44 pts have been treated with pazopanib (previous sunitinib  32; previous bevacizumab  12).  Additional pt characteristics', ' male/female, 77%/23%; Motzer risk low/intermediate/high, 25%/43%/32%; previous nephrectomy, 93%. The median duration of treatment was 24 weeks (range 0 to 52 weeks). After a median follow-up of 9 months, efficacy is as follows (see table). 37 pts remain alive, and 13 are continuing treatment.  Toxicity with pazopanib was similar to previous reports', '  frequent grade 3/4 toxicity included fatigue (14%), hypertension (11%), proteinuria (11%).  Three pts discontinued treatment due to toxicity, and 13 required dose reductions. Conclusions', ' Pazopanib is active and well tolerated following treatment with either sunitinib or bevacizumab.']",
        "Doc_id":"ASCO_84354-102",
        "Doc_title":" Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab",
        "_version_":1606189004747702272},
      {
        "Meeting_name":" Correlation of sorafenib plasma concentrations and clinical toxicity",
        "Background":"['Background', ' Sorafenib is an angiogenesis inhibitor recently approved for the treatment of metastatic renal cell carcinoma and hepatocarcinoma. This oral multi-targeted kinase inhibitor blocks the VEGF, PDGF receptors, BRAF and c-kit. In clinical trials, severe toxicities included rash, hand-foot syndrome and diarrhea. We investigated the relationship between severe toxicity and sorafenib plasmatic exposure. Patients and methods', ' From February 2008 to December 2008, 32 patients (pts) were treated with sorafenib (800 mg given daily). Clinical and blood exams were performed at baseline and every 2 weeks. Toxicity events were graded according to National Cancer Institute Common Toxicity Criteria 3.0. The sorafenib area under the plasma concentration-time curve over 12 hours (AUC0-12) was determined every 2 weeks by gradient elution liquid chromatography, data analysis with one-compartment disposition and a population approach using NONMEM software. Grade 3 toxicity free survival was estimated by Kaplan-Meier method. Results', ' Pts (23 males), ECOG 0-1 (27 pts), median age 62.8 years (range 37-78), with metastatic hepato-carcinoma (11), melanoma (6), thyroid cancer (8), renal cell carcinoma (7), received a median treatment duration of 94 days (range ', ' 7-330). 20 pts experienced grade 3 toxicities with 33 events', ' hand-foot hyperkeratosis (14), diarrhea (5), cutanous rash (4), asthenia (2), anorexia (2), dyspnea (1), scrotal toxicity (1), post surgical complication (1), hypertension (1), increase creatinine level (1), digestive hemorrhage (1). The median AUC0-12 was 62.4 mg/L.h, ranging from 28.7 to 202.2 mg/L.h. Amongst pts experiencing grade 3 toxicity, two groups of 16 pts were defined with the median AUC0- 12 as cut off', ' low exposure (Lw) and high exposure (Hi). Six Lw pts experienced grade 3 toxicity versus 14 Hi pts (exact Fisher Test p=0.009). The probability of free grade 3 toxicity survival was higher for Lw (Logrank test p=0.004). Conclusions', ' These results show that grade 3 toxicity occurrence may be related to high plasma sorafenib exposure. This supports the need for therapeutic drug monitoring to prevent toxicity grade 3 occurrence and therefore optimize the clinical management of patients under sorafenib.']",
        "Doc_id":"ASCO_35284-65",
        "Doc_title":" Correlation of sorafenib plasma concentrations and clinical toxicity",
        "_version_":1606189034655186945},
      {
        "Meeting_name":" Unlocking the potential of CD70 as a therapeutic target in non-small cell lung cancer",
        "Background":"['Introduction', ' Upon interaction of CD70, a type II transmembrane protein, with its receptor CD27, the NFB pathway is activated, leading to proliferation and survival. Hence, CD70 expression is tightly regulated and only transient on cells of the lymphoid lineage. In contrast, constitutive overexpression of CD70 has been documented in malignancies, where it appears to mediate immune escape through recruitment of CD27+ regulatory cells. Soluble CD27 (sCD27), the extracellular domain of CD27, can be released after lymphocyte activation and has been detected at increased levels in serum samples of lymphoid malignancies. To our knowledge, expression of CD70 has never been systematically characterized in non-small cell lung cancer (NSCLC).Methods', ' Fourty-nine primary NSCLC formalin-fixed paraffin embedded and 9 metastatic biopsies were stained by immunohistochemistry (IHC) for expression of CD70 (Clone 301731, 1/40) and CD27 (Clone 137B4, 1/40), using the Dako autostainer Link and Ventana ultra, respectively. Additionally, sCD27 levels were analyzed in 19 serum samples, taken before of biopsy, with the PeliKine Compact human sCD27 ELISA kit. Finally, we tested the efficacy of ARGX-110, a CD70-blocking monoclonal IgG1 SIMPLE Antibody endowed with enhanced ADCC properties (POTELLIGENT), using the xCELLigence RTCA technology in CD70+ and CD70- cell lines.Results', ' In tumor cells, CD70 positivity (>10%) was detected in 16% of cases with a higher percentage in squamous NSCLC (27%) than in adenocarcinoma (9%). Additionally, one neuro-endocrine NSCLC was CD70+. We demonstrated identical CD70 patterns in primary and metastatic tissue in 8/10 biopsies. Furthermore, CD70 was found in the micro-environment of the tumor (23/49). IHC revealed high levels of CD27 expressing tumor infiltrating lymphocytes (TIL) in all NSCLC biopsies, with increasing FOXP3 expression and higher CD4/CD8 ratios in stromal tissue adjacent to CD70+ tumor cells. High sCD27 levels (>500U/ml) were found to be significantly associated with poor overall survival and even though sCD27 levels did not show potential as a blood-based biomarker for CD70 overexpression on tumor cells, dual positivity of CD70 and sCD27 marked even worse prognosis. We also showed that a low concentration of ARGX-110 (0.5g/ml) induces efficient NK cell based tumor lysis in CD70+ cell lines.Conclusion', ' Expression of CD70 was demonstrated in tumor cells and TILs of NSCLC. Moreover, all biopsies revealed infiltration of CD27+ TIL in the micro-environment of the tumor and a trend towards increased FOXP3 expression and higher CD4/CD8 ratios in CD70+ biopsies. In addition, serum sCD27 levels have potential as a prognostic marker for NSCLC. Lastly, our in vitro results showed a maximum ADCC of ARGX-110 in CD70+ target cells stained by IHC. Hence, our data suggest that CD70 might be an interesting therapeutic target in NSCLC.']",
        "Doc_id":"AACR_2015-3563",
        "Doc_title":" Unlocking the potential of CD70 as a therapeutic target in non-small cell lung cancer",
        "_version_":1606189007879798784},
      {
        "Meeting_name":" Bioactive tanshinones and tea polyphenols inhibit prostate cancer stem cells by targeting bmi1",
        "Background":"['Prostate cancer (CaP) is the most common invasive malignancy and the second leading cause of cancer-related death in U.S. men. Androgen-independent/hormone-refractory CaP remains the primary cause of CaP death. The search for effective therapeutic and preventive strategies, particularly the ways to intervene in the progression of androgen-independent tumors remains the top priority of CaP research. Prostate cancer stem cells (CSCs) are suggested to be responsible for initiation, progression, drug resistance, recurrence and metastasis of CaP. Strategies that target prostate CSCs may significantly prevent and/or delay cancer progression and metastasis. The objective of this study was to identify the potent natural bioactive compounds for targeting prostate CSCs. The sphere-forming efficiencies in LNCaP, DUCaP, PC3 and DU145 prostate cancer cell lines were 2.8%, 15.7%, 1%, and 5.6%, respectively. The expression of several CSC related biomarkers, such as c-met, c-kit, bmi1 and CD44 were increased, whereas the expression of androgen receptor was decreased in prostate spheres. Natural compounds, especially tanshinones (tanshinone I (T1), tanshinone IIA (T2A), cryptotanshinone) and tea compounds (epigallocatechin gallate (EGCG) and theaflavines), inhibited the sphere-forming efficiency of CaP cells with T1 and T2A the most potent. Furthermore, T1 and EGCG significantly downregulated Bmi1 gene expression and protein level. Since Bmi1 has been reported to be a crucial regulator of stem cell self-renewal and malignant transformation, we further studied the functional role of bmi1 in self-renewal of prostate CSCs. Silencing of bmi1 dramatically inhibited the growth and decreased the sphere-forming ability of CaP cells. Animal studies showed that T1 and EGCG inhibited the growth and metastasis of prostate tumors associated with downregulation of bmi1 expression. The results derived from our preliminary studies suggest that bmi1 may play an important role in self-renewal ability of prostate CSCs, and that some natural bioactive agents, such as T1 and EGCG, may inhibit self-renewal of prostate CSCs in part via downregulation of bmi1 gene expression and function. Supported in part by NCI/NIH R21 CA153355.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-4647",
        "Doc_title":" Bioactive tanshinones and tea polyphenols inhibit prostate cancer stem cells by targeting bmi1",
        "_version_":1606189026945007616},
      {
        "Meeting_name":" Discovery of new therapeutic strategies for rare cancers with defined genetic lesions",
        "Background":"['Rare cancers are defined as those with an incidence of less than 0.05% in a given population, yet collectively make up 20% of all cancers. A proportion of these are characterized by a primary, driving genetic lesion which disrupts normal cell regulation, resulting in malignancy. Patients of rare cancer could potentially benefit from clinically approved targeted therapies developed for other cancers; however their rarity makes recruitment for clinical trials extremely difficult. Cell lines derived from these patients often maintain the genetic lesions present in the parent tumor, and therefore can serve as a platform to evaluate the efficacy of novel therapeutic strategies. Here we describe in vitro strategies for identifying novel treatment regimens for the rare, simple karyotype cancer Myxoid Liposarcoma (MLS). MLS is characterized by a single genetic event, the chromosomal translocation t(12;16)(q13;p11), which occurs in >95% of cases. The gene product of this translocation is the constitutively active fusion protein FUS-CHOP, which alters the expression of transcription factors responsible for regulating adipocytic differentiation. This drives the cells into a perpetual state of proliferation in the absence of differentiation, thus leading to malignancy. This study uses the cell lines MLS 402 and MLS 1765, which are derived from MLS patients, and express FUS-CHOP. Cells were screened with a panel of anti-cancer treatments, including antibodies, small molecule inhibitors and chemotherapies. Axitinib was identified as an efficacious treatment both alone and in combination with other therapies. Axitinib caused cell cycle arrest and induced apoptosis as verified by Annexin V flow cytometry assay. This multi-kinase inhibitor targets the membrane-bound receptors c-Kit, PDGFR/ and VEGFR1/2/3. Western blot and bioplex assays were utilised to determine the downstream target molecules inhibited by axitinib treatment. Axitinib significantly reduced signalling activity through the AKT/mTOR and MEK/ERK1/2 pathways. Axitinib also displayed additive and synergistic anti-tumor activity with other targeted therapies. The establishment of cell lines that retain the key genetic mutation found in rare cancers is a useful approach for identifying novel therapeutic options.']",
        "Doc_id":"AACR_2012-3711",
        "Doc_title":" Discovery of new therapeutic strategies for rare cancers with defined genetic lesions",
        "_version_":1606189035424841729},
      {
        "Meeting_name":" Diindolylmethane and its halogenated analogues induce autophagy in human prostate cancer cells via induction of the astrocyte-elevated gene-1 (AEG-1).",
        "Background":"['3,3-diindolylmethane (DIM) and its halogenated derivatives (ring-DIMs) are recently shown to induce protective autophagy in human prostate cancer cells. The mechanism of induction of autophagy by DIM has not been elucidated. As DIM is a mitochondrial ATP synthase inhibitor, we hypothesized that DIM and ring-DIMs induce autophagy via alteration of AMP/ATP ratio and activation of AMPK signaling in prostate cancer cells. Autophagic activity was monitored by LC3B-I to LC3B-II conversion in LNCaP and C42B prostate cancer cells. Autophagic vacuoles were examined using Cyto-ID autophagy detection kit and transmission electron microscope (TEM). Protein levels for AMPK, pAMPK, acetyl-CoA carboxylase (ACC), pACC, AEG-1, pULK-1 and -actin were measured by western blot. AMPK and AEG-1 gene expression was downregulated using siRNA. DIM and ring-DIMs induced autophagy by increasing autophagic vacuoles and LC3B-I to LC3B-II conversion in LNCaP and C42B cells. These compounds also induced AMPK, ULK-1 and ACC phosphorylation in a time dependent manner. Interestingly, DIM, 4,4 dibromoDIM and 7,7 dichloroDIM induced the oncogenic protein AEG-1 time dependently in LNCaP and C42B cells. Downregulation of AEG-1 or AMPK inhibited DIM- and ring-DIM-induced autophagy. Pretreatment with ULK1 inhibitor MRT 67307 or siRNAs targeting AEG-1 or AMPK potentiated the cytotoxicity of DIM and ring-DIMs. Interestingly, downregulation of AEG-1 induced senescence in cells treated with toxic concentrations of DIM or ring-DIMs, and inhibited the onset of apoptosis in response to DIM or ring-DIMs. In summary, we identified a novel mechanism for DIM- and ring-DIM-induced protective autophagy, via induction of AEG-1 and activation of AMPK. Our findings could help towards the development of novel drug therapies for prostate cancer that include selective autophagy inhibitors as adjuvants.']",
        "Doc_id":"AACR_2017-3298",
        "Doc_title":" Diindolylmethane and its halogenated analogues induce autophagy in human prostate cancer cells via induction of the astrocyte-elevated gene-1 (AEG-1).",
        "_version_":1606189029163794433},
      {
        "Meeting_name":" Transcription down-regulation of c-Myc through nucleic acid clamp-mediated stabilization of the promoter G-quadruplex",
        "Background":"[\"MYC overexpression occurs in up to 80% of all cancers. Down-regulating MYC's expression is an effective therapeutic strategy for the treatment of many of these cancers, and particularly for non-Hodgkin's lymphoma (NHL). NHL is the fifth most common cancer type, accounting for 5% of all cancers and 4% of all cancer deaths. Developing MYC-targeting therapeutics will be very impactful to NHL patients. In the current study, we have developed a nucleic acid clamp to transcriptionally down-regulate MYC expression by stabilizing the G-quadruplex (G4) formed in the nuclease hypersensitivity element III1 promoter region. The clamps complement nucleotides on the 5- and 3- regions flanking the G4-forming sequence, linked together with an 18 angstrom abasic moiety. To date, the binding affinity and specificity, G4 structure stabilizing ability, MYC down-regulation capability, and the selective cytotoxicity on cancerous vs non-cancerous cell lines of these clamps have been confirmed by EMSA and electronic circular dichroism, DMS footprinting, luciferase reporter assay, and MTS viability assay respectively. Recently, various replacements have been explored to replace the abasic moiety with non-complementary nucleic acids and to optimize the phosphate backbone with peptide nucleic acids. In addition, complexation with block co-polymers is under investigation to develop a functionalizable nanotherapeutic for NHL. The highly selective G4 stabilizing ability of the clamps used in the current approach offers an advantage over traditional G4 stabilizing small molecules. This novel approach is a promising therapeutic for the treatment of MYC related malignancies, and provides a framework for future G4-therapeutic development for other high-value genes, such as kRAS, VEGF, c-KIT and many more.\"]",
        "Doc_id":"AACR_2016-4514",
        "Doc_title":" Transcription down-regulation of c-Myc through nucleic acid clamp-mediated stabilization of the promoter G-quadruplex",
        "_version_":1606188974247772160},
      {
        "Meeting_name":" A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma.",
        "Background":"['Background', ' Pazopanib is a small molecule tyrosine kinase inhibitor of VEGFR1-3, c-kit, and PDGFR. Nasopharyngeal carcinoma (NPC) is endemic in Asia and angiogenesis is important for growth and progression. We hypothesized that anti-angiogenesis with pazopanib would be effective in NPC. Methods', \" An open-label monotherapy study of pazopanib in patients with WHO type II/III NPC and metastatic/recurrent disease who failed at least one line of chemotherapy was done. A Simon's optimal 2-stage design was employed. Patients with ECOG 0-2 and adequate organ function were treated with pazopanib 800 mg daily on a 21-day cycle. The primary endpoint was the best overall response (CR/PR/SD) achieved after 12 weeks of treatment. Secondary endpoints included toxicity and progression-free survival. Dynamic-contrast enhanced computed tomography (DCE-CT) of target lesions and pharmacokinetics (PK) of pazopanib was also done. Results\", ' Thirty-three patients were accrued (August 2007-August 2009). All patients were ECOG 0-1 with median age of 50 years (range 36-68). Patients had received median of 3 (range 1-7) prior chemotherapy. There were 2 (6.1 %) partial responses, 16 (48.5%) stable disease, 14 (42.4%) progressive disease, 4 (12.1%) not evaluable for response (2 deaths, 2 declined further evaluation), giving a clinical benefit rate of 54.5% (95% CI 38.0-70.2). Fifteen patients (45%) received more than 5 cycles of treatment, 6 (18.2%) had PR/SD that lasted at least 6 months and one patient remains on treatment. One patient each died from epistaxis and myocardial infarction before response evaluation. Grade 3/4 toxicities included fatigue (15.2%), hand-foot syndrome (15.2%), anorexia (9.1%), diarrhea (6.1%), vomiting (6.1%), dehydration (3%), hypertension (3%), hyponatremia (6%), neutropenic fever (3%), proteinuria (3%), pericardial effusion (3%). Serial DCE-CT scans demonstrate significant reductions in tumor blood flow, permeability surface area product, and fractional intravascular blood volume. Conclusions', ' Pazopanib appears to be active in nasopharyngeal carcinoma with an acceptable toxicity profile. Further PK/PD analyzes are ongoing.']",
        "Doc_id":"ASCO_49391-74",
        "Doc_title":" A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma.",
        "_version_":1606188997345804288},
      {
        "Meeting_name":" Evaluation of ENMD-2076 in combination with anti-PD1 in syngeneic cancer models.",
        "Background":"['ENMD-2076 is a clinical stage compound with potent activity towards Aurora A and angiogenic kinases. ENMD-2076 has shown promising activity in multiple Phase 1 clinical trials, as well as in a Phase 2 trial in advanced ovarian cancer. ENMD-2076 is currently the subject of several ongoing Phase 2 clinical trials including fibrolamellar carcinoma, triple-negative breast cancer (TNBC), advanced/metastatic soft tissue sarcoma (STS), and advanced ovarian clear cell carcinomas (OCCC). ENMD-2076 has been developed to date as a single agent, however ENMD-2076 inhibits a spectrum of targets including Aurora A, FAK, CSF1R, c-Kit, and KDR, that are potentially involved in immune evasion mechanisms. These kinases have been shown in published studies, when inhibited, to enhance or augment the activity of immune checkpoint inhibitors such as anti-PD1. A study was thereby conducted in syngeneic models to determine the utility of ENMD-2076 combined with immune checkpoint inhibition as a rational strategy for cancer therapy. The study evaluated the efficacy of ENMD-2076 administered daily by oral gavage in the MC38 and CT26 colon cancer models, alone and in combination with an anti-PD1 antibody. Xenografts were established in the appropriate mouse strain (C57BL/6 and BALBc, respectively) by the subcutaneous inoculation of MC38 or CT26 cells into the right flank of female mice. Treatment was initiated 7 days following inoculation when tumor volumes had reached a mean volume of approximately 85 mm3. All treatments were well tolerated, with no significant body weight loss seen during either study. While CT26 tumors were relatively refractory to single agent ENMD-2076, tumor regression was observed in several MC38-bearing animals suggesting an immune activating mechanism. In both models a trend was observed for an augmentation of anti-tumor response in combination relative to single agent ENMD-2076 and anti-PD1 alone. Further studies to evaluate mechanism and an assessment of re-challenge experiments in animals exhibiting complete regression of tumors will be discussed. These studies support the further evaluation of ENMD-2076 in combination with immune checkpoint inhibition as a strategy for cancer therapy.']",
        "Doc_id":"AACR_2017-1642",
        "Doc_title":" Evaluation of ENMD-2076 in combination with anti-PD1 in syngeneic cancer models.",
        "_version_":1606189011333808128},
      {
        "Meeting_name":" Microarray analysis reveals distinct gene set profiles between gastric and intestinal gastrointestinal stromal tumors",
        "Background":"['Background', \" Gastrointestinal stromal tumor (GIST) is known to originate from the interstitial cells of Cajal or its precursors with a gain-of-function mutation of the c-kit or PDGFRA gene. GISTs are most commonly found in the stomach, followed by the small intestine. It is known that patients with intestinal GIST have markedly higher risks for recurrence compared to those with gastric GISTs. According to Miettinen's risk classification, intestinal GISTs are categorized in higher risk group compared with gastric GISTs at the same size and mitotic index. In this study, we sought to address mechanisms underlying the clinically malignant phenotype of intestinal GISTs.Methods\", ' Fresh frozen samples of 6 primary gastric GISTs, 3 primary intestinal GISTs and 6 metastatic liver GISTs were utilized for cDNA microarray analysis. None of the patients had received imatinib therapy before surgery. Gene expression levels were compared between primary gastric and intestinal GISTs using gene set enrichment analysis (GSEA). Protein levels of SLIT2 were analyzed by immunohistochemistry in 25 primary gastric GISTs and 10 intestinal GISTs.Results', ' Microarray analysis of primary gastric and intestinal GISTs and metastatic liver GISTs classified them into two groups according their gene expressions. One group consisted of primary gastric GISTs without postoperative recurrence and the other consisted of clinically malignant GISTs, intestinal GISTs and metastatic liver GISTs, suggesting that intestinal GISTs potentially show gene expression profile similar to clinically malignant and metastatic GISTs. GSEA revealed that the gene set MITOTIC_CELL_CYCLE was upregulated in intestinal GISTs compared with gastric GISTs, consistent with previous reports that intestinal GISTs show higher mitotic count. The gene set NEURON_DIFFERENTIATION was downgulated in intestinal GISTs compared with gastric GISTs that may help explain mitosis-independent mechanisms underlying the clinically malignant phenotype of intestinal GISTs. In this gene set, we focused on SLIT2, downregulation of which has been reported to be associated with aggressive phenotypes in human cancers. Immunohistochemistry revealed that intestinal GISTs expressed lower SLIT2 protein than gastric GISTs, and that high-risk gastric GISTs and intestinal GISTs express comparable levels of SLIT2 protein which were lower than low-risk gastric GISTs. In SLIT2-high GISTs, tumor size was significantly smaller than in SLIT2-low GISTs, whereas mitotic counts and MIB-1 index were comparable among three groups according to SLIT2 intensity.Conclusions', ' Gene expression profile of intestinal GISTs was similar to that in metastatic liver GISTs. Expression levels of SLIT2 protein were lower in intestinal GISTs compared with gastric GISTs. Besides higher proliferative activity, downregulation of SLIT2 could be involved in clinically malignant phenotypes of intestinal GISTs.']",
        "Doc_id":"AACR_2015-2170",
        "Doc_title":" Microarray analysis reveals distinct gene set profiles between gastric and intestinal gastrointestinal stromal tumors",
        "_version_":1606189034322788353},
      {
        "Meeting_name":" Therapeutic potential of multi-kinase inhibitor sorafenib in osteosarcoma cells",
        "Background":"['Osteosarcoma (OS) is the most common primary malignant bone tumor in childhood and adolescence. The introduction of multiagent chemotherapy has greatly improved the survival of patients with osteosarcoma, however, the improvement in survival has reached a plateau. Therefore, search for novel agents focused on different mechanisms is mandatory to further improve the survival of osteosarcoma patients. Sorafenib is the first oral multi-kinase inhibitor that directly blocks the auto-phosphorylation of several receptor tyrosine kinases (VEGFR1, 2 and 3, PDGFR, c-Kit and RET) and inhibits Raf kinase isoforms (wild-type Raf1, and B-Raf and mutant b-raf V600E) activity to prevent tumour growth by anti-angiogenic, antiproliferative and/or pro-apoptotic effects. Here, we describe the effect of sorafenib in human OS cell lines on the proliferation and migration. And we also report combination effects with irradiation (IR) and cisplatin. We measured cell proliferation by MTT assay and used Annexin V and flow cytometry to assess whether sorafenib induce apoptosis in the OS cells. Next the migration of sorafenib-treated OS cells was determined by wound-healing assay and the synergistic effect between sorafenib and IR was evaluated using colony-forming assay. Also CI values of drug combinations of cisplatin and sorafenib in OS cells were calculated using Calcusyn software to assess whether sorafenib can be useful when used in conjunction with cisplatin. We found that sorafenib effectively inhibits cell proliferation, induced apoptosis, and prevents cellular migration. And our results demonstrate that the combination of two drugs, sorafenib and cisplatin, showed synergistic effects and colony-forming assay showed that sorafenib enhanced the radiosensitivity of OS cells. In conclusion, we found that sorafenib exerts therapeutic potentials in OS cells and suggests the possibilities of using sorafenib as a potential adjuvant therapy for the treatment of osteosarcoma.']",
        "Doc_id":"AACR_2012-2824",
        "Doc_title":" Therapeutic potential of multi-kinase inhibitor sorafenib in osteosarcoma cells",
        "_version_":1606188998788644864},
      {
        "Meeting_name":" Activity of the multi-tyrosine kinase inhibitor sunitinib in neuroblastoma tumors.",
        "Background":"['Background', ' Neuroblastoma (NB) is the most commonly diagnosed extracranial solid malignancy during infancy. Although curable in its early stages, metastatic tumors are associated with a bad prognosis and a poor survival. Receptor tyrosine kinases have been associated with oncogenic transformation in many human tumors. Sunitinib is multityrosine kinase inhibitor (c-kit, PDGFR and VEGFR) that has shown antitumor activity in some solid tumors. It was our intention to evaluate the antitumor activity of the multityrosine kinase inhibitor sunitinib in NB in order to identify novel therapeutic options of treatment. Methods', ' Here, we tested the antitumor activity of sunitinib, using cancer cell lines and in vivo xenografted mouse models. MTT proliferation, apoptosis assays and biochemical experiments were performed to investigate the molecular bases of the action of sunitinib alone or in combination with standard chemotherapy. Results', ' Sunitinib exhibited a potent antitumor activity in vitro (IC50 0.8-2.6 M) in a representative panel of NB cell lines (SH-SY5Y, SK-N-BE2 and SK-N-AS). It also showed a high therapeutic index when tested in the non-transformed cells 293T and MCF10A. When combined with chemotherapies (cisplatin and doxorubicin) used for the treatment of NB tumors sunitinib was synergistic at very low doses (0.1 M). Sunitinib induced cell cycle arrest and stimulates apoptosis at different doses. Mechanistically sunitinib inhibited several receptor tyrosine kinase proteins and the downstream PI3-AKT pathway. In vivo xenograft studies revealed a significant antitumor activity of sunitinib compared with the control group in two types of cells lines (SH-SY5Y, p=0.02 and SK-N-BE, p=0.08). Sunitinib demonstrated an anti-angiogenic effect in vivo with a reduction of markers associated with angiogenesis (factor VIII). Conclusions', ' Sunitinib demonstrates antitumor activity in several in vitro and in vivo models. Theses results support the development of sunitinib in clinical studies alone or in combination with chemotherapy.']",
        "Doc_id":"ASCO_44241-74",
        "Doc_title":" Activity of the multi-tyrosine kinase inhibitor sunitinib in neuroblastoma tumors.",
        "_version_":1606189032910356480},
      {
        "Meeting_name":" Cancer MET at the metastatic lesion preserves the malignant features acquired via EMT.",
        "Background":"['Purpose', ' Cancer EMT is one of the mechanisms to acquire malignant features including invasiveness, drug resistance and stemness. However, the subsequent mechanism after EMT toward progression has not been fully understood yet. Based on the EMT-centered theory, it is simply thought that the reversal event of EMT, MET,\" is caused in the tumor cells at the distant metastatic lesions. However, the molecular mechanism still remains unclear. In this study, we attempted to clarify the post-EMT mechanism in tumor cells.Results', ' Firstly, we prepared tumor cells harvested from metastatic lesions of mice after tumor implantation provisionally as post-EMT tumor cells. Murine metastatic melanoma B16-F10 cells were transduced with a neo resistant gene, and were subcutaneously (s.c.) implanted in many C57BL/6 mice to obtain spontaneous tumor metastasis. Three weeks later, various tissues including bone marrow were harvested from the mice, and the single-cell suspensions were cultured in G418-supplemented medium for tumor selection. To characterize the post-EMT tumor cells, RT-PCR, immunostaining and cellular functional assay were conducted. As compared to the primary tumor cells harvested from s.c. tumor tissues, these tumor cells proliferated extremely slowly, and were resistant to chemotherapeutics, but rapidly grew in vivo after implantation. However, these tumor cells were very adhesive accompanied by increase of epithelial markers such as E-cadherin, but not mesenchymal markers such as Snail, indicating epithelial features. In addition, its chemoresistance and in vivo tumorgenesis activity of these tumor cells were superior to those of even Snail-transduced B16-F10 tumor cells, which were harvested from the metastatic lesions in a similar way. DNA microarray analysis revealed the significant upregulation of epithelial markers and drug resistant genes such as c-kit and GDF15 in the post-EMT tumor cells, as compared to those of the Snail transfectant. These imply that MET may not be just a reversion of EMT.Conclusions', ' These results suggest that tumor cells revert into an epithelial state preserving malignant features acquired via EMT even after Snail lost at the metastatic lesions toward progression. We are now attempting to elucidate the molecular mechanism specific for the unique transition utilizing DNA microarray data.']",
        "Doc_id":"AACR_2013-283",
        "Doc_title":" Cancer MET at the metastatic lesion preserves the malignant features acquired via EMT.",
        "_version_":1606188981760819201},
      {
        "Meeting_name":" Analysis of signal pathway activation in hepatocellular carcinoma",
        "Background":"['Background', ' The pathogenesis of hepatocellular carcinoma invovles multi-stage development of molecular aberrations affecting signaling pathways that regulate cancer growth and progression. Treatment strategies have focused on inhibition of the Ras effector pathway with inhibitors of Raf, such as sorafenib in HCC. Greater understanding of the cellular response to sorafenib is needed to tailor targeted therapy for individual patients and identify those more likely to benefit. Methods', ' We performed immunohistochemistry on a tissue microarray of tumor and adjacent liver tissue from 40 HBV-infected HCC patients who were treated with sorafenib, and 20 normal liver. We compared the levels of 8 signaling proteins including growth factor receptors (PDGFRa, VEGFR1, VEGFR2, VEGFR3, c-kit, c-met, IGF-R, EGFR), tumor suppressors (PTEN) and their downstream phosphorylated (p-) signal transducers (p-RAF, p-MEK1/2, p-ERK1/2; PI3K, p-AKT, NFkB, axin, -catenin,p-GSK3, p-mTOR, p-S6, p-70S6K, p-JNK, p-SRC, p-STAT3, c-fos, c-jun) in cancer cells and endothelial cells of HCC to those in non-neoplastic liver. Results', ' The overall profiles of signalling protein expression levels, activation states and subcellular distribution in HCC cells and endothelial cells were distinguishable from non-neoplastic hepatocytes. The ERK pathway activation was correlated with low level of nuclear -cat and high level of p-mTOR (p<0.05). Long survival (>6m) patients were characterized by high level of nuclear pERK and low level of p-AKT, p-GSK3 (p<0.05) in tumor cells. The high microvessel density and the presence of micrometastases correlated with high level of VEGFR, p-ERK and p-SRC in endothelial cells. Conclusions', ' Sorafenib may affect signalling through the Ras/Raf/MAPK/ERK pathway. HBV-related HCC patients with. overactivation of signal transduction cascade MAPK/ERK and PI3K/AKT pathways in tumor cells and/or endothelial cells may benefit from the targeted treatment.']",
        "Doc_id":"ASCO_32870-65",
        "Doc_title":" Analysis of signal pathway activation in hepatocellular carcinoma",
        "_version_":1606188994002944000},
      {
        "Meeting_name":" AIP1 suppresses tumor metastasis by regulating tumor microenvironment and metastatic niche",
        "Background":"['AIP1 (also called DAB2IP, a new member of RAS-GAP family protein) is downregulated in a variety of human cancer tissues. We and others have recently reported that AIP1 functions as a tumor suppressor in prostate cancer models. However, the role of AIP1 in regulating tumor microenvironment and metastatic niche is not known. In the present study, we implanted tumor cells with the same genetic background into C57BL/6 wild type (WT) and AIP1-deficient (AIP1-KO) mice to address this question. In subcutaneous (SQ) allograft models using B16 melanoma and LLC Lewis lung carcinoma, tumor growth and metastasis to multiple organs including lymph node, lung, liver, spleen and bone marrow were significantly enhanced in AIP1-KO host, suggesting AIP1 in tumor microenvironment limits tumor metastases. However, a direct intravenously injection of tumor cells resulted in no differences in tumor metastasis between WT and AIP1-KO mice, indicating AIP1 in host regulates tumor metastasis at steps prior to extravasation to target tissues. We examined effects of AIP1 deletion on the induction of local inflammation, tumor cell epithelial-mesenchymal transition (EMT), generation of metastatic routes (formation of new blood and lymphatic vessels) and establishment of pre-metastatic niche in distance tissues. SQ tumors in AIP1-KO host showed more profound increases in macrophage infiltration, tumor cell EMT, intratumoral angiogenesis and peri-tumoral lymphangiogenesis as well as lymphangiogenesis in lymph nodes prior to the detection of metastatic tumor cells. Finally, SQ tumor induced an establishment of pre-metastatic niche in lung as indicated by increased immunostaining for fibronectin and accumulation of VEGFR1, c-Kit and CXCR-positive cells which were augmented in AIP1-KO mice. Importantly, WT recipient with AIP1-KO bone marrow-derived cells showed similar phenotype to AIP1-KO mice in tumor growth and metastasis. Taken together, our data suggest that AIP1 functions as tumor metastasis suppressor by regulating tumor microenvironment, metastatic routes and pre-metastatic niche.']",
        "Doc_id":"AACR_2014-129",
        "Doc_title":" AIP1 suppresses tumor metastasis by regulating tumor microenvironment and metastatic niche",
        "_version_":1606189005739655168},
      {
        "Meeting_name":" Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.",
        "Background":"['Background', '  Pazopanib is an oral multi-kinase inhibitor of VEGFR-1, -2, -3, PDGFR- and - and c-Kit.  In the phase III AGO-OVAR16 study (NCT00866697), pazopanib maintenance therapy significantly increased progression free survival (PFS) in patients with ovarian cancer who have not progressed after first line therapy; however such benefit was not observed in a phase II study (NCT01227928) conducted in East Asian countries. In both studies, there is heterogeneity in patient response (safety and efficacy) to pazopanib; we hypothesized that germline genetic variation may contribute to this heterogeneity.  Methods', '  GWAS analyses were conducted using combined patient data from the AGO-OVAR16 study (N=477, pazopanib) and the East Asian phase II study (N=73, pazopanib), which had similar eligibility criteria and treatment schedules.  In aggregate N=387 patients receiving pazopanib provided consent for pharmacogenetic research. GWAS were conducted using normal, ordinal, and Cox regression models to test 30M genetic variants (genotyped or imputed) for association with PFS, overall survival, CA-125 change, bilirubin elevation, transaminase elevation, blood pressure change, hand foot syndrome, diarrhoea, fatigue, neutropenia, thrombocytopenia, and dose reduction or dose discontinuation.  Results', '  At the genome wide significance level (P5x10-8), common variants near UGT1A1 were associated with bilirubin elevation (P=1.1x10-21), consistent with our previous observations in pazopanib treated patients with renal cell carcinoma. Common variants near a disintegrin and metalloprotease (ADAM) domain family genes ADAM28ADAM7 were associated with CA-125 change (P=2.9x10-10).  No other common variants reached genome-wide significance.  Conclusions', '  Some instances of isolated bilirubin elevation in pazopanib treated patients with ovarian cancer may be benign manifestations of Gilberts syndrome.  We identified a novel association between germline variants in ADAM28ADAM7 and CA-125 change; further studies of this finding may yield insights into mechanisms underlying differential response to pazopanib in patients with ovarian cancer.']",
        "Doc_id":"ASCO_132722-144",
        "Doc_title":" Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.",
        "_version_":1606189005772161024},
      {
        "Meeting_name":" Principal",
        "Background":"['Background', '    Pazopanib is an oral, selective, multikinase inhibitor of VEGF receptors 1/2/3, PDGF receptors /, and stem cell factor receptor (c-Kit) that is approved for first-line treatment of patients with advanced renal cell carcinoma (RCC) and for patients who received prior cytokine therapy.  The COMPARZ study of pazopanib versus sunitinib as first-line treatment demonstrated noninferiority of pazopanib for progression-free survival (PFS) in the intention-to-treat population, and pazopanib statistically favored health-related quality of life (HRQoL) in 11 of the 14 domains measured (NEJM 2013;369', '722-31).  The PISCES patient preference study demonstrated that significantly more patients preferred pazopanib over sunitinib due to overall better HRQoL and less fatigue (JCO 2012;30 suppl 15', 'CRA4502).  The purpose of the PRINCIPAL study is to evaluate the real-world effectiveness and safety of pazopanib in patients with advanced or mRCC.   Methods', '    This is a global, multicenter, prospective, observational study (VEG115232, NCT01649778) designed to enrol up to 700 patients. Primary endpoints include PFS, overall response rate, overall survival, relative dose intensity data, HRQoL data, and safety data.  Additional treatment strategies for RCC will be obtained post-progression.  Key inclusion criteria include a clinical decision to initiate treatment with pazopanib (before enrolment in the study), no prior systemic therapy for advanced or mRCC, and no participation in an interventional trial.  The study has enroled 339 patients to date and is currently recruiting in 15 countries, including Europe, Asia, Latin America, and the United States.  This study will determine patient outcomes with pazopanib in a real-world setting in terms of efficacy, safety, and patient compliance outside the normal parameters of a controlled trial.  PRINCIPAL will also provide further data in patient groups that were under-represented in the controlled clinical trials to date, such as the elderly and patients with co-morbidities. Clinical trial information', ' NCT01649778.']",
        "Doc_id":"ASCO_129989-144",
        "Doc_title":" Principal",
        "_version_":1606189037359464448},
      {
        "Meeting_name":" A retrospective, multicenter analysis of the clinicopathologic features of extra-gastrointestinal stromal tumor (EGIST).",
        "Background":"['Background', '  GIST is the most common mesenchymal tumor of the gastrointestinal tract although it constitutes only 1 percent of primary GI malignancy. Some GIST develops outside the alimentary canal such as omentum, mesentery, and retroperitoneum. These types are called extra-gastrointestinal stromal tumors (EGISTs). In this study, we retrospectively analyzed the clinicopathologic features of EGIST patients from 4 institutes in Korea Methods', '    From 2004 to 2012, a total of 43 patients with EGIST were identified. The clinicopathologic features including gender, age, location, tumor size, hisology, mitotic rate, IHC features, and genetic status were collected along with survival analysis.  Results', '    The median age was 55 (range 29-80) and M', 'F ratio was 20', '23. The most common sites were mesentery (11) and retroperitoneum (11) followed by omentum (7) and vagina (3). Other primary sites were liver (2), ovary (2), pancreas (2), perianal area (2), chest wall (1), pleura (1) and prostate (1). The median tumor size was 8.0 cm (range 2.6  30) and median mitotic rate was 5.0/50HPF (0  185) 4 cases were negative for c-Kit IHC, which were all confirmed by either IHC for DOG1 or mutational analysis. KIT analysis was performed in 10 cases with 6 wild-types and 4 exon 11 mutation were found. As for PDGFR, 4 cases were analyzed which were all exon 18 mutation. Among 43 patients, 26 patients had undergone curative resection and 8 patients had unresectable disease and had taken palliative imatinib. Among 26 patients who had undergone curative resection, 12 patients had taken adjuvant imatinib and 14 patients had been observed without imatinib. The median tumor size of two groups were 11.0 (3.0  19.0) vs. 5.85 (2.6  18.9) and the median mitotic rate was 7.0 (2  18.5) vs. 1.0 (0  45). Regarding the 9 patients taken palliative imatinib, median tumor size was 20.9 (16.5  30.0), median mitotic rate was 15.0 (3  60) and median PFS was 22.7 months (95% CI 7.7  37.7). Conclusions', '    As the biologic behavior of GISTs is different by location, a more stratified strategy is needed for managing EGISTs including incorporation of molecular features. We are planning to perform further mutation analysis in this cohort.']",
        "Doc_id":"ASCO_123080-143",
        "Doc_title":" A retrospective, multicenter analysis of the clinicopathologic features of extra-gastrointestinal stromal tumor (EGIST).",
        "_version_":1606189025462321152},
      {
        "Meeting_name":" High neuropilin-1 expression on monocytes is positively associated with trastuzumab-mediated antibody-dependent cellular cytotoxicity of the HER2-overexpressing breast cancer cell line",
        "Background":"['PurposeNeuropilin-1 (Nrp1) was initially characterized as a guide for migrating cells and axons in developing nervous systems and is essential for the precise formation of neurons and vasculature. However, it was recently reported to also play an important role in the immune system. This study aimed to investigate the role of Nrp1 on monocytes in trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) targeting the HER2-positive human breast cancer cell line SKBR3. In addition, we evaluated the gene expression profile of monocytes expressing high and low levels of Nrp1.MethodsPeripheral blood mononuclear cells from healthy volunteers were prepared using BD Vacutainer CPT Cell Preparation Tubes. The cells were stained with fluorescein isothiocyanate-conjugated anti-CD14 and allophycocyanin-conjugated anti-Nrp1 antibodies, and Nrp1high and Nrp1low monocyte subsets were sorted using FACSAria. These cells were used as effector cells in a conventional ADCC assay with SKBR3 as target cells and trastuzumab as the antibody. Target cell cytotoxicity was measured using the LDH cytotoxic test kit. The effector cell to target cell ratios of 20', '1 and 10', '1 were used. Gene expression analysis was performed by Affymetrix GeneChip microarrays. All study protocols were approved by the Ethics Committee for Clinical Research, Kyoto University Hospital, Kyoto, Japan (authorization number G424).ResultsThe LDH cytotoxic test revealed significantly higher target cancer cell cytotoxicity in sorted Nrp1high monocytes than in Nrp1low monocytes (75% vs. 45%, p<0.01). Trastuzumab-mediated ADCC was significantly suppressed by Nrp1 neutralization antibodies in a dose-dependent manner (Control arm 14.3%, Treatment arm 6%; p<0.01). Gene expression analysis revealed that 308 genes were up-regulated in the Nrp1high population, including monocyte-specific chemokine receptor and hematopoietic transcriptional factor.ConclusionThese results suggest that determination of Nrp1 expression can be used to classify monocytes as populations with and without cellular cytotoxic activity. Analysis of Nrp1 expression levels in monocytes can therefore be used to identify HER2-positive breast cancer patients for whom trastuzumab therapy will be less effective.']",
        "Doc_id":"AACR_2014-153",
        "Doc_title":" High neuropilin-1 expression on monocytes is positively associated with trastuzumab-mediated antibody-dependent cellular cytotoxicity of the HER2-overexpressing breast cancer cell line",
        "_version_":1606189000183250944},
      {
        "Meeting_name":" S100P is a potential biomarker in distinguishing mucinous from non-mucinous pancreatic cysts and predicting invasive adenocarcinoma",
        "Background":"['Introduction. Our previous publications demonstrated that S100P was a highly sensitive biomarker in identifying pancreatic mucinous neoplasms (PMNs) and invasive ductal adenocarcinomas (ADCs) on both cytological and surgical specimens. When working on pancreatic cystic lesions, there are two important undertakings', \" 1) distinguishing mucinous neoplasms from non-mucinous cysts and 2) predicting the presence of invasive adenocarcinomas. In this study, we investigated the potential utility of S100P for these purposes.Design. Thirty pancreatic cystic fluid samples obtained by EUS-FNA biopsy were retrieved from Geisinger Biospecimen Bank. Diagnosis was based on definitive cytological diagnosis in all cases and additional surgical pathology confirmation in 11 cases. These 30 samples included 7 benign cysts in Group 1, 14 PMNs in Group 2, and 9 ADCs in Group 3. The S100P protein level of each sample was quantitatively measured by enzyme-linked immunoassay (ELISA) (CircuLex S100P ELISA kit, MBL International Corporation) according to the vendor's protocol.Results. The results are summarized in Table 1. Marked elevation of S100P was seen in 6 of 9 ADCs (2129.81 + 1834.34 ng/ml), in contrast to the moderate increase in Group 2 (666.67 + 1439.91 ng/ml) and the minimal increase in Group 1 (22.27 + 18.62 ng/ml). Using 50 ng/ml as a cutoff value to differentiate a PMN/ADC (Group 2 and Group 3) from a benign cyst (Group 1), the sensitivity, specificity, positive predictive value and negative predictive value for identifying a PMN/ADC were 60.9%, 100%, 100%, and 43.8%, respectively.Conclusion. These preliminary data suggest that S100P is a useful biomarker in identifying invasive adenocarcinomas and in distinguishing mucinous neoplasms from non-mucinous cysts. Caution should be taken since some ADCs may show only mildly increased S100P levels, similar to some PMNs and non-mucinous cysts. Additional study in a large series of cases is needed to substantiate the current findings.Summary of S100P protein level (ng/ml) in 30 pancreatic cysts by ELISA\"]",
        "Doc_id":"AACR_2014-1861",
        "Doc_title":" S100P is a potential biomarker in distinguishing mucinous from non-mucinous pancreatic cysts and predicting invasive adenocarcinoma",
        "_version_":1606189008763748352},
      {
        "Meeting_name":" SRMS regulates normal and oncogenic KIT signaling.",
        "Background":"['SRMS (Src-related tyrosine kinase lacking C-terminal regulatory tyrosine and N-terminal myristoylation sites) belongs to a family of non-receptor tyrosine kinases, which harbours a Src homology 3 and a Src homology 2, as well as a protein kinase domain. SRMS was first identified in a screen for the genes that regulate the growth and differentiation of neuroepithelial cells. SRMS, however, is an understudied member of this family. The present study was undertaken in order to explore the role of SRMS in signaling downstream of KIT. The receptor tyrosine kinase KIT, also known as the stem cell factor receptor, plays a key role in several developmental processes and have been implicated in many human cancers such as gastrointestinal stromal tumors, acute myeloid leukemia and testicular carcinoma. To understand the role of SRMS in KIT signaling, we generated Ba/F3 cell lines overexpressing KIT and SRMS. We observed that SRMS regulates normal and oncogenic KIT signaling differentially with respect to cell proliferation and apoptosis. SRMS association triggers KIT ubiquitination which in turn downregulates the receptor. Further, expression of SRMS downregulates wild-type KIT-mediated phosphorylation of AKT, ERK1/2, p38. Taken together the data demonstrates that SRMS regulates both normal KIT and an oncogenic mutant of KIT, and have differential impact on receptor downstream signaling.']",
        "Doc_id":"AACR_2017-340",
        "Doc_title":" SRMS regulates normal and oncogenic KIT signaling.",
        "_version_":1606188979304005632},
      {
        "Meeting_name":" Evaluation of ALK-1 expression in circulating endothelial cells (CECs) as an exploratory biomarker for PF-03446962 undergoing phase I trial in cancer patients.",
        "Background":"['Background', \" ALK-1 is a member of the TRI family & a novel target for antiangiogenic therapy (Rx). PF- 03446962 (PF) is a fully human mAB (IgG2, ) generated against ALK-1 with dose-dependent preclinical antiangiogenic activities (Hu-Lowe et al, Proc AACR, 2009). This study's objectives were to determine whether\", ' 1) CECs in cancer patients express ALK-1; and 2) whether therapy with PF against ALK-1 will modulate ALK-1 expression or CEC function in an ongoing Ph I trial. Methods', ' The human mAb was conjugated with alexa fluor 647. ALK-1 expression was assayed by a standardized multicolor flow cytometry assay (Mancuso et al, CCR 2009). Results', ' ALK-1 expression was characterized on human vascular (HUVEC) & lymphatic (HDLC) endothelial cells; HUVEC & HDLC cells highly express ALK-1 (>99% of these cells are ALK- 1+). ALK-1 expression was assessed in healthy controls (n=17) & cancer patients after normalizing for CEC viability. Patients with advanced malignancies had increased numbers of ALK-1+ CECs', ' Patients with breast ca (n=12), melanoma (n=8), NSCLC (n=11), & CRC (n=4) had 1612, 3923, 5030, & 6225 ALK-1+ CECs/mL, respectively, vs 76 ALK-1+ CECs/mL in controls. In contrast, ALK-1 expression was minimally or not expressed in pts with hematologic malignancies; ALK-1 was absent in CD117+ or CD34+ bone marrow cells. In the Ph I trial, preliminary evidence suggests that PF may alter CEC function; ALK-1+ CECs were markedly reduced in the 1st two pts studied at EIO after 22 days on Rx. Conclusions', ' ALK-1 is expressed in CECs. Flow cytometry enables rapid assay of ALK-1 expression in cancer patient blood. ALK-1 is expressed in an increased number of CECs/mL in cancer pts with solid malignancies vs controls. ALK-1 expression in CECs in pts with NSCLC & CRC may correspond to high ALK-1 expression observed in corresponding nonmatched tumor microarrays in addition to other malignancies such as sarcoma, SCLC & neuroendrocine pancreatic ca (Fiedler, Proc ASCO, 2009). Additional preliminary Ph I results will be reported as part of assessing whether CECs may have any role as biomarkers to potentially detect patients with ALK-1+ solid malignancies or monitor anti-ALK-1 therapy.']",
        "Doc_id":"ASCO_33340-65",
        "Doc_title":" Evaluation of ALK-1 expression in circulating endothelial cells (CECs) as an exploratory biomarker for PF-03446962 undergoing phase I trial in cancer patients.",
        "_version_":1606189037127729152},
      {
        "Meeting_name":" Arsenic induces human bronchial epithelial cell transformation featured with tumor-initiating cells",
        "Background":"['Arsenic is a well-known human carcinogen. Chronic exposure to arsenic is associated with cancers in various tissues, including skin, urinary bladder, lung, liver, kidney and prostate. However, the mechanism underlying arsenic-induced carcinogenesis remains elusive. Here, we demonstrate that long-term (six month) exposure to low levels of sodium arsenite (0.25  M) in human bronchial epithelial cell line (BEAS-2B) results in altered morphology, increased cell proliferation and anchorage-independent colony formation in soft agar, indicative of malignant transformation of these cells. Moreover, tumorigenesis analysis revealed that s.c. inoculation of the arsenic-transformed cells can induce tumors in nude mice. The tumors can be observed after 2-3 weeks even only 500 arsenic-transformed cells were injected, suggesting that these transformed cells induced by long-term and low-dose arsenic treatment are highly tumorigenic. Additional studies indicated that some of these arsenic-transformed cells exhibit characteristics of tunor-initiating cells (TICs) or cancer stem cells (CSCs), such as overexpression of Oct3/4, Nanog, Sox2, Klf4, and C-myc. Tumor sphere formation assay, a general procedure in defining TICs or CSCs, suggested that about 5% of these arsenic-transformed cells can form tumor spheres in non-adherent plates. The tumor sphere forming cells were enriched through serial passage of the cells collected from tumor spheres. Flow cytometry sorting showed that 90% of these sphere cells are CD49f positive, whereas CD133, CD44, EpCAM, and c-kit were not detected. Overexpression of CD49f was confirmed by immunoblotting, which indicated an increased CD49f level in the arsenic-transformed cells relative to the non-transformed BEAS-2B cells. Finally, the ability of sphere formation and colony formation in soft agar was compared between the cells showed the strongest and the weakest CD49f expression and suggested that the cells with the strongest CD49f expression are more capable of forming tumor spheres and colonies. In conclusion, our data suggested that the transformed cells induced by arsenic have features of TICs or CSCs.']",
        "Doc_id":"AACR_2012-3298",
        "Doc_title":" Arsenic induces human bronchial epithelial cell transformation featured with tumor-initiating cells",
        "_version_":1606188988112044032},
      {
        "Meeting_name":" Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.",
        "Background":"['Background', ' No standard therapies are available in China for Soft tissues sarcomas (STS)patients who failed to chemotherapies. Anlotinib is a multi-target RTK inhibitor, with VEGFR1/2/3, FGFR1/2/3, PDGFR/, c-Kit, Ret ect. Recommended dose in phase I is 12 mg daily, 2 weeks on/1 week off. This single-arm, multi-center phase II study (NCT01878448) to assess efficacy and safety of Anlotinib for treatment of STS patients who failed to conventional therapies. Methods', ' Pathological types of advanced STS mainly include malignant fibrous histiocytoma (MFH), liposarcoma, leiomyosarcoma, synovial sarcoma (SS) and other sarcomas, but excluding RMS, chondrosarcoma, GIST etc. Patients with measurable indicators (RECIST1.1) were treated with Anlotinib. Efficacy was assessed every 6 weeks. The primary endpoint was disease PFR at week 12 (PFR12w ). Results', ' From April 2013, we recruited 166 patients in 15 centers in China, including 100 males and 66 females, average age is 44 (15-70). Pathological types included SS (n=47), leiomyosarcoma (n=26), fibrosarcoma (n=18), MFH (n=19), alveolar soft part sarcoma (ASPS, n=13), liposarcoma (n=13), others (n=30). As of May 2015, 154 patients were assessable for efficacy', ' PFR12w was 57.23%, mPFS was 5.63 months.22 patients achieved PR over time (19 pts confirmed, and ORR was 11.45%. See below table. 166 patients were assessable for safety. Common grade III/IV AEs include', ' hypertension(n=8), pneumothorax(n=5), thyroid hypofunction(n=2), proteinuria(n=1), hand-foot-skin reaction(n=1), diarrhea(n=1), triglyceride increase (n=2), hyperglycemia (n=1). 24 patients (14.5%) had dose adjustment during treatment, reducing to 10 mg daily, 2 weeks on/1 week off. Conclusions', ' Anlotinib is effective to many pathological types of soft tissue sarcoma, particularly to ASPS and SS. Overall PFR12w reached 57.23%. Meanwhile, Anlotinib is well tolerated, while pneumothorax needs to be noticed. A randomized, controlled clinical trial is ongoing. Yihebali Chi and Sun Yongkun contributed equally to this work. Clinical trial information', ' NCT01878448Case (n)RR%PFR12w %Overall16611.4557.23SS4712.7763.83leiomyosarcoma267.6969.23fibrosarcoma1811.1161.11MFH195.2647.37liposarcoma137.6953.83ASPS1346.1576.92others303.3333.33']",
        "Doc_id":"ASCO_167465-176",
        "Doc_title":" Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.",
        "_version_":1606189004221317120},
      {
        "Meeting_name":" Prognostic significance of proliferation markers and telomerase activity in gastrointestinal stromal tumors.",
        "Background":"['Background', ' Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the gastrointestinal tract, represent a heterogeneous group of neoplasms with an unpredictable biological behavior ranging from benign to malignant. It is difficult to determinate their aggressive behavior despite known prognostic factors such as tumor size, mitotic activity and tumor location or mutation status of genes c-kit or PDGFR. Molecular markers including mechanisms of proliferation (Ki67 and TPX2) or cellular senescence (reactivation of telomerase activity) may provide an additional information on biological behavior of these neoplasms. Methods', ' We measured Ki67 and TPX2 mRNA levels as proliferation markers and hTERT (human Telomerase Reverse Transcriptase) mRNA level as a marker of telomerase activity using absolute quantification real time RT PCR. Normalized levels of proliferation markers Ki67, TPX2 and hTERT (normalized to mRNA levels of ABL housekeeping gene) was correlated between the different groups of tumors such as GIST, leiomyoma and a group of tumors with aggressive and high proliferation status, and finally, between risk categories of GIST. Results', ' The group of patients with agrressive and high proliferate Burkitt lymphoma (n=19) expressed significantly higher levels of Ki67 (p<0.0001), TPX2 (p<0.0001) and telomerase subunit hTERT (p<0,0001) than a group of patients with GIST (n=89, 90 and 58 respectively) or leiomyoma (n=9, 9 and 4 respectively). Statistical correlation was also found in the levels TPX2 and high risk category of GIST, a subgroup of patients with high risk GIST (n=36) expressed significantly higher levels of TPX2 proliferation marker (p=0.0101) than patients in the group with very low (n=4), low (n=3) and intermediate risk (n=5). Conclusions', ' Molecular evaluation of telomerase activity and biological markers involved in proliferation of cells may define an increased risk of aggressive behavior and to help to predict prognosis of GISTs. Assessement of the expression of TPX2 proliferation marker may become a suitable tool to determine biological behavior of GISTs. Supported by VZ FNM MZO 00064203/6704.']",
        "Doc_id":"ASCO_49738-74",
        "Doc_title":" Prognostic significance of proliferation markers and telomerase activity in gastrointestinal stromal tumors.",
        "_version_":1606189024299450368},
      {
        "Meeting_name":" Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors.",
        "Background":"['Background', ' Despite the tremendous promise of new signal transduction and angiogenesis inhibitors, these targeted drugs have met with mixed results so far in the clinic. In solid tumors, inhibition of multiple targets may be necessary for significant clinical effects. Dasatinib is an inhibitor of all SRC-family kinases, as well as BCR-ABL, c-KIT, multiple EPH-family kinases, PDGF receptor and other tyrosine kinases. Bevacizumab is a humanized IgG1 monoclonal antibody that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF) with high affinity. Attenuation of both c-Src and VEGF pathways simultaneously provides the potential for synergistic antitumor activity, as there is a extensive interaction between these pathways. VEGFR transmits its downstream signal through multiple pathways involving c-Src (including activation of the prosurvival FAK pathway). Alternatively, VEGF production is known to be Src-mediated (including via STAT5 signaling). Thus, inhibition of c-Src may block the VEGF angiogenic stimulus in at least two independent ways. As they have a largely non- overlapping toxicity profile, we have initiated a Phase I trial combining these two drugs. Methods', ' Objectives', ' Determine the safety and toxicity of the combination of dasatinib and bevacizumab. Determine biochemical changes in the src-FAK and src-PLC-g and VEGF signal transduction pathways in tumor and stromal cells in response to treatment at the MTD. Eligibility', ' Adults with histologically documented solid tumor malignancy that is metastatic or unresectable and for which standard curative therapies do not exist or are no longer effective. Design', 'This is an open-label phase I dose escalation study. Dasatanib will be orally administered daily and bevacizumab will be given intravenously every two weeks. At the MTD, pharmacodynamic endpoints related to signal transduction pathway alterations and tumor vascularity will be measured with tumor biopsies and DCE-MRI. Approximately 48 patients will be needed to achieve the objectives of the trial.']",
        "Doc_id":"ASCO_52928-74",
        "Doc_title":" Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors.",
        "_version_":1606189041106026496},
      {
        "Meeting_name":" A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD).",
        "Background":"['Background', ' P, an oral small molecule inhibitor of VEGFR-1,2,3, PDGFR-, , and c-Kit is FDA approved for advanced renal cancer. However the maximum tolerated dose (MTD) in Pts with varying degrees of LD has not yet been determined. Because P is primarily eliminated through the hepatic route, we sought to determine the MTD in Pts with advanced malignancies and LD. Methods', ' Pts with advanced malignancies, KPS  60%, adequate renal function, and hematologic values were enrolled in cohorts defined by degree of LD', ' none (N), mild (M) (bilirubin < 1.5x ULN or ALT > ULN), moderate (Md) (bilirubin > 1.5 - 3x ULN), and severe (S) (bilirubin > 3x ULN). Pts in the N cohort received P at the approved 800mg/d, while Pts in the other cohorts received doses according to a 2/6 phase I dose escalation schema. Dose-limiting toxicity (DLT) was defined as grade 4 hematologic toxicity, grade 3 nausea, diarrhea, or bleeding; any other grade 4 nonhematologic toxicity. Bilirubin increases leading to cohort changes of M or Md to S, or increases in S levels > 1.5x baseline for > 1-2 weeks were also DLTs. PK analysis was performed using a validated HPLC/MS/MS method. Results', ' 69 Pts are enrolled thus far (N-20, M-20, Md-17, S-12). 82.2% were white and 10.1% were Asian. 40.4% had colorectal cancer. Among evaluable Pts, the M cohort MTD was 800 mg/d with 1/6 Pts having an increased AST at 400 mg/d and 1/10 Pts with grade 5 bleeding at 800 mg/d. The Md cohort MTD was 200 mg/d with 2/6 Pts at 400 mg/d having DLT level increases in AST/ALT. 10 Pts have been treated at 200 mg/d without a DLT. Dose escalation in the S cohort is ongoing with the current dose at 100 mg/d. Conclusions', ' The MTD of P in M, Md, and S LD is 800mg/d, 200 mg/d, and not yet established respectively. Based on these data, a dose reduction in P is recommended for Pts with moderate or higher LD. Supported by U01 CA 62505. Preliminary steady-state P PK at week 3, normalized to a dose of 800 mg/day (medians and ranges)Normal dose 800 mg(n=12)Mild dose 400 mg (n=5)Moderate dose 200 mg (n=7)Cmax (mg/ml)48.6 (17.1-85.7)45.4 (29.2-97.6)95.6 (25.6-131.6)tmax (hr)2.7 (1.0-24.1)3.0 (2.0-4.1)2.0 (1.0-4.0)AUC0-6 (mg  hr/ml)249.1 (92.0-475.9)250.2 (156.6-411.6)507.6 (138.4-731.6)']",
        "Doc_id":"ASCO_44621-74",
        "Doc_title":" A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD).",
        "_version_":1606189020934569985},
      {
        "Meeting_name":" Sunitinib malate in advanced hepatocellular carcinoma",
        "Background":"['Background', \" In 2007, sorafenib (SOR) was shown effective in improving overall survival (OS) when compared to best supportive care in patients with hepatocellular carcinoma (HCC) and a good liver function (Child A). Sunitinib is another multi-kinase inhibitor that is active against VEGF-R, PDGF-R and c-KIT. We designed a phase II study, according with a two-step Simon's model, to assess safety and efficacy of sunitinib in HCC patients. Methods\", ' Eligibility criteria were', ' unresectable or metastatic HCC; no prior chemotherapy. PS (ECOG) 0-1; measurable disease according to RECIST criteria. Child C patients were excluded. Schedule', ' 50 mg each day, four weeks on, two weeks off. CT scan', ' every two cycles. PET-TC scan', ' at baseline and after the first cycle. Primary end-point was response rate according to RECIST criteria. Results', ' Thirty-three patients enrolled. ChildA/ChildB = 21/12 (64%/36%). Seventy-five cycles were administered. Grade 3 adverse effects included fatigue (26.6% of cycles), piastrinopenia (17.3%), neutropenia (13.3%), encephalopathy (8%), gastrointestinal bleeding (5.3%), nausea/vomiting (5%), diarrhea (4.1%), stomatitis (2.6%). Seven pts (21%) required dose reductions because of toxicity. Six pts (18%) died within 60 days since enrollment. Five of them belonged to Child B group and died because of liver failure. The Child A patient had a bone metastasis to the clivus, that was the probable cause of death but autopsy was not performed. Objective response rate was 10%. Thirteen patients (43.3%) experienced a disease stabilization and 14 (46.6%) progressed. All responders and seven patients (53%) among those with stable disease had a significant metabolic response at PET-TC and they experienced a prolonged time to progression with a significant clinical benefit. Conclusions', ' The dose of 50 mg is probably high in HCC patients with liver cirrhosis and it is not tolerable for Child B patients. However, sunitinib is able to induce a low but definite response rate and a high percentage of disease stabilization; PET-scan may select good responders.']",
        "Doc_id":"ASCO_48590-74",
        "Doc_title":" Sunitinib malate in advanced hepatocellular carcinoma",
        "_version_":1606189004231802880},
      {
        "Meeting_name":" PDGFR activation defines a subset of astrocytes in the neuroinflammatory microenvironment of breast cancer brain metastasis, inhibitable by pazopanib.",
        "Background":"['Brain metastases occur in approximately 35% of metastatic breast cancer patients whose tumors overexpress HER2. Brain colonization of cancer cells occurs in a unique environment, containing microglia, oligodendrocytes, astrocytes and neurons. While a neuroinflammatory response has been documented in brain metastasis, its contribution to cancer progression and therapy remains poorly understood. Using a model system to study experimental brain metastasis of breast cancer, we intensively characterized the brain metastatic microenvironment of a brain tropic, HER2-transfected MDA-MB-231 human breast carcinoma subline (231-BR-HER2). The 231-BR-HER2 cell line was injected into the left cardiac ventricle of immunocompromised mice; mice were treated with vehicle, 30mg/kg or 100mg/kg pazopanib twice a day beginning on day 3 post-injection, for 4 weeks. Pazopanib, a multispecific tyrosine kinase inhibitor targeting VEGFR-1, -2, and -3, PDGFR- and , and c-kit, directly targeted tumor cells through the disruption of B-Raf pathway, prevents the outgrowth of 231-BR-HER2 large brain metastases by 73% (p<0.0001). Here we evaluated the effect of pazopanib on the brain micro-environment microenvironment. A novel subpopulation of metastasis-associated astrocytes expressing phosphorylated (Y751) PDGFR was identified surrounding brain metastases. This subpopulation of p751-PDGFR + astrocytes was also identified in human brain metastases from five different craniotomy specimens. Expression of p751-PDGFR was studied in primary cultures of astrocyte-enriched glial cells. p751-PDGFR expression was increased in response to soluble factors from cultured breast cancer cells, and was inhibited by pazopanib treatment. In the mouse mode, pazopanib treatment resulted in a 70% (p=0.023) decrease of the p751-PDGFR+ astrocyte population, at the lowest dose of 30mg/kg, twice daily. In contrast, pazopanib did not have any effect on microglia expression. Collectively, the data identify a new subpopulation of activated astrocytes in the perivascular stage of subclinical brain metastases and demonstrate that they are inhibitable by pazopanib, suggesting its potential to prevent the development of brain metastases from breast cancer patients.']",
        "Doc_id":"AACR_2013-1442",
        "Doc_title":" PDGFR activation defines a subset of astrocytes in the neuroinflammatory microenvironment of breast cancer brain metastasis, inhibitable by pazopanib.",
        "_version_":1606189006478901248},
      {
        "Meeting_name":" Direct in vivo evaluation of tumor VEGFR in response to treatment with pazopanib",
        "Background":"['Background', ' Several small molecule tyrosine kinase inhibitors (TKI) targeting VEGFR are already approved for use in anti- angiogenic therapy either alone or in combination with chemotherapeutics. Unfortunately, the clinical response to such therapy varies markedly among individuals. We hypothesize that noninvasive assessment of changes in VEGFR prevalence in response to TKI treatment would identify responsive patients. We report here that SPECT(single photon emission computed tomography) imaging of VEGFR-2 in HT29 tumor xenografts allows for detailed assessment of its prevalence in the course of treatment with pazopanib, a TKI targeting VEGFR, PDGFR and c-Kit, recently approved for the treatment of advanced renal carcinoma. Methods', ' VEGFR-2 SPECT imaging was done using scVEGF/Tc, an engineered single chain (sc) form of VEGF radiolabeled with 99mTc. This tracer binds to and is internalized by VEGFR-2 in tumor vasculature, allowing for selective accumulation of 99mTc in tumor endothelial cells. All SPECT imaging experiments were carried out on HT29 tumor xenografts on Swiss nude mice. A dose of 2-4 mCi of [99mTc]scVEGF was injected into the retro-orbital venous sinus in a volume of 100 to 220 L followed by imaging two hours later. Quantitative histogram analysis of the SPECT images was performed. At the end of imaging experiments the mice were sacrificed and the tumors were harvested for immunohistochemical analysis (IHC) of VEGFR-2 and VEGFR-1, as well as panendothelial marker CD31. Results', ' The imaging results, which are consistent with IHC analysis, show that VEGFR-2 levels in tumors were significantly reduced upon treatment with pazopanib as early as day 5 after the initiation of therapy, when morphological changes were barely detectable. A detailed kinetic study to understand the dose dependence of the effects of pazopanib on tumor VEGFR is in progress and those results will also be presented. Conclusions', ' This is the first direct evaluation of tumor VEGFR in response to a VEGFR targeted therapy. In principle, this technology can be extended to human use providing for new opportunities in treatment management of VEGFR-targeted therapies including patient selection, dose, and optimal drug regimen.']",
        "Doc_id":"ASCO_50360-74",
        "Doc_title":" Direct in vivo evaluation of tumor VEGFR in response to treatment with pazopanib",
        "_version_":1606189027689496577},
      {
        "Meeting_name":" Association of germ-line genetic markers in IL8, HIF1A, VEGFA, and VEGFR2 with treatment response to pazopanib in renal cell carcinoma.",
        "Background":"['Background', ' Pazopanib (Votrient, P), an oral angiogenesis inhibitor targeting VEGFR-1, -2, and -3, PDGFR- and -, and c-Kit, is approved in the US for the treatment of advanced renal cell carcinoma (RCC). No valid biomarker has been identified to predict the response to P treatment, or indeed other agents in this class. This study sought to identify genetic markers associated with efficacy and blood pressure response (a pharmacodynamic marker) to P in RCC. Methods', \" 40 polymorphisms in 20 candidate genes were evaluated in 370 P-treated RCC patients (pts) from three clinical trials. Association with progression-free survival (PFS), response rate (RR) and average mean arterial pressure (MAP) during P treatment was evaluated using Cox regression, Fisher's exact test, and generalized linear modeling, respectively. No adjustments for multiple comparisons were made. Polymorphisms that met nominal levels of significance (p<0.05) were reported which require confirmation. Results\", ' The IL8 +2767A>T polymorphism was associated with PFS (p=0.03); pts with wild type AA (n=105) and heterozygote AT (n=176) genotypes had longer median PFS (49 and 41 weeks, respectively) than pts with the variant TT genotype (n=59, 28 weeks). The HIF1A +1790G>A (Ala588Thr) polymorphism was associated with RR (p=0.02); pts with the wild type GG genotype (n=323) had better RR (PR+CR, 43%) compared with the variant AG genotype (n=20, 30%). The VEGFR2 +1416T>A (His472Gln) polymorphism was associated with average MAP during P treatment (p=0.005); pts with the variant AA homozygote experienced higher MAP than wild type TT and heterozygote AT genotypes. The mean (SE) MAP change from baseline for the TT (n=208), AT (n=128) and AA (n=26) pts was 4.4 (0.5), 5.7 (0.6) and 9.8 (1.6) mmHg, respectively. Similar findings were observed for the -2578C>A, -1498C>T and - 634G>C polymorphisms in the VEGFA gene (p<0.05). Conclusions', ' Associations between treatment response to P with variants in the IL8, HIF1A, VEGFA, and VEGFR2 genes were observed in RCC pts. These associations are considered exploratory and require confirmation in an independent dataset.']",
        "Doc_id":"ASCO_51238-74",
        "Doc_title":" Association of germ-line genetic markers in IL8, HIF1A, VEGFA, and VEGFR2 with treatment response to pazopanib in renal cell carcinoma.",
        "_version_":1606189035776114688},
      {
        "Meeting_name":" Phosphoproteomics of a panel of AML cell lines reveals oncogenic signaling and candidate drivers",
        "Background":"['Background', ' Acute myeloid leukemia (AML) is a malignant hematopoietic stem cell disease, caused by a differentiation block at the level of immature progenitors, leading to massive accumulation of malignant cells in the bone marrow and suppression of normal hematopoiesis. The disease is highly heterogeneous with 2 year survival rates, after intensive chemotherapy regimens depending on cytogenetic and molecular risk factors, varying between 70% for patients with good risk and less than 10% in those with poor prognostic features.In recent years clinical success has been achieved in the treatment of several cancer types with kinase inhibitors (KIs) and they may prove to be a valuable addition to standard therapy in AML. However, a proper rationale to select a suitable KI is still lacking. Phosphoproteomics based on tandem mass spectrometry (MS/MS) is a powerful approach for unbiased, global profiling of protein phosphorylation, and could identify aberrancies in signal transduction pathways and associated key kinases that may be suitable for targeted treatment with KIs.The aim of this study is to identify candidate driver kinases and signaling routes that may be targets for kinase inhibitor treatment by analyzing 16 selected AML cell lines.Methods', ' Sixteen different AML cell lines were cultured (EOL-1, HEL, HL-60, Kasumi-1, Kasumi-3, Kasumi-6, KG-1, KG-1a, ME-1, ML2, MM6, MOLM-13, MV-4-11, NB-4, OCI-AML3, THP1). For each cell line 10 mg protein lysate was processed. Phospho-Tyrosine containing peptides were captured from AML cell line lysates using the pY1000 antibody in an immunoprecipitation (IP) experiment. Both whole cell lysate and pTyr IP fractions were measured using nanoLC-MS/MS (2-hour gradient, QExactive). MaxQuant version 1.4.1.2 was used for phosphopeptide identification and label-free quantification.Results', ' The whole phosphoproteome dataset of 16 AML cell lines contained 4853 identified phosphopeptides corresponding to 2280 phosphoproteins, including 138 phosphokinases. Ranking of phosphokinases identified in each of the 16 AML cell lines confirmed FLT3, PDGFRa, JAK2 and c-KIT as hyperphosphorylated kinases in AML cells with mutations in these genes. Interestingly, AML cell lines without known kinase-related genomic aberrations also showed high activation of several kinases which could be potential KI targets. Current data analysis will link phosphokinases to downstream phosphoprotein substrates and pathways, in order to prioritize (combinations of) candidate driver kinases for functional perturbation experiments.Conclusion', ' Phosphoproteomics analysis of a panel of 16 AML cell lines showed differential (hyper-) activation of multiple kinases, including those already implicated in AML. The current analysis gives us insight into the heterogeneity of activated signaling pathways in AML and allows for the identification of possible new targets for treatment of AML with KIs.']",
        "Doc_id":"AACR_2015-1820",
        "Doc_title":" Phosphoproteomics of a panel of AML cell lines reveals oncogenic signaling and candidate drivers",
        "_version_":1606188977909399552},
      {
        "Meeting_name":" Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors.",
        "Background":"['Background', ' Malignant peripheral nerve sheath tumors (MPNSTs) are generally resistant to chemotherapy. Receptor tyrosine kinases (RTKs) play a role in MPNST growth and include c-KIT, PDGFR, and CSF1R, all of which are inhibited by pexidartinib (PLX3397, PEX). We reported that the combination of PEX and the mTOR inhibitor sirolimus (S) synergistically inhibited MPNST growth (Patwardhan P. et al CCR 20', ' 3146, 2014). Inhibiting CSF1R resulted in a marked depletion of tumor-associated macrophages (TAMs) in MPNST xenografts and a shift from M2 (tumor promoting) to M1 (tumor inhibiting) TAMs within tumors. This effect on TAMs was enhanced and sustained by mTOR inhibition with S. Therefore, this drug combination, by potently blocking RTKs and by altering tumor macrophage infiltration, represents a novel drug combination. The goal of this first-in-man trial is to prove safety and test efficacy of PEX and S in sarcomas and MPNST. Methods', ' This is an open label, multicenter, investigator-initiated study testing PEX in combination with S in patients with advanced sarcomas (phase 1, N = 24) and MPNST (phase 2, N = 25). The primary objective of the phase 1 component is to determine the safety, tolerability, and the recommended phase 2 dose (RP2D) using the time-to-event continual reassessment method. The phase 1 component enrolls patients with sarcoma who have progressed on standard of care therapy or for whom no standard treatment exists. The primary outcome for phase 2 is progression free survival (PFS). Assuming a median PFS of 6 weeks in patients treated with standard of care, we have 90% power to detect a difference of 12 weeks in median PFS given a 2-sided test with an alpha of 0.05. Secondary objectives include response rate and overall survival. Patients enrolled to the phase 2 component will undergo mandatory biopsies at baseline and at end of cycle 1 and an optional biopsy on progression. Exploratory studies include analysis of RTK activity and assessment of TAMs within the tumor samples. This trial has started in December 2015 and has enrolled 4 patients to the phase Ib (2 PVNS, 1 MPNST, and 1 Epithelioid sarcoma) as of January 2016. Clinical trial information', ' NCT02584647']",
        "Doc_id":"ASCO_163934-176",
        "Doc_title":" Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors.",
        "_version_":1606188982402547712},
      {
        "Meeting_name":" CTEP #8342 autophagy modulation with antiangiogenic therapy",
        "Background":"['Background', '  Angiogenesis inhibitors promote autophagy, a response to nutrient deprivation in which autophagosomes (AP) and lysosomes fuse to recycle intracellular constituents, leading to sustained tumor viability.  We hypothesized that the VEGF-R2, c-kit, PDGFR inhibitor Su induces autophagy. The autophagy inhibitor HCQ may then interfere with autophagy dependent tumor survival, possibly improving patient (pt) outcomes.  Methods', '  This trial determined the MTD of Su+HCQ in pts with advanced malignancies using a 3+3 design. Su 50 mg qd was given in 4 week on/2 week off cycles (C) with daily HCQ in escalating dose cohorts. A MTD expansion cohort of 12 pts was also enrolled.  Modulation of autophagy was measured by changes in the AP marker light chain-3 (LC3)II/I ratio in paired PBMC samples from C1 and C2. Results', '   21 pts, median age 59, PS 0 (7), 1 (13) or 2 (1) enrolled, including 5 colon, 2 renal and 5 sarcomatous tumors.  4 DLTs were observed', ' 3 DLTs (gr 3 confusion, gr 3 colon fistula, gr 3 thrombocytopenia) in DL2  (50 mg Su, 200 mg bid HCQ), and 1 DLT (gr 3 dehydration) in DL1 (50 mg Su, 200 mg HCQ). DL1 was thus declared the MTD. Gr 3/ 4 toxicities included', '  related to Su, thrombocytopenia (14%), fatigue (19%), neutropenia (14%), hypertension (14%), intestinal perforation (10%); related to HCQ, fatigue (14%). PK data of Su alone, its active metabolite SU012662 and the total were evaluated using noncompartmental analysis. Cmax and AUCs of the active metabolite SU012662 significantly increased (p<0.005) during C2 relative to C1, indicating drug-drug interactions between HCQ and Su. 9 of 21  (43%) had stable disease for > 3 cycles (median 73 days).  Inconsistent autophagy modulation was seen in PBMCs.  LC3 immunohistochemistry on baseline tumor blocks to assess individual tumor autophagy levels is in progress. Conclusions', '  pK interaction between Su and HCQ resulting in accumulation of Su metabolites may be responsible for the predominantly Su-associated toxicities observed which prohibited further HCQ dose escalation. Lack of evidence for autophagy modulation is likely due to the inability to escalate HCQ to doses necessary to induce autophagy inhibition. Further study of this combination seems unwarranted. Clinical trial information', ' NCT00813423.']",
        "Doc_id":"ASCO_111919-132",
        "Doc_title":" CTEP #8342 autophagy modulation with antiangiogenic therapy",
        "_version_":1606188990704123904},
      {
        "Meeting_name":" Profiling drug sensitivity and kinomic pathways utilizing a novel human tumor derived MicroTumor assay",
        "Background":"['Introduction', \" At present, drug screening studies are commonly performed using monolayer or spheroid culture and xenograft models of tumor cell lines. However these do not fully replicate the primary tumor's microenvironment and fail to accurately predict clinical endpoints. Vivo Biosciences has developed a novel MicroTumor 3D matrix based assay system that emulates primary tumor multicellular growth and biology ex vivo, providing an advanced drug screening platform. We postulated that MicroTumors established from patient-derived xenograft (PDX) tumors will allow for accurate analysis of drug response and preserve molecular signaling of parent tumors. Glioblastoma multiforme (GBM), the most common primary brain malignancy, was used to test our hypothesis. MicroTumors were evaluated by comparing kinome activation profiles of GBM-MicroTumors with corresponding parental orthotopically implanted PDX; and determining single and combination treatment effects of small molecule kinase inhibitors (SMI) on GBM MicroTumors.Methods\", ' We investigated 6 GBM PDX tumor lines representing the 4 known molecular subtypes', ' Classical (JX10, X1016, X1046); Proneural (XD456); Mesenchymal (JX22P); and Neural (JX10). Four SMIs (primary kinase target indicated) were studied', ' WP1066 (JAK2), selumetinib (MEK1/2), crizotinib (c-MET, ALK), and cediranib (VEGFR, FLT-1, FLT-4, c-KIT, PDGFR). MTT assays and Calcein AM imaging were used for cytotoxicity assessment and PamStation 12 Kinomic analyses were performed (UAB Kinome Core).Results', ' Kinomic analyses of GBM orthotopic PDX and GBM-MicroTumors revealed similar kinase signaling profiles based on comparison of commonly shared, most-variant phosphopeptides. Upstream kinase analyses identified these peptides as substrates of EGFR, AXL, ZAP70 and MERTK kinases. Initial drug response studies demonstrated dose dependency and PDX-specific responses for each drug used independently informing doses for ongoing combination studies. Interestingly, the least cytotoxic drug across all 6 MicroTumors, selumetinib, did impact MicroTumor morphology observed with Calcein AM imaging.Conclusions', ' We identified kinomic alterations that may correlate MicroTumor and patient tumor biology and guide the use of molecularly targeted SMIs. SMI activities towards these targets highlighted that this novel 3D translational model for GBM can provide relevant drug sensitivity information. Future studies with in vivo PDX tumors will examine the most promising SMI combinations based on MicroTumor data. We believe this two-stage approach (Microtumor screening to predict PDX sensitivities) will improve preclinical drug screening in GBM and other cancers.']",
        "Doc_id":"AACR_2015-312",
        "Doc_title":" Profiling drug sensitivity and kinomic pathways utilizing a novel human tumor derived MicroTumor assay",
        "_version_":1606188994381479936},
      {
        "Meeting_name":" Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients.",
        "Background":"['Background', '  Cancer genomic profiling via NGS in a clinical setting can reveal additional actionable genomic alterations (GA) in patients with lung cancer (LC) previously tested only by hotspot analysis and leading to unanticipated avenues of targeted treatment.  Methods', '  We performed an NGS-based diagnostic test (FoundationOne) to characterize all classes of GA across 3,320 exons of 182 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer on 386 LC FFPE specimens in a CLIA-certified lab (Foundation Medicine). Specimens included fine needle aspirates, core needle biopsies, and malignant effusions.  95% of cases were NSCLC (367/386). Actionable GAs are defined as those linked to targeted anti-cancer therapies approved or being evaluated in clinical trials.  NGS confirmed known hotspot results for EGFR, KRAS and EML4', 'ALK in 100% of cases.  Results', '    Genomic profiles were generated from 364/386 (94%) of lung cancer cases, identifying 1205 GA, averaging 3.31 alterations per tumor (range 0 to 10).  85% of tumors (310) harbored at least one actionable GA, with a mean of 1.79 GA per tumor (range 0 to 6). In 68% of tumors (248), at least one GA was detected that would be missed by current hotspot assays. ERBB2 harbored base substitutions or indels in 1.3% of cases.  BRAF and C-Kit were altered at frequencies of 2% and 1% respectively. The mTOR/PI3K pathway is likely to be activated via alterations in tumor suppressors STK11 (11%), NF1 (6%) and PTEN (4%), as well as by alterations of PIK3CA (10%) and in AKT1/2/3 (4%), suggesting possible benefit from mTOR/PI3K inhibitors.  The Hedgehog pathway (PTCH1/SMO/SUFU) was altered in 2% of cases.  ALK and RET were rearranged in 4% and 2% of cases, respectively, with several cases initially diagnosed negative by FISH testing.   Conclusions', '  Profiling the tumor genomes of 364 LC patients led to the identification of a series of GA not detectable by hotspot testing that could significantly inform targeted treatment decisions.  Moreover, actionable GA appeared in unexpected tumor type, i.e. an EGFR mutation in a SCLC, reinforcing the likely utility of clinical cancer genomic profiling for the personalized treatment of LC patients.']",
        "Doc_id":"ASCO_118079-132",
        "Doc_title":" Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients.",
        "_version_":1606189004042010624},
      {
        "Meeting_name":" A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients.",
        "Background":"['Background', ' MP-470 (MP) is an oral multi-targeted tyrosine kinase inhibitor which inhibits a number of validated tumor targets including c-kit, flt3, and PDGF. MP470 targets cancer cells by disrupting DNA repair, an important survival pathway in many human cancers. Results presented herein are from two arms of a phase-Ib five arm trial of MP combined with standard of care (SOC) anti- cancer therapies. Methods', ' MP is administered in combination with SOC in a 21-day cycle. Adults with ECOG PS of 0-2 and malignant disease appropriate for SOC regimens consisting of paclitaxel/carboplatin (PC), carboplatin/etoposide (CE), topotecan, docetaxel, and erlotinib were enrolled. Each arm follows a 3+3 design where MP is escalated based on the modified Fibonacci sequence until the MTD of MP in combination with SOC agents is reached. RECIST and CTCAE are utilized to assess response and safety, respectively. The primary objectives of the study are to determine the MTD, DLTs, and quantify the effects of MP on the PK of SOC agents. Results', ' Between Dec 2007 and Aug 2008, 26 subjects were enrolled in the PC and CE arms and received a total of 70 cycles (median 2; range, 0-8) of MP at 4 dose levels (100-500 mg/day). Median number of prior therapies was 2 (range, 0-19). Male/Female', ' 14/12. Median age, 56 years (range, 24-76). Subjects completing  6 and  4 cycles were 5 and 7, respectively. Six PRs (2 neuroendocrine, 2 SCLC, 1 NSCLC, 1 small cell of anal canal) and 3 SDs ( 4 cycles) was observed. The MTDs have not been reached and DLTs have not been identified. Adverse events occurring in  15% of patients were myelosuppression, diarrhea, constipation, nausea, reflux, fatigue, alopecia, rash, neuropathy, anorexia, hypokalemia, dyspnea, and myalgias. MP470 did not alter the kinetics of SOC agents. Dose escalation in the PC and CE arms is ongoing. Conclusions', ' MP470 combined with carboplatin-containing regimens may promote tumor regression and may also sensitize/resensitize tumors to the anticancer effects of such agents. An amendment will be issued to collect tumor tissue biopsy at baseline and during treatment to adequately evaluate DNA damage in tumor tissue.']",
        "Doc_id":"ASCO_35278-65",
        "Doc_title":" A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients.",
        "_version_":1606189009002823680},
      {
        "Meeting_name":" Unraveling the mechanism of action",
        "Background":"['The tumor suppressor 2A (PP2A) is a multi-enzyme complex that targets a variety of oncogenic signaling cascades such as Raf, MEK and AKT. Numerous reports have now emerged indicating that the inhibition of PP2A leads to the development of tumors including breast, gastric and lung and a range of hematological malignancies such as chronic and acute myeloid leukemia (CML and AML, respectively). We and others have shown that inhibition of PP2A is crucial for the oncogenic effects of leukemia associated receptor tyrosine kinases such as BCR/Abl, c-KIT and FLT3. Importantly when PP2A is reactivated using pharmacological agents (FTY720 and AAL(S)), growth and survival of these cells is inhibited. This approach targets molecules downstream of these oncogenic kinases and thus PP2A reactivation is designed to avoid resistance associated with kinase inhibitor therapy. As the mechanism of action of these PP2A activators is unknown, it is essential that we now determine the molecular targets of these compounds to generate more effective drugs. Using a chemical proteomics approach incorporating click chemistry linking the drugs to beads, unbiased pull down assays were performed in myeloid leukaemia cells and protein isolates were identified by mass spectrometry. Using this approach we have identified a novel cellular target, which is known to be overexpressed in a range of cancers, including leukemias. We have also shown that this protein associates with PP2A complexes in these cells, and thus may act as an endogenous inhibitor of PP2A activity. We have also performed phospho-proteomics and co-immunoprecipitation studies to identify protein changes in myeloid leukemia cells in response to PP2A activators. In addition to identifying known PP2A targets, such as Akt and ERK, we have also identified a number of novel protein changes, including altered expression of the SET oncoprotein. SET is a known inhibitor of PP2A, suggesting that FTY720 may act via inhibition of SET. Other PP2A regulatory proteins such as CIP2A, PME-1 and PP2A-B56alpha are also affected by FTY720/AAL(S) treatment. Our research findings are thus providing the vital clues necessary for determining the mechanism of action of clinically relevant PP2A activators, thereby moving us towards the provision of novel anti-cancer treatment regimes.']",
        "Doc_id":"AACR_2013-2038",
        "Doc_title":" Unraveling the mechanism of action",
        "_version_":1606189022134140928},
      {
        "Meeting_name":" Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR).",
        "Background":"['Background', ' SUN and SOR are multi-targeted tyrosine kinase inhibitors (TKIs) inhibiting several kinases (VEGFR- 1,2; c-kit; PDGFR-,; flt-3; RET). SUN is approved for treatment of imatinib-resistant gastrointestinal stromal tumors (GIST) and metastatic renal cell carcinoma (RCC), SOR is used for RCC and hepatocellular carcinoma. We observed in some pts with fatigue under TKI treatment low testosterone (T) levels and started assessing the incidence and severity of gonadal dysfunction prospectively in male pts receiving these TKIs. Methods', ' Gonadal status (serum total testosterone (TT), free testosterone (FT), sex-hormone binding globulin (SHBG), luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were evaluated in pts with RCC or GIST under SUN or SOR. SUN was given at a daily dose of 50 mg p.o. 4 weeks on, 2 weeks off, SOR at a daily oral dose of 800 mg. Results', ' We identified 27 pts (median age 63, range', ' 27-77), for which data on gonadal function were available, 23 RCC (85 %), 4 GIST (15%), with 22 (85.5%) receiving SUN and 5 (18.5%) SOR. Median treatment duration was 48 (2-202) weeks, 13 (48%) underwent dose reductions, in 4 (15%) pts due to grade 3 fatigue. All pts had at least once during TKI treatment T levels lower than normal (TT < 300 ng/dL and/or FT < 5 ng/dL), 17 (63%) had a low T with normal LH/FSH, 4 (15%) a low T with an elevated LH/FSH and 6 (22%) a low T and elevated FSH, but normal LH. The median TT level in the whole group was 194 ng/dL (21-477, normal range', ' 300-1,000 ng/dL), the median FT level in the whole group was 4.01 (0.45-9.07, normal range', ' 5-20 ng/dL). In the SUN cohort the median levels for TT and FT were slightly lower on day 28 in comparison to day 1 (184.5 vs 206 ng/dL for TT and 3.935 vs 4.225 ng/dl for FT). Pts with information available on testosterone at baseline (n = 8) tended to have slightly diminished baseline T levels (median', ' 222.5 [61-319] ng/dL), but 50% of these pts had been treated with other TKIs before. Two pts with grade 3 fatigue under SUN had very low T levels shortly after starting SUN (21 and 28 ng/dL, respectively). Conclusions', ' We observed a high incidence of hypogonadism in male RCC and GIST pts under treatment with SUN or SOR. Hypogonadism may likely contribute to the fatigue associated with these agents.']",
        "Doc_id":"ASCO_32297-65",
        "Doc_title":" Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR).",
        "_version_":1606189002295083008},
      {
        "Meeting_name":" Treatment with regorafenib inhibits the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic nude mice model of colon cancer",
        "Background":"['Bone marrow-derived mesenchymal stem cells (MSCs) have been reported to migrate to tumor stroma as well as injured tissue. We reported that, in an orthotopic nude mice model of colon cancer, MSCs travel to tumor stroma and differentiate into carcinoma-associated fibroblasts (CAFs), and then, they promote growth and metastasis of colon cancer. We also found that CAFs express platelet-derived growth factor receptor-beta (PDGFR-), at a high level and that imatinib therapy targeting PDGFR in CAFs combined with administration of a cytotoxic drug significantly inhibits growth and metastasis of human colon cancer. A novel oral multi-kinase inhibitor, regorafenib not only inhibits oncogenic receptor tyrosine kinases such as c-KIT, RET, and B-RAF, but also inhibits stromal cells which express VEGFR1-3, TIE2, PDGFR-, and fibroblast growth factor receptor 1 (FGFR1). These cell surface receptor tyrosine kinases are known to be involved in tumor neovascularization, vessel stabilization, lymphatic vessel formation as well as activation of stroma. We examined whether the effect of MSCs on tumor growth and metastasis was inhibited by regorafenib. KM12SM human colon cancer cells alone or KM12SM cells mixed with MSCs in a 1', '2 ratio were transplanted into the cecal wall of nude mice. Orthotopic transplantation of KM12SM cells + MSCs, in comparison to transplantation of KM12SM cells alone, resulted in tumors of greater weight and volume, and higher rate of lymphatic metastasis. Co-injection of MSCs with tumor cells promoted tumor growth and metastasis of colon cancer by enhancing angiogenesis, lymphangiogenesis, and tumor cell proliferation and by inhibiting tumor cell apoptosis. When CRC tumor + MSCs bearing animals were treated with regorafenib (by oral gavage once daily at 10 mg/kg for 35 days), primary tumor size or the number of lymph node metastases were significantly decreased compared to those treated with vehicle, and reached to the level with no significant difference from KM12SM tumor cells alone. Our data suggest that targeting tumor microenvironmental signaling pathways by regorafenib influences the interaction between bone marrow-derived MSCs and tumor cells and, hence, inhibits the progressive growth of colon cancer.']",
        "Doc_id":"AACR_2015-5068",
        "Doc_title":" Treatment with regorafenib inhibits the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic nude mice model of colon cancer",
        "_version_":1606188991080562688},
      {
        "Meeting_name":" Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.",
        "Background":"['Background', ' Medullary thyroid carcinoma (MTC) is a rare disease with no standard therapies available in China for unresectable, advanced or relapsed MTC patients. Anlotinib is a multi-target RTK inhibitor, with inhibition activities to VEGFR1/2/3, FGFR1/2/3, PDGFR/, c-Kit, Ret etc in nanomole level. Recommended dose in phase I study is 12mg daily, 2 weeks on/one week off. We conducted a single-arm, multi-center phase 2 study (NCT01874873) to assess efficacy and safety of anlotinib in advanced MTC patients. Methods', \" Pathology-confirmed advanced or relapsed MTC patients, who cannot receive radical surgery and have measurable indicators (RECIST1.1), were treated with anlotinib. Assess efficacy every 6 weeks. The primary endpoint is PFS. This study used Simon's Two-Stage design, assuming DCR of anlotinib can achieve 70%. Results\", ' From Sept. 2013, we recruited 58 patients in 8 centers in China, including 34 male patients and 24 female patients. Average age is 48 (22-71). One patient dropped after one cycle treatment, 2 patients without measurable lesions, 55 patients are assessable for efficacy. As of May 2015, average PFS is 12.8 months and median PFS is still not reached. 7 patients achieved PR at second treatment cycle, and 31 patients achieved PR over time (28 patients confirmed), overall ORR is 48.28% (FAS). DCR is 92.16% at week 24, and 84.53% at week 48. 58 patients are assessable for safety. Common grade III/IV AEs are', ' hand-foot-skin reaction (n=5), hypertension (n=3), mucositis (n=2), stomachache (n=1), diarrhea (n=1), fatigue (n=1), cholesterol increase (n=2), triglyceride increase (n=2), amylase increase (n=2), lipase increase (n=2), ALT increase (n=1), and proteinuria (n=1). 12 patients (20.7%) have dose adjustment during treatment, reducing to 10mg daily, 2 weeks on / 1 week off. Conclusions', ' Anlotinib has a high ORR (48.28%) for treatment of MTC, average PFS is 12.8 months and median PFS is still not reached. The disease can be controlled for long term (DCR is 92.16% at week 24). The primary endpoint of this study has been met. Meanwhile, anlotinib is well tolerated. The randomized, controlled clinical trial is ongoing. Sun Yongkun and Yihebali Chi contributed equally to this work. Clinical trial information', ' NCT01874873']",
        "Doc_id":"ASCO_167412-176",
        "Doc_title":" Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.",
        "_version_":1606188998205636608},
      {
        "Meeting_name":" Treatment of endometrial cancer cells with a new small tyrosine kinase inhibitor targeting mutated fibroblast growth factor receptor-2.",
        "Background":"['Endometrial cancer (EC) is the most common uterine malignancy in industrialized countries and is the most frequent gynecologic cancer in the United States with an estimated 60,050 new cases in 2016. Traditionally observed in peri-, postmenopausal women, the incidence rate of EC has steadily increased among younger women of reproductive age over the past two decades partially owing to a more sedentary lifestyle and rampant obesity epidemic. Surgery in combination with either radio- and or chemotherapy is commonly curative for the early stage of the disease. However, patients with recurrent or metastatic disease, who only respond poorly to cytotoxic chemotherapy are in desperate need of therapeutic alternatives as are patients of reproductive age. Thus, innovative, safe and more effective therapies are mandated. Several studies have demonstrated the increased expression of various tyrosine kinase receptors involved in the development of EC. We hypothesized that a targeted therapeutic approach using a pan-tyrosine kinase inhibitor would prevent the proliferation and progression of EC. Anlotinib (AL3818) is a multi-targeted receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors 1 to 3 (VEGFR1-3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGF), and fibroblast growth factor receptors 1 to 3 (FGFR1-3). We tested a panel of seven human endometrial cancer cell lines (AN3Ca, Ishikawa, HEC1A, HEC1B, KLE, MFE280 and MFE296) to assess the cytotoxicity of anlotinib in vitro. A lower IC50 value was observed in AN3Ca cells (25 nM), a cell line characterized by a high level of expression of an FGFR2 mutant protein, while cell lines expressing FGFR2 wild-type are less sensitive to anlotinib (HEC1A', ' 33 M, or HEC1B', '36 M). Somatic mutations of FGFR2 have been observed in 12% of EC, indicating the potential for this drug in a subset of EC patients. In summary, these results suggest improved efficacy of anlotinib for the treatment of ECs expressing an increased level of FGFR2 mutant proteins. The safety and efficacy of anlotinib are currently being evaluated in an orthotopic AN3Ca mouse model of EC. Experimental groups include a tumor bearing control not subjected to any treatment, anlotinib alone, carboplatin/paclitaxel, a combination of anlotinib and carboplatin/paclitaxel. Primary study endpoints include tumor growth retardation, the delayed onset of local metastases as well as reduced toxicity as secondary endpoint.']",
        "Doc_id":"AACR_2017-3244",
        "Doc_title":" Treatment of endometrial cancer cells with a new small tyrosine kinase inhibitor targeting mutated fibroblast growth factor receptor-2.",
        "_version_":1606188987963146240},
      {
        "Meeting_name":" Pazopanib and lapatinib in patients with relapsed malignant glioma",
        "Background":"['Background', ' Pazopanib (paz) is an oral angiogenesis inhibitor targeting VEGFR, PDGFR, and c-kit; and lapatinib (lap) is an oral tyrosine kinase inhibitor of EGFR (ErbB1) and HER-2 (ErbB2). Combination of VEGFR, PDGFR, and ErbB1 inhibitors may provide synergistic antitumor activity in malignant glioma. Phase I determined the optimally tolerated regimen (OTR) of paz and lap when given with enzyme-inducing anticonvulsants (EIACs). Phase II, which evaluated the efficacy of daily paz/lap (400 mg/1000mg) in relapsed grade 4 glioma without EIACs, was previously reported. Methods', ' Patients (pts) with grade 3 or 4 glioma, on EIACs, and with adequate organ function were eligible. Doses of paz and lap were escalated in a 3 + 3 design. OTR was defined as the highest dose of paz/lap at which no more than 1 of 6 pts had dose limiting toxicity (DLT) and target concentrations were achieved. Results', ' 32 pts have been enrolled at doses of paz/lap (mg, daily unless specified) of 200/1500 (N = 4), 800/1500 (N = 6), 800/500 bid (N = 5), 800/750 bid (N = 7), 800/1000 bid (N = 6), and 600 bid/1000 bid (N = 4). Data on 28 pts', ' the most common adverse events (AEs) were', ' fatigue (25%); diarrhea (25%); headache (21%); ALT increase (18%); nausea (18%); and insomnia (14%). Hepatobiliary lab abnormalities were reversible, uncomplicated, and included', ' AST elevation (11%), hyperbilirubinemia (7%), ALT elevation (36%; 7% Gr 3), and Alk phos elevation (14%). DLTs were elevated liver enzymes (800/1500; 1 pt), elevated lipase (800/750 bid; 1 pt) and thrombocytopenia, fatigue, diarrhea, confusion (800/1000 bid; 1 pt). 2 pts dose reduced and 3 pts had a dose interruption. At 600 bid/1000 bid, the target paz Cmin of 17.5 g/mL was achieved; median lap Cmin of 0.447 g/mL approached the target of 0.5 g/mL. Phase I best response (MacDonald criteria) was PR in 3 pts (11%) and SD  8 weeks in 5 pts (18%). Two pts remain on the phase II, at 21 months (PR) and 23 months (CR) of therapy. Conclusions', ' The paz/lap combination has a manageable safety profile with a preliminary OTR with EIACs of paz 600 mg bid/ lap 1000 mg bid. EIACs decreased plasma paz and lap concentrations. Responses and lengthy periods without disease progression were seen in some pts in phase I and II.']",
        "Doc_id":"ASCO_34010-65",
        "Doc_title":" Pazopanib and lapatinib in patients with relapsed malignant glioma",
        "_version_":1606188997715951616},
      {
        "Meeting_name":" Synergistic anticancer activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein.",
        "Background":"['Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the selective toxicity that some chemotherapy drugs have for cancer cells. This \"synthetic lethality\" (Nature 434', '913, 05) can be enhanced by agents that inhibit DNA repair (Mol Onc 8', '1429, 14; Proc AACR 57', '3718, 16). To exploit this potential \"Achilles heel\", we tested the ability of a small molecule inhibitor of RAD51 to potentiate the cytotoxicity of established chemotherapy drugs. 2-(benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-dihydroisoquinoline (IBR2) was obtained from Drs. J-W Zhu and W-H Lee (Univ. California - Irvine). IBR2 inhibits RAD51-mediated double-strand DNA break repair, but also enhances induction of apoptosis by the ABL inhibitor imatinib against K562 cells (EMBO Mol Med 5', '353, 13). There is potential value of such synergistic interaction among other tumor types and with other drugs. IBR2-drug combinations were therefore examined across a spectrum of cancer cell lines from various tissues (AML, CML, carcinoma of breast, colon, stomach, lung, and head) representing a range of oncogenic drivers (ABL, c-kit, Raf, Ras, ER, mutant p53). Cells were exposed to IBR2 simultaneously with inhibitors of various tyrosine kinase receptors, DNA-damaging agents, or inhibitors of microtubule function. Cells were cultured in 96-well plates, exposed to drugs alone and in combination, and cell density determined by viability staining (alamarBlue or neutral red) 4 days later. Inhibition of proliferation by drug combinations was normalized to that of IBR2 alone. Depending on the drug sensitivity of the cell line, IBR2, at concentrations that inhibited proliferation between 0% and 75% as a single agent, enhanced toxicity of imatinib by up to 80%. IBR2 also greatly enhanced antiproliferative activity of regorafenib (targets RAF, kit, others), EGFR inhibitors erlotinib, gefitinib, afatinib and osimertinib, and microtubule inhibitor vincristine (VCR). However, IBR2 was antagonistic with VP-16, cisplatin, irinotecan, melphalan, and olaparib. To determine a possible mechanism of the observed synergy, the interaction between IBR2 and imatinib or VCR was compared with that between verapamil, a P-glycoprotein inhibitor, and the latter 2 drugs. The VCR-resistant head and neck cell line HN-5a/V15e was not cross-resistant to imatinib, but IBR2 enhanced imatinib toxicity in this cell line, its HN-5a parent, and HT-29 by up to 60%, much better than verapamil (up to 40% at similar concentrations, P<0.05). IBR2 enhanced VCR toxicity in these 3 lines to degree similar to verapamil, decreasing the IC50 by up to 90%. IBR2 appears to enhance drug toxicities via mechanisms other than just inhibition of RAD51 and may potentially interfere with microtubule function. The results indicate that this agent may be useful as a clinical adjuvant to numerous cytotoxic drugs.']",
        "Doc_id":"AACR_2017-2019",
        "Doc_title":" Synergistic anticancer activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein.",
        "_version_":1606188981070856192}]
  }}
